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Abstract 
 
Background 
The number of cystic fibrosis patients is increasing around the world, Latest forecasts 
published in the European Respiratory Journal indicate an increase of approximately 
50% by 2025 (20% in the child population; 75% in the adult population).  
There is no accurate epidemiological data on CF disease in Palestine. The general 
impression has been that the disease is rare, but this is most likely the result of under-
diagnosis or misdiagnosis due to limited awareness of the condition in the region. 
This disease has high treatment burden and some of the novel technology used for 
drug delivery is highly beneficial because it may ease patient burden by decreasing 
administration time and offer more efficacy and safety. These options are not 
available for CF patients in Palestine, only basic traditional therapies are available and 
this is the fundamental problem.  
Assessment of the patient's perspective of symptom improvement, satisfaction and 
their reported increase in health related quality of life (HRQoL) should be part of the 
treatment decision making. Most of the cystic fibrosis patients QoL studies have been 
conducted in developed countries and only a few in developing countries but no 
studies were done in Palestine. 
 
Objective 
The purpose of this project was to study the Palestinian health situation by using 
specific comparison tools including; Quality of life issues of Palestinian CF patients 
attending the Caritas baby hospital, their health status, their related cost effective 
treatment (Economical burden) and summarize the available evidence on the use of 
new options for the treatment by using a willingness to pay survey. 
 
Method 
A descriptive narrative study conducted for patients from West Bank suffering from 
cystic fibrosis disease. These patients used basic classic therapies and attending 
pediatric pulmonology clinic in Caritas Baby Hospital. Around 77 participants 
completed four quantitative assessment measures and provided demographic 
information. The status of CF patients were studied by using different aspect. Their 
quality of life score using CFQ-R questionnaire were measured. Their health status 
were screened by measuring different parameter; pulmonary function test, body mass 
index, their age at diagnosis and mortality rate related to CF disease. Their health 
related cost and the amount of money they are able to pay for improving their 
treatment options using a willingness to pay survey were calculated. Caritas Baby 
Hospital (CBH) Medical Research Committee/Ethical Review Board approved this 
study and a written informed consents form for the patients and their families were 
obtained. Results were analyzed using scoring software and SPSS software. 
IV 
 
 
Results and conclusion 
The overall score for CF patients QoL parameters is less than 60% (ranges from 14.5-
55.6) which indicate poor quality of life relative to other countries worldwide. The 
lowest score is for body (14.5), treatment (17.5), and respiratory (27.5). The highest 
score appears to be for eat (55.6) and emotion (50). Illness severity as measured by 
FEV1 percent predicted with mean value of 69.6%. BMI recorded with mean value 
15.998 (Kg/m
2
). With the overall mean age at diagnosis in our sample was 4.16 years 
of age. The study showed that 58.3% (7/12) of patients from Hebron district had high 
mortality rate related to CF disease.          
The result revealed that quality of life for CF patients is influenced by age, gender, 
taking vacation without disease, work or school status, BMI measures, age at 
diagnosis for the patient's parameters. In addition, QoL as scored by their parents 
parameter which included: the age, educational level and work status of both parents 
and is also affected by total number of CF patients in each family. 
QoL for CF patients is not influenced by marital status, geographic distribution, place 
of residency (city, village and camp), FEV1 measures, willingness to pay answers, 
their parent's relationship (father or mother), monthly income, and the effect of taking 
influenza vaccine yearly.         
For willingness to pay, results indicate that 93.5% said yes and 6.5% said no. 51.4% 
of patients are able to pay 100 NIS out of pocket to 2.7% able to pay 2000 NIS or 
more out of pocket to get new drugs. With economical evaluation for CF patient, the 
total costs for patient with the mean age of our sample 10.7 years of age were 
estimated to be around 35650.2 NIS per patient per year. Cost reduction were 
estimated after applying Dornase-alfa as a mucolytic drug and Tobramycin nebulizer 
solution. This added value can help in part of the cost for making these drugs 
available for CF patients in our region. 
Overall, quality of life for patients with CF is poor relative to international standards, 
the medications used including Hypertonic saline and Gentamycin IV form used as 
nebulizer solution are not first line therapies around the world, patients and their 
families demand better treatment and are willing to pay to get better treatment. Now 
we have an objective proof to submit for the need of new therapies for CF patients in 
Palestine in order to improve their QoL, health status and longevity. 
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Chapter 1: Introduction 
1.Background 
1.1Cystic fibrosis disease    
Cystic Fibrosis (CF), also called Mucoviscidosis, is a life threatening inherited disease 
defined by Flume et al., as “a recessive genetic disease characterized by dehydration 
of the airway surface liquid and impaired mucociliary clearance” [1]. The discovery 
of cystic fibrosis can be dated back to the Middle Ages, when people had the saying: 
“Woe to that child which when kissed on the forehead tastes salty. He is bewitched 
and soon must die.” This is one of the earliest references to cystic fibrosis, 
recognizing the association between the salt loss in CF and illness, although the 
condition was unnamed at that time [2].                                                                       
CF with a defective gene located on chromosome 7. A 3 base-pair deletion (~F508) 
causes about 70% of CF cases with the remainder arising from >600 different 
mutations of the gene [3]. The five classes of CF mutations affect cystic fibrosis 
transmembrane regulator (CFTR) protein through different molecular mechanisms – 
classes I and V affect CFTR production, and classes II, III, and IV affect CFTR 
processing, regulation and conduction, respectively [4]. 
It affects the functioning of several organ systems, which can result in significant 
discomfort and pain. Due to a defective gene, individuals with CF lack a protein 
(CFTR) needed to regulate the exchange of salt and water across the cell membrane. 
This leads to thick, sticky mucus secretions in the respiratory, digestive, pancreatic, 
and reproductive systems. Over time, thick mucus clogs the bronchi that carry air in 
and out of the lungs, causing persistent coughing, wheezing, mucus production, 
inflammation and recurrent infections. Additionally, mucus blocks tubes within the 
digestive track that carry enzymes from the pancreas to the small intestine. Thus, 
nutrients are not efficiently absorbed from food, resulting in poor weight gain and 
growth, abnormal bulky stools frequent greasy, constipation, and intestinal blockage. 
Females with CF may have difficulty getting pregnant due to thick vaginal secretions 
and 99% of males with CF are sterile due to blocking of the vas deferens in utero [5].  
Also patients with CF diagnosed with electrolyte imbalance particularly in countries 
with warm weather [6].  
There are three common tests used to diagnose cystic fibrosis: the newborn screening 
test, the sweat test, and the genetic test. The sweat test (high Cl level in sweat is a sign 
of the disease ≥ 60 mmol/L) is convenient and fast, with no needles involved. It can 
be done in less than an hour, and results can be obtained on the same day the test is 
performed. A genetic test could be further performed to confirm individuals with a 
positive sweat test result [7].  
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Due to advances in therapy in the world, the life expectancy of people with CF has 
increased. From 1992 to 2012, the predicted median survival increased from 29.4 to 
41.1 years. During the same time period, the median age at diagnosis decreased from 
6 months to 4 months, likely because of increased newborn screening. Earlier 
detection of CF prevents further functional deterioration that can occur without 
preventive care [8].  
As per a Cystic Fibrosis Foundation annual report, more than 70,000 people across 
the world suffer from CF [6]. However, this estimate is based on the data available 
from the existing registries in developed countries (primarily the United States, 
Europe and Australia [6, 9]. And it shows that CF is most common in European and 
European-derived populations as the prevalence of CF is highest in Caucasians and 
Ashkenazi Jews; where one child in every 2,500 and 2,300 births is affected, 
respectively. Nevertheless, CF is present in other populations such as Native 
Americans (1 in 10,900), African Americans (1 in 15,000), and Asians (1 in 35,000). 
Although previously considered rare in those of non-Caucasian descent, CF has now 
been found in all ethnic groups, with an estimated prevalence of 1 in 10,000 births 
among Arabs and with affected individuals from India, Iran, South East Asia and 
Turkey. Determining the precise magnitude of prevalence of CF in South East Asian 
and Middle East countries remains elusive [6]. 
 
Although cystic fibrosis is not as common in Arab populations as it is in Europe and 
the United States, there are still very high rates of children born with CF in the Middle 
East. According to Middle East Cystic Fibrosis Association (MECFA) reports for 
every 100,000 live births, CF will affect approximately 7 babies in Oman and Qatar, 
17 in Bahrain, 24 in Saudi Arabia, and 33-39 in Jordan. Cases of CF have also been 
reported in the UAE, Kuwait, Egypt, Lebanon, Palestine, Iraq, Iran, and Pakistan. 
Unfortunately, many of these babies are diagnosed after one year or more, and many 
die in childhood. A comprehensive neonatal screening program in Middle Eastern 
countries could identify babies born with CF in their first days of life and treat them 
sooner, thereby reducing morbidity and mortality of the disease in the region [6].  
       
1.2Treatment  
The management of CF pulmonary disease requires a multidisciplinary approach with 
numerous treatment options as daily medical treatment, including physiotherapy and 
oral and inhaled respiratory medication to minimize deterioration of lung function, 
and dietary supplementation with pancreatic enzymes and vitamin supplements to 
prevent mal-absorption [10]. Adoption of these techniques increased the median 
survival age of patients with CF by 10-fold, from 3 to at least 30 years [3]. The 
primary cause of morbidity and mortality among CF patients is pulmonary disease 
caused by the most common bacterial infection Pseudomonas aeruginosa; in 2010, 
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approximately 37.5 % of UK patients were reported to have chronic P. aeruginosa 
[11, 12]. 
All over the world, clinical management of cystic fibrosis (CF) has improved during 
the past years. Increased standardization of care and a focus on maintenance therapies, 
including nutrition, combined with the introduction of dornase-alfa a mucolytic agent 
in 1993, tobramycin inhalation solution (TIS) in 1998, and the widespread long-term 
use of azithromycin (a macrolide antibiotic) have been associated with an 
approximate 8-year increase in median predicted survival age (increase from 1990 to 
2005 to 36.5 years of age) and a 10% increase in median FEV1 percent predicted 
(from 1990 to 2005) [13]. Unlike the treatment in Palestine which still depends on the 
traditional old basic treatment of hypertonic saline as mucolytic and gentamicin 
intravenous form used as nebulizer solution antibiotic. 
 
1.2.1 Chronic Respiratory Complications 
Active treatment against bacterial colonization and overgrowth is necessary to prevent 
and control CF-related respiratory exacerbations. The Cystic Fibrosis Foundation 
(CFF) guidelines on chronic CF respiratory care recommend inhaled tobramycin for 
patients aged ≥6 years that have persistent airway cultures growing Pseudomonas 
aeruginosa, including asymptomatic carriers, to reduce the incidence of exacerbations. 
Other inhaled antibiotics with activity against P aeruginosa, including colistin, 
gentamicin, and ceftazidime, have been found to have inconclusive evidence for 
routine chronic administration for prevention of exacerbations [1].  
 
Mucolytic Therapies: Several none antibiotic agents may be utilized to control 
respiratory complications. Pulmozyme® (dornase alfa) is strongly recommended to 
improve lung function and prevent exacerbations by degrading free DNA within 
mucus secretions. This drug effect modifies the viscosity of the secretions and allows 
the patient to more easily clear the airway. Hypertonic saline should also be used 
chronically to prevent exacerbations by altering the viscosity of mucous secretions. 
Studies have used various concentrations, often 6% to 7% sodium chloride. Nebulized 
hypertonic saline may cause a reactive airway and may be used concomitantly with 
short-acting beta2-receptor agonists. For patients with airway cultures persistently 
positive for P aeruginosa, oral azithromycin is recommended and has been shown to 
be effective at preventing exacerbations of CF [14].  
 
Bronchodilators have been evaluated in chronic CF respiratory care. Inhaled short-
acting beta2-adrenergic receptor agonists should be used chronically; however, 
inhaled anticholinergic lack the data to recommend chronic administration. Chronic 
use of inhaled N-acetyl-cysteine lacks sufficient evidence of efficacy for exacerbation 
prophylaxis [1].  
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1.2.2 Chronic GI Complications 
 
Due to the chloride channel mutation and thickened viscous secretions in CF, 
pancreatic and biliary ducts become obstructed, leading to hepatic and pancreatic 
fibrosis by retrogradation of digestive enzymes. The decreased clearance and fibrosis 
lead to respective enzyme deficiencies for various exocrine and endocrine functions. 
With the decreased amount of pancreatic enzymes secreted into the small intestine, 
nutritional absorption is further decreased, specifically of fat and protein along with 
fat-soluble vitamins. Pancreatic enzyme supplementation may help to decrease 
symptoms such as steatorrhea and abdominal pain. The addition of antacid therapy 
with a histamine H2 receptor blocker or a proton pump inhibitor may increase the 
amount of enzymes that are delivered to the small intestine for absorption by 
increasing the pH of the gastric acid [14].  
A separate manifestation but also related to the pancreas, CF-related diabetes (CFRD) 
ultimately affects up to half of all adult patients with CF. Liver manifestations occur 
in up to 70% of patients, most commonly hepatic steatosis [15].  
1.2.3 Fertility Issues 
Nearly all males with CF are born without a vas deferens, resulting in infertility. 
Women with CF also can experience fertility issues due to mucus-related obstruction 
of the cervix. Advances in nutrition and lung function have also contributed to an 
increased number of healthy pregnancies in women with CF [14]. From 1997 to 2012, 
the number of women reported to be pregnant by the CFF Registry increased from 
137 to 249 annually [16]. 
1.2.4 Pulmonary Exacerbations [14] 
Respiratory administration of antibiotics has become a novel area for disease 
management. Potential systemic toxicities may be avoided by employing the local 
administration of nebulized medications.  
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Table (1): Specific approved nebulized antibiotics for CF exacerbations are listed 
Comments Indication Dosing Route Drug 
For persons ≥7 y Management of 
pulmonary exacerbations 
in CF 
75 mg nebulized tid for 28 days; 
administer in alternating 28-day 
periods 
Inhaled Cayston® 
(aztreonam for 
Inhalation 
solution) 
For persons ≥6 y Management of CF 
patients with 
pseudomonas aeruginosa 
112 mg inhaled bid for 28 days; 
administer in alternating 28- day 
periods 
Inhaled TOBI® Podhaler 
(tobramycin 
Inhalation 
powder) 
For persons ≥6 y Management of CF 
patients with P aeruginosa 
300 mg bid for 28 days; administer 
in alternating 28 day periods 
Inhaled TOBI® 
(tobramycin 
Inhalation 
solution) 
Safety and efficacy 
not established in 
infants 
Prevention or treatment of 
pneumonia in CF patients 
Adults: 100-150 mg bid 
Children: 75 mg bid 
Inhaled Colistin 
Inhalation 
For persons ≥6 y Improving pulmonary 
function in CF patients 
colonized with P 
aeruginosa 
250-500 mg 3 days weekly Oral Zithromax® 
(azithromycin) 
Doses up to 12-15 
mg/kg/day have 
been investigated in 
children with CF 
Management of CF 
patients with 
pseudomonas aeruginosa 
10 mg/kg  q24h IV Tobramycin 
Injection 
May also be given 
via continuous IV 
infusion 
Prevention or treatment of 
pneumonia in CF patients 
2.5-5 mg/kg/day in  
2-4 divided doses 
IV Colistin 
Injection 
Continuous infusion of beta-lactam antibiotics has become popular at some 
institutions for control of CF exacerbations; and consensus in the literature indicates 
14 to 21 days based on the patient’s response to therapy [17].  
1.2.5 New or Emerging Therapies  
CFTR (cystic fibrosis transmembrane conductance regulator) modulator therapies   
are designed to correct the function of the defective protein made by the CF gene. 
Because different mutations cause different defects in the protein, the medications that 
have been developed so far are effective only in people with specific mutations. There 
are currently two FDA-approved CFTR modulators: Ivacaftor (Kalydeco
®
) and 
lumacaftor/Ivacaftor (Orkambi
®
). 
Ivacaftor (Kalydeco
®
) was FDA-approved in 2012 for treatment of CF in patients 
aged ≥6 years that have certain CFTR genetic mutations. Unfortunately, only 4.3% of 
patients with CF in 2012 had the necessary mutations to benefit from therapy.            
It is the first approved drug for CF that is disease-modifying rather than addressing 
only the consequences of the disease, thus giving hope for future pharmacologic 
targets [14]. According to FDA news release in May 2017, U.S. Food and Drug 
Administration expanded the approved use of Kalydeco (Ivacaftor) for treating cystic 
fibrosis. The approval triples the number of rare gene mutations that the drug can now 
treat, expanding the indication from the treatment of 10 mutations, to 33. 
The lumacaftor/Ivacaftor combination therapy is prescribed for people ages 6 and 
older who have two copies of the F508del mutation, which is the most common CF 
mutation. Several problems are caused by the F508del mutation, which prevents 
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CFTR from achieving the correct shape and reaching the cell surface. The 
combination therapy works to correct this in two ways. Lumacaftor moves the 
defective CFTR protein to the correct place on the cell surface, and Ivacaftor 
increases the protein's activity once it is in place [18].  
 
1.3Cystic fibrosis-related quality of life (CFQ( 
Health-related quality of life (HRQoL) was established as a paradigm to include the 
patients’ perspective in clinical practice and research. Typically, HRQoL is defined as 
a multidimensional construct comprising (at least) physical, psychological and social 
well-being and functioning as perceived by the individual. Asking the patient “how 
they are” or about the effectiveness of treatments is nothing new. HRQoL 
instruments, however, can provide a formal, standardized, valid and reliable way of 
gaining the patients’ perspective as to the benefits and limitations of a specific 
intervention [19].  
QoL questionnaires have been included as part of most clinical trials of CF new 
drugs, but in many cases the instrument used was not clearly identified. A commonly 
employed tool consisted of 5 questions on general well-being (feeling, energy, 
physical activity, appetite, sleep pattern) and 4 on CF-related symptoms (ease of 
sputum  expectoration, cough frequency, cough severity, congestion). Responses were 
ranked on a Likert scale, where 1 is the worst and 5 is the best outcome. However, 
there appears to have been no assessment of the reliability, validity or responsiveness 
of this questionnaire [3].  
Later on two types of measures can be used to assess quality of life: generic and 
disease- specific instrument. Different types of scales have previously been employed 
and include: global rating of change, ad hoc, generic (SIP, NHP, SF36; CHQ, 
PedsQL), utility (QWB, EuroQoL), non-standardized profiles (SEIQoL), respiratory 
(CRDQ, SGRQ) [19]. The SIP is reliable and valid, although lengthy and therefore 
unwieldy in practice. The SF-36 has the advantage of brevity and is a valid tool, but is 
generally only applicable to adults. The QWB Scale is designed for general 
populations and measures physical symptoms combined with functionality (mobility, 
physical activity and social activity). This scale has been positively correlated  with 
pulmonary function and physical status in some studies of patients with CF but not 
others, and its usefulness in children and adolescents has been questioned [3]. 
The first evidence that the QWB scale may be useful in tracking general life quality 
over time in patients with CF from 1987-1989 was from Pittsburgh CF center, this 
scale (QWB) applied in 28 patients with CF before and after a two-week course of 
oral ciprofloxacin used to treat pulmonary exacerbations. There were significant 
correlations between changes in QWB and various pulmonary function test results; 
Most of the patients showed improved pulmonary function and improved QWB after 
two weeks of oral ciprofloxacin treatment of their pulmonary exacerbations [20].  
Using the NHP, pulmonary function (FEV1 values) has been identified by some 
investigators as the main determinant of quality of life in patients with CF. Aspects of 
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daily living, such as social life, sex life, holidays, hobbies, employment and looking 
after the home, have been rated as significantly better in patients with higher FEV1 
values (about >50% of predicted). In contrast, other researchers, using the SIP, have 
found that overall scores correlated strongly not with FEV1 but with dyspnea scores. 
Dyspnea may therefore be an important surrogate measure of physical functioning [3].  
CF specific scales (CFQ, CFQoL, FLZ-CF, DISABKIDS). Only the CFQ has scales 
for both children and adults. Apart from CF specific scales, the only scales that have 
CF psychometric evaluation data for investigators to consult are the SF36 and GRQ. 
Thus far, only the respiratory scale of the CFQ has been approved by the US Food 
and Drug Administration (FDA) for use as an endpoint in trials. It is noteworthy that 
it is the CFQ domain (adolescent and adult) with the most acceptable interclass 
correlation coefficient for test-retest reliability. The scale captures perceived 
respiratory function/symptoms which is only one aspect of the much broader 
construct of HRQoL [19].  
The quality of life for CF patients in developed countries have improved dramatically 
the last decades, due to regular periodic evaluations, monitoring for complications of 
the disease, and new interventions by physicians and other healthcare workers 
specifically trained in management of CF. The Cystic Fibrosis Questionnaire-Revised 
(CFQ-R) has been validated as a subjective measure to assess multiple domains of 
patient quality of life and is approved by the FDA as a patient reported outcome 
measure to be used as disease specific questionnaire [21].                    
CFQ-R is currently the most widely used HRQoL instrument for CF and was rated 
“well-established” in the recent reviews. The CFQ-R has not only been translated into 
34 languages, with validation studies in all countries, but has demonstrated 
responsively in several clinical trials of medications with different mechanisms of 
action (e.g., antibiotics, mucus hydrators, gene potentiators) [21]. 
 
1. Problem statement  
According to Cystic fibrosis foundation, Respiratory Tract Infections (RTIs) are a 
major cause of hospitalization for CF patients.  More than one-third of the CF patients 
are hospitalized each year, and 20% of the CF patients are hospitalized more than 
twice a year. Of all CF-related hospitalizations, more than 75% is for treatment of 
RTIs [22].  
The treatment goals for patients with CF lung disease are to halt or slow disease 
progression by maintaining FEV1 and preventing pulmonary exacerbations, to 
provide symptom relief, and to improve quality of life. As discussed, despite the 
availability of proven therapies, significant variability exists in these outcomes and 
the use of medications. Many issues likely contribute to this variability, including 
genetic, medical, and environmental factors. Understanding how these factors affect 
outcomes and addressing the barriers to care is a critically important task. Some 
specific obstacles facing patients, clinicians, and researchers (Table 2) are considered. 
By targeting barriers in each group for intervention, we hope to advance the 
development and delivery of CF care [23].  
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Table (2) Barriers to optimal therapy 
 
The status in Arab countries is more severe as the median survival for CF patients was 
estimated to be from 10 to 20 years of age, which reflects poor management strategy 
relative to other country for many reasons such as: delayed diagnosis due to decreased 
awareness of the variable presentation of the disease, lack of availability of diagnostic 
tool such as quantitative sweat chloride test and delayed institution of treatment due to 
delayed referral to a specialized CF center. Early pseudomonas colonization at 3 years 
compared to 7 years in the western countries.  Poor compliance to treatment and chest 
physiotherapy, poor distribution of CF specialized centers, delayed nutritional 
rehabilitation [6], lack of  more effective and potent medicines approved worldwide. 
In addition, poor adherence is a problem, especially during adolescence. The three 
most common barriers encountered were lack of time, forgetfulness, and 
unwillingness to take medication in public [10]. 
 
Also the major problem of CF in our countries is that CF is costly disease; patients 
with Cystic Fibrosis have thick, tenacious sputum. They are chronically colonized 
with bacteria. This leads to frequent exacerbations and is a burden for these patients. 
Of the patients in UK which are hospitalized each year (around 33%), 75% is treated 
for pulmonary infections [22].  
 
Costs of patients with chronic P. aeruginosa infection were more than three times 
higher than of uninfected patients [24]. Therefore, medical professionals worldwide 
have limited treatment options that have shown to be both safe and effective in P. 
aeruginosa treatment. With continued research and patient compliance, CF patients 
will have improved quality of life and clinical outcomes [12]. Unfortunately, this 
medical progress isn't applicable in Palestine since old traditional treatment is 
available, this contributes to accelerated progressive obstructive disease which leads 
to major morbidity, reduced quality of life and, ultimately, high mortality rate. 
Wherefore the automatic therapeutic substitution is one method utilized to reduce 
healthcare costs while sustaining patient quality of care. The characteristics of these 
new medications are described below:  
Patient/family Medical care providers Researchers 
 
- Adherence. 
- Treatment burden. 
- Mental health/depression. 
- Lack of insurance, 
underinsurance. 
- Lack of understanding (disease 
seriousness, treatment benefits, 
etc). 
- Heterogeneity of response 
(pharmacogenetics). 
 
 
- Lack of resources/time. 
- Implementation of 
guidelines/evidence-
based medicine. 
- Drug interactions. 
- Relaying hope vs. 
seriousness of disease. 
- Managing treatment 
failures, adverse events. 
 
- Identifying appropriate 
outcome measures. 
- Need for large sample size. 
- Appropriate selection of 
controls. 
- Navigating regulatory 
guidelines. 
- Balancing need for new 
therapies with patient safety. 
- Lack of resources/time. 
- Competing clinical trials. 
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Table (3): Hypertonic saline compared to Dornase alfa (rhDNase) solution 
 
Available: Hypertonic saline New: Pulmozyme
®
 
(Dornase alfa sol. rhDNase) 
 
 
3%, 7% inhalation solution vial made to 
order by hospital pharmacy sterile 
products personnel in accordance with 
standards issued by pharmacopeia. 
Delivered by nebulizer. 
 
Inhalation solution in single-use ampules 
(2.5mg/2.5ml) delivered by nebulizer. 
It is new world wide available medication. 
Packaging  
and  
mechanism 
of delivery 
_ potential problems with drug stability as 
it prepared locally in hospital.  
_ High dose uniformity as it given by 
nebulization and performance doesn't 
depend on patient's inspiratory flow 
profile.     
_ less potential problems with drug stability.  
_ High dose uniformity as it given by 
nebulization and performance doesn't depend on 
patient's inspiratory flow profile.     
 
Compliance 
 and  
Adherence 
_ It is approved to use in CF patients but 
not the first choice. 
_ may cause bronchospasm which 
necessitates the need to use bronchodilator 
as pre-medication.  
 
_ According to the studies it's the most efficient 
mucolytic agent used for CF patients. 
_ It offers a therapeutic opportunity to reduce 
RTI-related health care use.  
_ Reduce number of hospitalization and the 
need to parenteral antibiotic and other 
antibiotics.  
_ Reduce the side effect of hypersensitivity and 
bronchospasm caused by HTS. (no need for 
bronchodilator).  
_ Improve general health perceptions and so the 
ability to function during the daily life (QOL).  
Efficacy  
 
Less expensive 
 
Expensive 
 
Cost  
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Table (4): Gentamycin compared to Tobramycin and Azetreonam lysine 
 
New: Cayston
®
                       
(azetreonam lysine) 
Available: Zetamycin
®
 
(gentamycin) 
New: TOBI
®
(tobramycin)  
 
Single-use vial (75 mg of 
aztreonam) reconstituted with 
1 mL of sterile diluent (0.17% 
sodium chloride) administered 
3 times a day for a 28-day 
course by inhalation using an 
Altera® Nebulizer System.  
 
Intravenous gentamycin 
ampule (20, 40, 80mg) 
given as inhalation 
solution by nebulizer.   
- TOBI Podhaler (TIP) consists of a 
dry powder formulation filled into 
clear, colorless hypromellose 
capsules (28mg) for oral inhalation 
only with the podhalar device twice 
daily on cycle of 28-day.  
- TOBI 300 mg (TIS) single-use 
ampule, administered by inhalation, 
using a hand-held PARI LC PLUS 
Reusable Nebulizer with a 
DeVilbissPulmo-Aide compressor. 
Packaging 
and 
mechanism 
of delivery  
 
- Patients should use a 
bronchodilator before 
administration. 
- It is delivered by specific 
nebulizer.   
- High deposition efficiency. 
- Short administration time 
(mobility(.  
- No potential problems with 
drug stability as it delivered 
by specific nebulization 
technique.  
- High dose uniformity and 
performance doesn't depend 
on patient's inspiratory flow 
profile. 
 
 
 
- There is a Preservative to 
be used for IV injection 
which may cause hyper 
sensitivity RXN such as 
bronchospasm. 
- It is delivered by simple 
type of nebulizer or by IV 
injection route so it need 
an medical intervention or 
hospital admission to give.  
- Low deposition 
efficiency.  
- Long administration 
time.  
- Need for power supply or 
pressurized air 
(immobility).  
- They have potential 
problems with drug 
stability.  
- High dose uniformity as 
it given by nebulization 
and performance doesn't 
depend on patient's 
inspiratory flow profile.     
 
- Propellant and preservative free if 
used TIP which reduce 
hypersensitivity RXN probability. 
- They have high deposition 
efficiency. 
- Short administration time 
(mobility). 
- Less potential problems with drug 
stability. 
- No need for power supply or 
pressurized air (immobility) with 
TIP use.  
- Performance depends on the 
patient's inspiratory flow profile in 
case of TIP and so there is a 
potential difficulties to obtain dose 
uniformity but it is opposite for 
TIS.   
 
 
Compliance 
and  
Adherence 
 
It is the most effective 
antibiotic drug used for CF 
patients with pseudomonas  
aeruginosa infection as it 
Reduce total Hospital resource 
use and community service 
use and cost more efficiently.  
 
 
Less efficient than 
tobramycin and used as 
added on therapy for CF 
patients in the world.   
- Studies show that it is more 
effective against pseudomonas 
aeruginosa infection in CF patient 
than aminoglycoside drugs in 
reducing;  
- Total Hospital resource use and 
cost;  
By improve pulmonary function 
test FEV1, FVC and ability to 
function during the daily life 
(QOL).  
 _ Community service use and cost.      
Efficacy 
study  
 
Very expensive 
 
Less expensive than TOBI 
 
Expensive 
 
Cost  
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The cost of administering aerosolized tobramycin three times a day is one-half the 
daily cost of administering two intravenous antibiotics at home and one-fifth the daily 
cost of administering two intravenous antibiotics in hospitals [25]. 
 
  
3. Aim of Current Study 
 
To obtain a comprehensive understanding of CF patient's health status, one must 
monitor variables, such as disease severity related to health status, treatment 
adherence relative to health related cost, social support, and HRQoL. Health related 
Quality of life (HRQoL) issues are important when one considers that CF is a disease 
with high morbidity (mostly related to pulmonary involvement) and early mortality. 
With the various treatment options for CF pulmonary disease, the question to 
optimize medical treatment is a crucial issue in CF care and, basically, the approach 
of a survey on evidence based therapy in CF can give some answers to this basic 
question.  
The overall objective of this study was to evaluate the Palestinian CF Patients health 
situation by studying quality of life issues, health status and economic burden. In 
addition, the study summarizes the available evidence on the use of new treatment 
options and examines its application in Palestine by using a willingness to pay survey. 
To date, few studies were done on CF disease in Palestine and the studies done only 
determined the CF mutation spectrum in our patient population [26, 27], but no study 
have discussed QoL of cystic fibrosis patients and factors that affect it.  
 
The following objectives and hypotheses were evaluated. 
       Study aims and hypotheses:  
1. The first aim was to measure quality of life (QoL) scores for children, teens, and 
adults with CF and parent caregivers to provide data about their status.  
 
a. Hypothesis 1: Low quality of life scores for adult group than children 
group with the treatment domain as the most one.  
b. Hypothesis 2: A good agreement between the mean scores on the CFQ 
Parents 6-13 and the information obtained by means of the questionnaires 
applied to their patients. Differences are expected especially regarding 
physical, weight and emotional aspects. 
 
2. The second aim was to compare QoL score for our patients (using basic 
therapies) to patients in developed countries (using advanced therapies). 
 
a. Hypothesis 3: Low quality of life (QoL) domain scores for CF- patients in 
Palestine compared with other population worldwide. 
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3. The third aim was to correlate the relationship between HRQoL and clinical (lung 
functional test, BMI and diagnostic age) and with demographic factors of patients 
using basic therapies. 
 
a. Hypothesis 4: There is a correlation between CFQ-R scores and gender, 
Females may be expected to have lower QoL score on specific domains of 
functioning than male. 
b. Hypothesis 5: In general, as both education and income levels increase, the 
QoL parameter would be enhanced. 
c. Hypothesis 6: Most of patients suffering from CF disease was from 
southern region countries with more than one CF patient in each family. 
d. Hypothesis 7: There is a high percentage of families we interviewed have a 
child died from CF disease.  
e. Hypothesis 8:  Most of patients diagnosed later on not at the first year of 
their life. And so for the patients diagnosed earlier in their life, CFQ-R 
scores are higher than patients diagnosed later on their life. 
 
4. The fourth aim was to examine the total healthcare resources use and cost of our 
patients then looked up literature to see the percentage of reduction in the cost 
after using such new medication and using this percentage to apply to our cost. 
 
a. Hypothesis 9: healthcare resources costs of our patients are very high and 
expensive and will be decreased as the new advanced therapeutic options 
supplied to our patients.  
  
5. The fifth aim was to assess the willingness of CF patients/families to contribute to 
the cost of new therapies and to examine the association between the QoL and 
willingness to pay survey.  
 
a. Hypothesis 10: Patients willing to pay the highest amount in order to 
reduce symptoms of CF disease. 
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Chapter 2: Literature review 
 
 Issues:  
• What evidence is available for the efficacy and safety of inhaled tobramycin, 
aztreonam, and dornase alfa for cystic fibrosis (CF)?  
• Is there comparative evidence that either inhaled tobramycin or aztreonam is 
superior in efficacy or safety?  
• Are there specific subpopulations or clinical situations in which one inhaled 
antibiotic provides clear benefit over another?  
 
Systematic search of all the published literature that has considered the evidence for 
antimicrobial therapies in CF with key findings were as follows: inhaled 
antipseudomonal antibiotic improves lung function, and probably the safest/most 
effective therapy; anti staphylococcal antibiotic prophylaxis increases the risk of 
acquiring P. aeruginosa; azithromycin significantly improves respiratory function 
after 6 months of treatment; a 28-day treatment with aztreonam or tobramycin 
significantly improves respiratory symptoms and pulmonary function; aztreonam 
lysine might be superior to tobramycin inhaled solution in chronic P. aeruginosa 
infection; oral ciprofloxacin does not produce additional benefit in those with chronic 
persistent pseudomonas infection but may have a role in early or first infection [28]. 
And also published clinical data show that inhaled tobramycin reduces the bacterial 
load, improves lung function and reduces the number of hospital admissions. Inhaled 
tobramycin has been used successfully to eradicate P. aeruginosa in patients with 
early infection. Maintaining clinical benefits requires chronic tobramycin treatment, 
and the concept of chronic intermittent inhaled treatment (typically, alternating drug 
and drug-free periods of 28 days) was introduced to minimize the emergence of 
aminoglycoside resistant P. aeruginosa strains. Other therapeutic advances include the 
development of different tobramycin formulations and nebulizers that reduce delivery 
time without compromising efficacy [9].  
RhDNase offers a therapeutic opportunity to reduce RTI-related health care use in CF  
patients. The objective behind therapy with rhDNase is improving health related 
quality of life and additionally lowering the costs of CF including several cost 
components hospitalization, exacerbations, symptoms, therapy, RTI related, 
antibiotics, etc. [22].  
 
1. Efficacy studies   
A J MARTIN, Birmingham Children's Hospital study results show that P. aeruginosa 
can successfully be eliminated or suppressed with high-dose aminoglycoside plus 
carbenicillin, but such elimination is usually short lived. In vitro studies showed 
gentamicin to be 2- to 4-fold less active against isolates of mucoid P. aeruginosa than 
tobramycin. The MIC to tobramycin ranged from 0.5 to 1 mg/l  and from 0.5 to 2 mg/l 
for gentamicin [29].  
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Some studies suggest that tobramycin may be less nephrotoxic than gentamicin. Acute 
renal failure has been very rarely reported in patients with CF. Smyth et al. recently 
published a case-control study of 24 patients with CF from 20 UK centers. They 
found that use of intravenous aminoglycoside is a risk factor for renal impairment, 
with gentamicin being more nephrotoxic than tobramycin [9]. 
TIP via the Podhaler has been shown to be safe, similarly effective to Tobramycin 
inhalation solution (TIS) and faster to deliver if compared to TIS delivered through 
the PARI LC PLUS jet nebulizer (mean time for delivery 5.7 versus 19.7 minutes 
respectively) though delivery would have been faster through other commonly used 
vibrating mesh nebulizers such as the e-Flow. Patient-rated satisfaction scores favor 
TIP over TIS, though there was a higher rate of cough, dysphonia and taste 
disturbance and of discontinuation of TIP [30].  
The EAGER trial enrolled 553 CF patients comparing TIP to TIS over 3 cycles of 
treatment. The EVOLVE trial, including 102 CF patients, was placebo-controlled for 
1 cycle followed by open label treatment with the TOBI Podhaler for 2 additional 
cycles of treatment. The Podhaler formulation displayed similar tolerability and 
efficacy to TIS and significantly improved FEV1 compared with placebo. Cough was 
the most frequently reported adverse reaction related to the dry powder in both 
clinical studies. The recommended dose is 112 mg (four 28 mg capsules) inhaled 
twice daily in alternating cycles of 28 days on treatment followed by 28 days off 
treatment. TIP is currently available in some European countries, South America, and 
Canada [31].  
In several clinical studies Cayston
®
 (aztreonam) has been shown to be safe and 
efficacious in suppressing chronic P. aeruginosa lung infection in CF patients. In a 
randomized, placebo-controlled study of 164 CF patients, Cayston
®
 significantly 
improved CFQ-R Respiratory Symptoms Score (RSS) and FEV1 after one cycle of 
use at 28 days, with a treatment difference compared to placebo of 9.7 points and 
10.3%, respectively. In a second pivotal trial of 211 patients with CF, Cayston
®
 
increased the median time to need for additional anti-pseudomonas antibiotics for 
symptoms of pulmonary exacerbation by 21 days, versus placebo. In the open-label 
follow-on study of these two trials, Cayston
®
 safety and efficacy was examined in 274 
patients over 18. FEV1 values, CFQ-R RSS, and body weight increased with each 28 
day course of Cayston
®
, and this effect was maintained over 18 months. No 
significant safety concerns were observed in studies over 12 months and 18 months; 
including no evidence of development of antibiotic resistance [31].  
In a 6 month active comparator trial of 273 CF patients receiving either Cayston
®
 
(aztreonam) or TIS, Cayston
®
 was superior to TIS with regard to lung function 
improvements, with a treatment difference of 7.8% at 28 days and 2.7% at 24 weeks. 
Significant reductions in pulmonary exacerbations and mean change in CFQ-R RSS 
after 28 days of Cayston
®
 treatment were also seen, compared to TIS. In the follow-on 
6 month open-label extension of this active comparator trial, the FEV1 response of 
previous TIS subjects who were switched to Cayston
®
 improved and was sustained 
over time. Patients receiving Cayston
®
 also gained weight throughout the 12 month 
trial, compared to those who received TIS who initially lost weight and then improved 
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upon switch to Cayston
®
. Cayston
®
 is available in the EU, Switzerland, USA and 
Canada. Cayston
®
 is licensed for use in patients 6 years and older [31].  
The Pulmozyme (rhDNase) Early Intervention Trial (PEIT) of Robinson et al, showed 
reduction in the risk of pulmonary exacerbations and thereby a reduction of 34% in 
parenteral antibiotic therapy. This study also showed an improved forced expiratory 
flow at 25 to 75% of FVC and improvement in FEV1 over a 2 year period in CF 
patients with almost normal lung function. The results of this study, conducted at 49 
sites in 12 countries in a randomized trial (placebo-controlled) design, showed 
benefits from rhDNase in CF patients from early intervention in the course of their 
lung disease. In another, this time short term, study of rhDNase of Robinson et al, an 
increase of 7.5% in FEV1 and 5.4% in FVC from baseline was seen in patients who 
received rhDNase compared with placebo [22]. 
Fuchs et al. found a reduction in exacerbations of respiratory symptoms and a slight 
improvement in pulmonary function after 2.5mg rhDNase therapy in a randomized, 
double-blind, placebo-controlled study in which 968 patients participated. One or 
more exacerbations occurred in 27% of the patients who received a placebo, 22% in 
patients who received once daily rhDNase and 19% in patients who received twice 
daily rhDNase (2 x 2.5 mg). The FEV1 improved with about 6% in patients who 
received rhDNase [22]. 
Hypertonic saline and recombinant human DNase: a randomized crossover pilot study 
in patients with cystic fibrosis demonstrated the first evidence that the effects of HS 
and rhDNase on FEV1 (% predicted) were comparable in a group of mild to 
moderately severe ill children with CF. Approximately 30% of patients showed a 
clinically relevant increase of FEV1 (>10%) with rhDNase and the same was observed 
for HS. The substantial variations in the same individual in the response to HS or 
rhDNase might reflect the diverse influences of HS (viscoelasticity) and rhDNase 
(spinnability) on sputum which might have different relevance in the individual 
patient. Thus, a patient not respond to HS might be successfully treated with rhDNase 
and vice versa [32].  
Suri et al. compared the consequences of three therapies in children: 1) daily rhDNase 
(2.5 mg), 2) alternate day rhDNase (2.5 mg) and 3) hypertonic saline (two times per 
day) during 12 weeks. The study was an open randomized cross-over trial, in which 
48 children with CF were allocated. This resulted in a significant greater increase in 
mean FEV1 (2-14%) with daily rhDNase compared with hypertonic saline, while 
daily and alternate daily rhDNase did not differ significantly [33]. 
In another clinical trial, Grieve et al. investigated the effect of 12 weeks treatment 
with daily rhDNase, alternate day rhDNase or hypertonic saline (HS) in a randomized, 
crossover study, in which 40 children with CF were allocated. They found a 14% (5-
23%) improvement in FEV1 for daily rhDNase compared with HS, while alternate 
day rhDNase compared to HS resulted in a 12% (2-22%) improvement in FEV1. 
There was, as also described by Suri et al, little difference between FEV1 of daily and 
alternate day rhDNase [22].  
Ballmann and colleagues did a pilot cross-over trial comparing 3 weeks of daily 
rhDNase with 5.85% hypertonic saline in 14 patients. Both drugs were administered 
16 
 
by jet nebulizer. Increases in mean FEV1 were 8% and 9% for hypertonic saline and 
rhDNase, respectively. Statistical testing was not done owing to small numbers [33]. 
 
2. Studies of Quality of Life considerations 
 
The respiratory symptoms of CF can adversely affect daily activities of the patient 
with CF, because of the unpredictability of these symptoms and serious consequences 
of exacerbations. It is difficult to predict the degree to which the quality of life of an 
individual can be affected by CF. Some studies mention that the great majority of CF 
patients live well in adulthood with an acceptable quality of life, due to basic 
therapies. New therapies can help to improve the quality of life. However, all patients 
suffer from deterioration in their disease, which leads to limitations and thus 
ultimately reduces quality of life significant. The majority of morbidity and mortality 
in CF results from inflammation and infection of the airway lumen, which leads to a 
certain degree of disability in patients with CF. In one study, the impact of pulmonary 
exacerbations on quality of life in CF patients was studied. The objective was to 
compare health-related quality of life (HRQoL) of CF patients to general population 
and to determine the relationship between HRQoL and clinical and demographic 
factors [22]. 
HRQoL measures the individual ability to function in different area and the 
individual's evaluation of their functioning. The study of Britt et al. showed that 
exacerbations do not have a profound negative impact on HRQoL that is not 
explained by differences in function of lungs, nutrition status or demographic factors. 
In spite of this, lung function, nutrition, 6-min walk, age, gender, and insurance status 
were not significantly associated with HRQoL in this study population [34].  
On short term, well-being and quality of life of CF patients is improved by rhDNase, 
through improvement in lung function and a reduction of RTI incidence. In the study 
of Oster et al, questionnaires were developed to evaluate well-being (feeling, energy, 
activity, sleep, appetite) and physical symptoms (sputum production, frequency and 
severity of cough, chest congestion). The results mentioned that compared to the 
placebo group, there was significantly less dyspnea, significantly improved wellbeing 
and there were significantly fewer CF related symptoms in the rhDNase-group. This 
implies that when CF patients are treated with rhDNase they have a better quality of 
life compared to patients who are not treated with rhDNase [35].  
Another study noted that baseline HRQoL assessments show that adults with CF, 
reported decrements in health status and functioning. In this study, a significant 
association was found between the rhDNase therapy and one-year change in HRQoL. 
One of their suggestions was that a further evaluation of the relation between hospital 
admission and changes in HRQoL is required [36].  
As opposed to life expectancy, morbidity and mortality, quality of life is mainly not 
affected by the CF disease as such (e.g. dietary requirements), but much more by the 
symptoms and respiratory tract inflammations and infections. Hospitalization affects 
quality of life also in a negative sense. RhDNase has a positive short-term effect on 
the quality of life as mentioned above [22]. 
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Three-month data from the 24-week Australian rhDNase Phase IIIb Study in 69 
patients demonstrated significant improvements from baseline (p < 0.05) in total CF-
specific score (3%) and SF- 36 total score (7.5%) with dornase alfa 2.5mg once daily. 
Significant improvements also occurred in the domains of emotional functioning, 
energy levels, coughing, sputum production, congestion, chest pain and sleep patterns 
[3]. 
Alexandra L. Quittner study examined the effects of TSI on global ratings of health-
related quality of life (HRQoL) by patients (or their parents) in 520 patients with CF 
and chronic pseudomonas aeruginosa infections were analyzed retrospectively. They 
receive 24 weeks of placebo or treatment with TSI 300 mg bid both in 3 cycles of 28 
days followed by 28mg days off, there was strong agreement between the paired 
patient/parent and physician global HRQoL rating across the three cycles. And they 
more likely report improvements in HRQoL than were patients in placebo group. And 
change in FEV1% predicted values was rated significant improvement only at the end 
of the cycle 1. The result of this provide consistent evidence that TSI was associated 
with improved global ratings of HRQoL completed by both patients or parents and 
physicians [37]. 
 
3. Economic evaluation studies  
 
There have been relatively few economic evaluations of antibiotic treatments in CF, 
with three different areas of interest: (a) the economic value of home- versus hospital-
based intravenous therapy, (b) assessment of cost-effectiveness of inhaled antibiotics, 
specifically TIS and AZLI and (c) the relationship between costs, including patient 
co-payments and out of pocket expenses, and adherence and (d) the economic value 
of antibiotic eradication therapy [31]. 
The main economic findings were that (i) the annual costs of care for CF vary greatly 
with disease severity; (ii) hospitalizations account for the greatest portion of costs for 
CF patients; and (iii) the costs of expensive therapies may be partly offset by savings 
in other resources [38]. 
One of the economic evaluations of TIS have been conducted in the UK from the 
perspective of the National Health Service (NHS) and in Canada from the perspective 
of the Canadian Health Service in Ontario and Quebec. In Canada, the acquisition 
cost of TIS was estimated to be CA$8602 over a 24-week period. Mean offsets in 
direct medical costs for all patients treated with TIS versus placebo were CA$4916 in 
Quebec and CA$4055 in Ontario. In the UK, in all patients the cost of TIS was 
partially offset by savings of £3719 per year compared with placebo in 2001. This 
was primarily because of a reduction in the mean number of days spent in the hospital 
(7.8 days), resulting in savings of £2345 and a reduction in the mean number of days 
treatment with intravenous antibiotics (6.4 days), resulting in savings of £1344. The 
net direct cost was £6292 per year, based on a TIS acquisition cost to the NHS of 
£10,010 in 2001. Inpatients  aged ≤18 years, the direct cost offset was £6180, 
resulting in a net cost versus placebo of £3830 [39].  
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A study was designed to investigate in a British population the impact of TNS on 
usage of costly health care resources that have a high consumption in CF. The study 
set out to compare utilization of specified healthcare resources over two 1 year 
periods before and during treatment with TNS in patients with CF. Use of inhaled 
TNS for 12 months in the study population of moderately severely affected CF 
patients gave rise to important clinical and social benefits such as reduction of 
hospitalization and the use of intravenous antibiotics, which would be expected to 
improve patients’ quality of life as well as to reduce interference with work and 
schooling. Its acquisition cost was partially offset by the savings that occurred in these 
expensive components of patient care [38].  
Recently, a cost-effectiveness analysis of the AZLI–TIS active comparator study was 
performed using a Markov model with health states defined principally by FEV1 % 
predicted levels. Over 3 years, AZLI use was associated with increased life-years, 
reduced number of hospitalizations, increased QALYs, and a subsequent cost savings 
of over $6000 over TIS [31]. 
Oster et al. used data from a U.S. clinical trial that compared the effectiveness of 
rhDNase with placebo in adults with CF. However, this study excluded the cost of 
rhDNase and only assessed respiratory tract infection–related health costs. The study 
suggested that rhDNase (administered once or twice daily) improved patients’ lung 
function and reduced hospitalizations, which could potentially offset around 25% of 
the drug’s cost. Menzin et al. used data from the same U.S. trial to compare the costs 
of rhDNase with placebo in four different European countries. The analysis used 
expert opinion to adapt the resource use observed in the trial to a European context, 
and concluded that rhDNase could reduce health service costs by between US $700 
and $1,000 over 6 months. The validity of the latter study was limited by the extent to 
which data could be transferred between the United States and Europe [40]. 
The cost effectiveness of dornase alfa was evaluated in the North-West region of 
England (cost per in-hospital day avoided, £2857) was found to be considerably less 
than for clozapine in schizophrenia but much better than for interferon in multiple 
sclerosis. A caveat to such comparisons is that costs and drug use are influenced by 
differences in approaches to treatment for the various diseases and among different 
countries [3].  
Suri et al. compared mean incremental costs of daily and alternate day rhDNase with 
hypertonic saline (HS) over a 12 week period as investigated in a clinical trial, in 
which they labeled themselves a cost-consequence analysis. The mean incremental 
costs of daily rhDNase compared with HS were €1409 and the incremental cost of 
using daily over alternate day rhDNase was €513. A formal cost-effectiveness 
analysis to analyse whether the increased effectiveness of daily rhDNase compared to 
HS twice daily delivered by nebulizer was not done. It was merely concluded that 
daily rhDNase was more expensive and significantly increases health care costs. 
Administering rhDNase on an alternate day rather than on daily basis may be as 
effective, with a potential cost saving [33].  
A U.K. study has recently compared the effectiveness and costs of treating children 
with CF with daily rhDNase (2.5 mg), alternate day rhDNase (2.5 mg) and HS. The 
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study was based on a randomized controlled trial with a crossover design, with 40 
patients receiving each treatment for 12 weeks, with a 2-week washout period 
between treatments. The primary outcome measure was the patients’ lung function 
measured by forced expiratory volume in 1 second (FEV1). Comparing mean FEV1 
between the treatments, the trial reported an 8% (95% CI, 2% to 14%, p = .01) 
advantage for daily rhDNase over HS, but none for daily compared with alternate day 
rhDNase (2%, 95% CI, −4% to 9%, p = .55) [40]. 
Grieve et al. study show compared the relative cost-effectiveness of daily recombinant 
human deoxyribonuclease (rhDNase), with alternate day rhDNase and hypertonic 
saline (HS) for treating children with cystic fibrosis (CF). A randomized controlled 
trial with a crossover design allocated 40 CF children consecutively to 12 weeks of 
daily rhDNase, alternate day rhDNase, or HS. The primary outcome measure was 
forced expiratory volume in 1 second (FEV1), a measure of lung function. All health 
resource use was prospectively documented for each patient and multiplied by unit 
costs to give a total health service cost for each 12-week treatment period. The non-
parametric bootstrap method was used to present cost effectiveness acceptability 
curves and net benefit statistics for each treatment comparison, for various 
hypothetical levels of the decision maker’s ceiling ratio. Compared with HS, there 
was a 14% improvement in FEV1 for daily rhDNase (95% CI, 5% to 23%), and a 
12% improvement (95% CI, 2% to 22%) for alternate day rhDNase. For a ceiling ratio 
of £200 per 1% gain in FEV1, the mean net benefits of daily and alternate day 
rhDNase compared with HS were £1,158 (95% CI, −£621 to 2,842) and £1,188 (95% 
CI, −847 to 3,343), respectively; the mean net benefit of daily compared with 
alternate day rhDNase was −£30 (95% CI, −£2,091 to 1,576). If decision makers are 
prepared to pay £200 for a 1% gain in FEV1 over a 12-week period, then on average 
either rhDNase strategy is cost-effective [40]. 
 
4. CF in Palestine  
The rate of consanguineous marriages in Palestine, was found to be 45% in 2004 [41], 
indicating that Palestine has a very high risk of congenital disorders including CF, but 
there are no accurate epidemiological data on CF. The general impression has been 
that the disease is rare, but this is most likely the result of under-diagnosis or 
misdiagnosis due to limited awareness of the condition in the region.  
In Palestine, the only studies published discussed the disease and the mutation causing 
it. As the mutation of the disease in the Cystic Fibrosis Transmembrane Conductance 
Regulator gene (CFTR) that contributes to the clinical presentation of CF are ill 
defined. Two studies have been done to determine these mutation one of them was 
from September 2011 until November 2012, Caritas Baby Hospital (CBH) personnel 
conducted it to determine the CFTR mutations in a Palestinian cohort affected with 
CF. A total of thirty three patients from twenty one different families residing in the 
central and southern part of Palestine with the exception to Gaza district were 
incorporated in this study. Nine different CFTR mutations were identified, c.1393-
1G>A, appeared to be the most common (28.6%), followed by F508del (19%) and 
W1282 (14.3%) in the cohort of Palestinian families evaluated in West Bank only 
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[26]. Unlike other countries where F508del is the most common mutation, c.1393-
1G>A is the most occurring CFTR mutation among a cohort of Palestinians affected 
by CF despite the fact that this mutation is infrequent in the neighboring countries, 
and considered rare worldwide [26].   
Another broader study was in Clinical Laboratory Science, Birzeit University 
published on December 2014 [27]. Samples from 60 unrelated CF patients residing in 
the West Bank and Gaza were collected and their respective CF mutations were 
determined. Eighteen different CF-causing mutations were identified. Although most 
mutations are rare, the three-base-pair deletion p.(Phe508del) is most common (35% 
of the positive cases). mutations c.1393-1G>A, p.(Gly85Glu), p.(Trp1282X), and 
p.(Asn1303Lys) were only present among Palestinians in the West Bank, while 
mutations p.(Lys684Serfs∗38) and c.1585-1G>A were only present among 
Palestinians residing in Gaza. Interestingly, the p.(Phe508del) mutation was primarily 
prevalent among patients living in Gaza (68%) as compared to patients in the West 
Bank (32%) [27]. 
Unfortunately, all of the mutations observed and studied in our CF patients are not 
mentioned in approved mutations for CFTR genetic treatment options as Ivacaftor 
(Kalydeco
®
) drug until now. 
 
Status in Gaza 
A project was established by Dr. Mahmoud Shamaly to manage CF resources poor 
settings in Gaza resulted on the following data [42]:  
"After yearlong training period, a CF center was opened in Gaza. A database was 
established to register all known CF patients.  They are currently aware of 80 patients 
with CF in the Gaza strip.  Based on population projections, it is estimated that there 
are between 140-321 patients with CF in Gaza, a large number of which have not 
been diagnosed and others whom have died of CF complications without an 
established diagnosis. Limited resources under the current government continue to be 
problematic. Medications are still in short supply and are available mainly by private 
donations. Prior to the arrival of the trained CF team, the medical staff frequently 
dosed those medications that were available such as pancreatic enzymes incorrectly.  
Trained personnel are still unable to provide physiotherapy to many patients.  
Appropriate and effective inhalation machines are not available and have been 
replaced by cheaper, less efficient units. Hypertonic Saline is the standard 
mucolytic/secretion clearance treatment. Families commonly prepare this at home by 
mixing 15% Hypertonic Saline with 0.9% Normal Saline.  Inhaled antibiotics such as 
TOBI are not available and are replaced by inhalation of intravenous solutions such as 
Gentamicin. Nutritional supplements are rarely available and again, only by private 
donation. Food enrichment is done by families by mixing cereal with oil.  Appropriate 
next steps in the evolution of the CF program in Gaza are to work with health 
authorities to understand the importance of providing basic therapies to patients".  
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5. Role of pharmacist in CF disease  
Pharmacotherapy has long been the cornerstone of effective treatment for cystic 
fibrosis. To a growing extent, pharmacists become involved in developing formularies 
for CF care and in supporting disease management pathways for CF. Pharmacists play 
a unique role in managing complex pharmacotherapy regimens around unique 
pharmacokinetic profiles. Novel formulations of medications and unusual sites of 
administration make a pharmacist a central provider of proper CF care. The document 
specifically cites that a dedicated CF clinical pharmacist reduces medication errors 
and increases availability of medications [14].  
The European Cystic Fibrosis Society (ECFS) Cystic Fibrosis Centre, describes the 
CF Clinical Pharmacist as pivotal to the medicines management program to support 
the optimization of medicines for patients, and describes the role of the CF clinical 
pharmacist [43].   
Common roles and responsibilities of the pharmacist:  
 Managing formularies, clinical guidelines and treatment protocols. 
 Medication reconciliation/history taking. 
 Prescription monitoring and medication review service. 
 Identifying patient and medication risk factors. 
 Preventing, detecting and reporting adverse drug reactions. 
 Individualizing drug and dosage requirements. 
 Educating and counseling patients and cares.  
 Evaluating medicine use and assess patient compliance. 
 Order and evaluate appropriate laboratory tests. 
 Pharmacists today intend to collaborate with doctors to develop treatment 
algorithms and evidence based guidelines for drug classes and disease states as 
well as to write monographs describing the use of specific agents. 
The benefits of a dedicated CF pharmacist have been described, including benefits in 
terms of financial savings, improvements in patient care, adherence and efficient use 
of resources as they may use prescription records in order to provide information for 
improving quality of treatment and to ameliorate patient satisfaction [44]. 
 
Off-label use of medicines   
During the clinical care of people with CF, there is often a need to use medicines 
outside of their product license. A new medicine, for example, may not have been 
subject to the rigorous trials necessary to gain a pediatric product license; or it may be 
necessary to manipulate a formulation so that it can be administered via an unlicensed 
route, such as nebulization of an intravenous drug formulation. Although off-label use 
of medicines is not routinely recommended, it is often necessary in the CF population 
due to the complexities of the disease, and heterogeneity of the complications 
encountered. The CF pharmacist will be involved in ensuring these medicines are used 
in the most safe and effective way and can apply pharmacokinetic and 
pharmacodynamics principles to determine appropriate dosing [43]. 
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Chapter 3: Method 
 
Design 
  
This was a descriptive narrative study for patients with cystic fibrosis who visited the 
pediatric pulmonologist clinic of Caritas Baby Hospital from January 2017 until May 
2017. Participants completed four quantitative assessment measures and provided 
demographic information. The patients’ routine medication was not altered during the 
study. According to Caritas Baby Hospital records and files there is around 86 
patients from West Bank suffered from cystic fibrosis disease.   
 
Participants 
 
Participants were recruited through their normal routine visit to the clinic or by 
contact with them to come to the clinic. A total of seventy seven eligible participants 
from fifty eight different families residing in the northern, central and southern part of 
Palestine with the exception to Gaza district consented to take part in the study. 
Questionnaires were fully completed by all participants and calculations were carried 
out to establish the size of correlation which could be confidently detected for a 
sample size of 77. The majority of the families 38 (65.52%) came from Hebron 
district, followed by 5 (8.62%) from Jenin district, 4 (6.89%) from Nablus, 4 (6.89%) 
from Bethlehem district, 4 (6.89%) from Ramallah district, 1 (1.73%) from Jerusalem 
district, 1 (1.73%) from Tulkarem district and 1 (1.73%) from Qalqilia district. 
Potential participants and their parents were approached during routine clinic visits 
while waiting for their appointments. 
 
Inclusion and exclusion criteria:  
 
Patients were included in the study if they met the following criteria: a proven clinical 
diagnosis of CF as evidenced by a positive sweat test or the presence of two known 
CF mutations; which confirmed by a pediatric pulmonologist doctor based on their 
clinical manifestations. The principal inclusion criteria were:  
1. The caregiver must have a child diagnosed with CF. 
2. The diagnosis of CF must have been made by specialist doctor.   
3. The caregiver must have a reasonable understanding of the study, understand what 
is involved of them and be competent enough to refuse participation.  
Participants were excluded from the study if their Caregivers or children have 
physical or mental disabilities which prohibit them from participating in the study 
successfully. But in our study we don't exclude any family member diagnosed with 
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CF disease. There were other CF patients that Caritas was aware of, but three of them 
refused to participate as they do not acknowledge the existence of the disease and 
three others cannot be reached because they traveled to other countries for treatment.   
 
Procedure 
 
After recruiting and screening participants and standardized the study protocol, we 
interviewed family that came to the clinic, administered consent forms, and instructed 
to administer questionnaires to both children and their parents. The protocol and 
consent forms were approved by the ethical review board at the hospital. 
The CFQ-R versions were administered to all patients. Parents of participants were 
asked to complete a demographics, health status, socioeconomic burden, willing to 
pay questionnaire and the CFQ-Parent version, a proxy measure of HRQoL for 
children with CF. After completion the versions of the CFQ and all questionnaires, 
pulmonary functioning tests, BMI (weight/length percentile) and physical exams were 
conducted to assess health status. We confirmed the data by reviewing the medical 
charts and files for each patient. 
We contacted Dr. Alexandra L. Quittner professor and director in Department of 
Pediatrics and Otolaryngology, Head & Neck Surgery, University of Miami/School of 
Medicine, Miami, Florida to get the international data for QoL to compare it with our 
result and to demonstrate the status of our CF patients. 
 
Measures 
 
1. Cystic Fibrosis Questionnaire – Revised (CFQ-R) 
 
In this study Cystic Fibrosis Questionnaire-Revised a Health Survey was used to find 
the QoL of CF patients. CFQ-R is a disease-specific health-related qualify of life 
(HRQoL) measure for children, adolescents and adults with cystic fibrosis (CF). It is a 
profile measure of HRQoL with several different domains. It was initially developed 
through focus groups and interviews with CF patients and health care professionals 
and has undergone extensive reliability and validity testing [45]. It is one of the most 
widely used HRQoL measures for CF and was judged as "well-established" in a 
review of evidence-based measures. It is being used in the United States and 
internationally in a number of clinical trials. It is also used clinically during routine 
CF care. 
The CFQ-R has been translated into several languages including Arabic-Israel is the 
one we used in this study without any modification. Linguistic validation has been 
conducted with input from Dr. Alexandra Quittner [45].   
 
There are 4 versions of the CFQ-R currently available we used in this study: 
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 Teen/Adult version (≥14 years).  
 Child version with two formats  
- Interviewer-administered format for 6-11 years  
- Self-report format for 12-13 years 
 Parent version for children 6-13 years. 
 Preschool version for ages less than 6 years [46, 47].  
Cystic Fibrosis Questionnaire–adult Version 
CFQ-Teen/Adult for ages ≥ 14 years (self-report) contains 50-items within twelve 
domains [48]. Which include Physical functioning; this part contains questions such 
as climbing stairs, kneeling and walking, Role limitations; limitations because of 
physical functioning, Vitality,  Emotional functioning, Social functioning; this part 
contains questions about the effect of physical and emotional health on social life, 
Body image, Eating disturbances, Treatment burden, Health perceptions, Weight 
problems, Respiratory symptoms, Digestive symptoms.  
CFQ-R subscales items of physical functioning (eight items), emotional functioning 
(five items), role functioning (four items), social functioning (six items), vitality 
functioning (four items), body (three items), eat (three items), treat (three items), 
health (three items), weight (one item), respiratory (seven items) and digest (three 
items) were rated on a four-point Likert scale. A standardized score ranging between 
0 – 100 is obtained for each subscale, with higher scores indicating better functioning. 
 
Cystic Fibrosis Questionnaire–Child Version. The CFQ-Child is a disease-specific 
HRQoL measure for children with CF between the ages of 6 and 13 [49]. Two format 
of the CFQ-Child were established: an interviewer-administered format for children   
6 –11 years of age and a self-report format for 12 –13 year olds. The CFQ-Child is a 
35-items instrument that assesses multiple domains of HRQoL. This questionnaire 
includes three broad domains of HRQoL, including Physical Symptoms (6 items), 
Emotional Functioning (8 items), and Social Functioning (7 items). The CFQ-Child 
also assesses five domains specific to CF, which include Body Image (3 items), 
Eating Disturbances (3 items), Treatment Burden (3 items), Respiratory Symptoms   
(4 items), and Digestive Symptoms (1 item). Nineteen items required a true or false 
rating on a 4-point scale ranging from not at all true to very true. Sixteen items 
required a frequency response ranging from always to never on a 4-point scale. The 
CFQ-Child took approximately 15 minutes to complete. Raw scores for each of the 
eight scales were converted into standardized scores (0-100), with higher scores 
representing better HRQoL. 
 
Cystic Fibrosis Questionnaire–Parent Version. The CFQ-Parent is a measure of the 
parent’s report of their child’s HRQoL for children aged 6 to 13 [48, 49]. It is a 44-
item self-report measure that assesses four broad domains: Physical Symptoms (8 
items), Emotional Functioning (5 items), Vitality (5 items), and School Functioning (4 
items); and seven CF specific domains: Eating Disturbances (2 items), Body Image (3 
items), Treatment Burden (3 items), Respiratory Symptoms (7 items), Digestive 
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Symptoms (3 items), and Weight (1 item), along with an overall Health Perception 
scale (3 items). The CFQ-Parent took approximately 15 – 20 minutes to complete. 
Raw scores were converted into standardized scores (0 –100) for each of the 11 
scales, with higher scores indicating better HRQoL. 
 
2. Health status and Socio-economic sheet 
The health profile and Socio-economic information sheet covered the following areas 
of interest: 
  
a. Current used medication and influenza vaccine.  
b. Forced expiratory volume in one second as a percent of predicted (FEV1%). 
Health Status/Spirometry. Pulmonary function tests are the gold standard for 
measuring respiratory functioning and lung damage for individuals with CF. Illness 
severity ratings are based on established cutoffs for mild (≥ 70%), moderate (40–
69%), and severe (≤ 39%) disease [50]. 
 
c. Body mass index (weight/length percentile for ages less than 2 years). This 
measure used as a reflection of growth. 
 
These values (FEV1% and BMI) were both included as measures of health 
status and were taken from the last clinical visit. 
 
d. Patient's knowledge about his disease.  
e. Age at CF diagnosis.  
f. Number of deaths per family we interviewed. 
g. Income status.  
h. Address and any external help. 
i. Health related economical end point:  
     Total health care resources use and cost. 
 
j. The third part contained themes asked about financial situation, support, 
patients believes about management strategies and mechanism of treatment, 
and asked about the effect of disease burden on social life. They were graded 
on a scale of 1-4 (1= never, 2= sometimes, 3= often, 4= always).   
 
3. Willingness to Pay (WTP) section  
Willingness to pay (WTP) survey was used in this study to examine the patient's 
preference for the new treatment options and their willingness to pay for them. 
WTP is the maximum amount of money that the individual would pay to get the 
benefits of a service or intervention. WTP will be different between patients 
depending on the preferences and income. In order for healthcare decision makers to 
determine to reimburse a certain intervention or treatment the incremental benefits are 
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found, the incremental benefits are the sum that each patient is willing to pay; if the 
incremental benefits are higher than the incremental costs then the treatment is 
preferred [51].   
WTP questions are either closed-ended question, in which the patients are asked if 
they would pay a specific amount of money for the health service, the answer will be 
yes or no, or open ended question, in which the patients can be asked what is the 
maximum amount they are willing to pay or a payment scale can be used, in which 
the patients are presented with a scale of possible WTP values [52].   
In this study, we asked about their willingness to pay for new therapies with yes or no 
answer and a payment scale was used in order to ask about the amount of money they 
are willing to pay for the new medication if they answered yes to first question. Then 
we asked about the most important factors they want to achieve through their 
contribution to payment.     
The health status, Socio-economic and willingness to pay parts of the questionnaire 
translated into Arabic and validated by two experts in clinical research. 
Data analysis  
The Statistical Package for the Social Sciences, version 22.0 (SPSS) was used for data 
processing. The scores are expressed as means and standard deviations. The Mann-
Whitney test was used for comparing two groups, whereas the Kruskal-Wallis test 
was used for comparing more than two groups. Pearson correlation coefficients (r) 
were calculated between CFQ-R scores and clinical outcomes such as BMI, The level 
of significance was set at p<0.05. The data from health status, socioeconomic and 
WTP questionnaires were analyzed using SPSS program. Descriptive statistics (means 
and standard deviations) were used to characterize the demographic variables. 
Patient oriented outcomes measured included change in different area specificity 
respiratory symptoms measured by the Cystic Fibrosis Questionnaire-Revised where 
points ranged from 0-100 and increasing scores indicated improvement of symptoms. 
CFQ-Child data for ages 6–11 and 12–13 years were combined because they contain 
the same questions. We assessed parent-child reporting concordance by including 
indicators for parent versus child report, CFQ-Child versus CFQ-Teen/Adult version, 
and their interaction in the model. We calculated to determine the relationship 
between health status (FEV1 % predicted and BMI) and CFQ-R scaled scores 
(predictive validity). Next, correlations were conducted to examine demographic data 
differences in the HRQoL score. And a comparison between the QoL international 
data and our QoL score was done.   
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Ethical consideration 
This study was approved by Caritas Baby Hospital (CBH) Medical Research 
Committee/Ethical Review Board (approval number: MRC-21). Written informed 
consents were obtained from the patients and parents (father or mother) of the 
children involved in this study. All signed informed consent forms were deposited in 
the patient's hospital medical chart. 
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Chapter 4: Results 
Part one  
Descriptive statistics 
1.1Demographic characteristics 
A total of 77 cystic fibrosis patients (58 families) have participated in this study. 
There were 46.75 % (36/77) male patients and 53.25 % (41/77) females. The patients 
were divided into groups by age: those < 6 years of age (CFQ<6), ≥ 6 and < 12 years 
of age (CFQ6-11 group); those ≥ 12 and < 14 years of age (CFQ12-13 group); and those 
≥ 14 years of age (CFQ14+ group). Table (5) shows the distribution of the data for 
cystic fibrosis patients and table (6) for their parents. The mean age of the patients 
was 10.7 years (range: 0.5-36 years). Most of the patients were children (6-13 years 
old) as shown. The patients were distributed throughout the different regions of the 
West Bank, as shown in Table (7). 
Table (5): Demographic data distribution for Cystic fibrosis 
 
Characteristic 
 
                                Group 
 CFQ<6               CFQ6-11    CFQ12-13    CFQ14+     
                           n (24)        n (9)           
      n (22)                   n (33)              n (22)                            
      Age (mean/SD) 3.159 (1.475) 9.21 (2.118) 19.36 (5.77) 
      Gender 
Male/Female, n/n % 
 
 
     11/11      
(50% / 50%) 
          
        12/21     
(36.4% / 63.6%)  
 
 
       13/9          
(59.1%/40.9%)                
         
       Vacation not related to disease 
                                           Yes 
                                            No  
 
 
 
 
 
22 (100%) 
 
 
8 (24.2%) 
25 (75.8%) 
 
 
 
 
9 (40.9%) 
13 (59.1%) 
        Marital status 
                      Single 
                      Married 
 
   22 (100%) 
 
 
33 (100%) 
 
 
20 (90.9%) 
2 (9.1%) 
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             Education  
- Some high school or less 
-  High school diploma/GED 
- College degree 
- Professional or graduate degree 
 
9 (40.9%) 
 
 
 
 
33 (100%) 
 
 
 
 
15 (68.2%) 
2 (9.1%) 
4 (18.2%) 
1 (4.5%) 
    Current work or school status 
- Attending school outside the home 
- Taking educational courses at home 
- Seeking work 
- Working full or part time (either  outside 
the home or at a home-based business) 
- Not attending school or working due to 
my health. 
 
9 (40.9%) 
 
 
 
 
 
 
33 (100%) 
 
 
 
 
 
 
12 ( 54.5%) 
1 (4.5%) 
1 (4.5%) 
5 (22.7%) 
 
3 (13.6%) 
            Monthly income (NIS) 
o   < 1500  
o   1500-3000 
o    3001-5000 
o    > 5000 
 
6 (27.3%) 
15 (68.2%) 
1 (4.5%) 
 
 
11 (33.3%) 
19 (57.6%) 
3  (9.1%) 
 
 
3 (13.6%) 
17 (77.3%) 
2 (9.1%) 
 
CFQ: Cystic Fibrosis Questionnaire; CFQ6-11: patients ≥ 6 and < 12 years of age; CFQ12-13: patients ≥ 
12 and < 14 years of age; and CFQ14+: patients ≥ 14 years of age and n: number of patients. SD: 
standard deviation. Values expressed as frequency and percent. 
 
- Parent's demographic data:  
Demographic data for parents of CF child 6-13 years of age and children less than 
6 years of age were determined as following.                                                       
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Table (6): Demographic data distribution for parents 
        SD: standard deviation; CFQ: Cystic Fibrosis Questionnaire; CFQ6-11: patients ≥ 6 and < 12 years      
of   age; CFQ<6: patients < 6 years of age and n: number of patients. Values expressed as frequency and 
percent.                        
 
 
 
 
Characteristic 
 
Parent's group 
        CFQ <6                   CFQ 6-13 
         n(22)                       n(33) 
Age (mean/SD) 29.27 (6.356) 
 
Parents of CFQ <6              
34.67 (7.326) 
 
Parents of CFQ 6-13 
      Family relationship with patients 
                     Mother 
                     Father 
                 Grandfather 
                     Other  
 
22 (100%) 
 
 
 
28 (84.8%) 
 
3 (9.1%) 
 
         1 (3%) 
 
         1 (3%) 
     Vacation not related to disease 
                          Yes 
                           No 
 
 
22 (100%) 
 
11 (33.3%) 
22 (66.7%) 
      Marital status 
                 Married 
                Divorced 
 
22 (100%) 
 
 
31 (93.9%) 
2 (6.1%) 
    Education 
- Some high school or less 
- High school diploma/GED 
- Some college 
- College degree  
 
9 (40.9%) 
8 (36.4%) 
4 (18.2%) 
1 (4.5%) 
 
17 (51.5%) 
9 (27.3%) 
        3 (9.1%) 
4 (12.1%) 
         Work status  
- Seeking Work 
- Working full or part time (either outside the 
home or at a home-based business) 
- Full time homemaker 
- Not working due to my health 
- Not working for other reasons 
 
1 (4.5%) 
 
 
20 (90.9%) 
 
1 (4.5%) 
 
        1 (3%) 
9 (27.3%) 
 
 22 (66.7%) 
        1 (3%) 
31 
 
Table (7): Geographical Distribution of the participants 
 
City 
 
Number of  
patients 
 
Number of families 
Jerusalem 
Bethlehem 
Hebron 
Ramallah 
Nablus 
Jenin 
Qalqilia 
Tulkarem 
      1     (1.3%) 
     6     (7.8%) 
      50   (64.9%) 
    5     (6.5%) 
    7     (9.1%) 
    6    (7.8%) 
   1    (1.3%) 
   1    (1.3%) 
1 
4 
38 
4 
4 
5 
1 
1 
Total         77   (100%) 58 
Cystic Fibrosis Questionnaire-Revised 
Quality of life dimensions were assessed using Likert scales and scores were 
standardized from 0 to 100, with higher scores indicating better HRQoL. Scores 
above 50 are considered to reflect good QoL.  
All participants completed the questionnaires without any problems. And the result 
was determined in Table (8). In the CFQ14+ group, the mean scores ranged from 20.2 
for the treatment domain to 55.6 for eat domain. The lowest mean score was for 
question 10 'You felt energetic?' with a value of 13.6 for vitality domain. And the 
highest score was for question 25 'I think I look different from others my age?' with  a 
value of 83.3 for body domain. 
Table (8): Descriptive Statistics of  the score for CFQ14+ group  
 N Minimum Maximum Mean Std. Deviation 
Physical 22 .00 91.67 31.0614 24.42242 
Vitality 22 .00 91.67 28.4095 22.95386 
Emotion 22 6.67 100.00 47.2727 24.85114 
Eat 22 11.11 100.00 55.5568 22.48673 
Treatment 22 .00 66.67 20.2005 17.69651 
Health 22 .00 100.00 26.7664 23.67253 
Social 22 11.11 66.67 44.9486 12.70508 
Body 22 .00 88.89 22.7268 27.32017 
Role 22 .00 91.67 40.1527 21.76737 
Weight 22 .00 100.00 22.7264 27.95759 
Respiratory 22 .00 77.78 28.2832 22.73846 
Digest 22 .00 100.00 39.8986 28.20616 
Valid N (list wise) 22     
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In the CFQ6-13 group Table (9), the mean scores ranged from 14.48 for the body 
domain to 48.23 for the emotion domain. The lowest mean score was for question 30 
'Doing your treatments bothered you?' with a value of 9.09 for treatment domain and 
the highest score was for question 23 'You felt left out?' with a value of 91.92 for 
social domain. 
Table (9): Descriptive statistics of  the score for CFQ6-13 group 
 N Minimum Maximum Mean Std. Deviation 
Physical 33 .00 72.22 26.4310 19.59418 
Emotion 33 12.50 87.50 48.2323 15.13217 
Social 33 28.57 61.90 45.4545 9.22837 
Eat 33 .00 100.00 46.1279 26.94891 
Treatment 33 .00 55.56 17.5084 13.61686 
Body 33 .00 55.56 14.4781 17.67436 
Respiratory 33 .00 66.67 27.5253 19.92661 
Digest 33 .00 66.67 23.2323 26.98360 
Valid N (list wise) 33     
 
In the CFQ<6 parent version Table (10), the mean scores ranged from 25.76 for the 
weight domain to 59.26 for the school domain. The lowest mean score was for 
question 30 'My child spends a lot of time on his/her treatments every day?' with a 
value of 15.15 for treatment domain and the highest score for question 14 'The extent 
to which your child participated in sports and other physical activities, such as gym 
class?' with a value of 90.91 for physical domain. 
Table (10): Descriptive statistics of the score for CFQ<6 group 
 N Minimum Maximum Mean Std. Deviation 
Physical 21 16.67 83.33 49.7222 18.22569 
Emotion 22 13.33 73.33 50.0000 14.94257 
Vitality 22 13.33 60.00 36.9697 16.55228 
School 9 41.67 83.33 59.2593 15.27778 
Eat 22 .00 100.00 43.1818 28.94032 
Body 22 .00 100.00 32.8283 30.76093 
Treatment 22 11.11 66.67 38.3838 14.83885 
Health 22 22.22 66.67 41.4141 13.79356 
Respiratory 22 19.05 85.71 42.2078 14.49547 
Digest 22 .00 100.00 39.3939 30.61726 
Weight 22 .00 66.67 25.7576 28.97147 
Valid N (list wise) 9     
 
Table (11) shows the data regarding the questionnaire completed by the parents for 
children 6-13 years of age. In the CFQ Parents 6-13 the mean scores ranged from 14.8 for 
the body domain to 51.1 in eat domain. The lowest was mean score for question 21 
'My child thinks that he/she is too thin?' is 11.1for body domain and the highest score 
was for question 31 'How difficult is it for your child to do his/her treatments each 
day?' with a value of 73.7374  for treatment domain.  
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Table (11): Descriptive statistics of the score for CFQ Parents 6-13 group 
 N Minimum Maximum Mean Std. Deviation 
Physical 33 12.50 83.33 37.6263 14.30102 
Emotion 33 6.67 93.33 45.8586 22.09560 
Vitality 33 .00 73.33 33.9394 21.94460 
School 33 .00 91.67 45.9596 22.44991 
Eat 33 .00 100.00 51.0101 28.54680 
Body 33 .00 44.44 14.8148 16.35511 
Treatment 33 22.22 55.56 41.4141 8.45865 
Health 33 22.22 77.78 46.1279 15.24522 
Respiratory 33 9.52 61.90 31.7460 14.41738 
Digest 33 .00 77.78 30.6397 22.05323 
Weight 33 .00 100.00 15.1515 23.70377 
Valid N (list wise) 33     
 
Health profile section 
After screening the outpatient medication all patients took Vitamin A&D (Adol
®
) 
drops, Tocopherol (Evitol
®
)
 
tablet, Vitamin K 2mg ampoule, Hypertonic saline      
(3%, 7%) solution, Creon 10000 IU tablet, Salbutamol 5mg/ml (Ventolin
®
) nebulized 
solution, Gentamycin 80 mg ampoule (every other month) and other oral antibiotic.   
Pulmonary function test (FEV1) 
Illness severity as measured by FEV1 for only 26 patients, ranged from 33 to 111 
percent predicted with mean value of 69.6, the majority of patients (53.8% from the 
available data) fell into the moderate category (40≤ FEV1<70% predicted). Of the 26 
patients evaluated, 2 patients had an FEV1 < 40% of predicted (mean = 36), 14 
patients had 40≤ FEV1<70% (mean = 61.3), 10 patients had FEV11≥70 (mean = 88). 
Table 12 shows the spirometry data results by group. 
Table (12): Distribution of the spirometry values in cystic fibrosis patients, by group 
Parameter 
                      
       FEV1 
               Group 
      CFQ14+           CFQ6-13                        
                
Total sample a 
 
Mean 
of FEV1 n (=22)           n (=33)         n (=77) 
FEV1 ≥ 70    2 (9.1%)           8 (24.2%) 
 
     10 (13%) 
 
88 
 
70 > FEV1 ≥ 40    9 (40.9%)         5 (15.2%) 
 
14 (18.2%) 
 
61.3 
 
 FEV1 < 40    2 (9.1%)                  
 
2 (2.6%) 
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      NA    9 (40.9%)        20 (60.6%) 51 (66.2%)
a  
      Values expressed as frequency and percent. CFQ: Cystic Fibrosis Questionnaire; CFQ6-13: patients 
≥ 6 and < 14 years of age; and CFQ14+: patients ≥ 14 years of age. n: number of patients and NA: not 
available. a: 22 patients in the CFQ<6 group did not undergo spirometry test.   
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Body mass index (Kg/m
2
) and Weight/Length percentile. 
BMI recorded for 72 patients sample with mean value 15.998 ranged from 9.60-
23.12.  
Table (13): BMI results 
Group N Minimum Maximum Mean Std. Deviation 
CFQ14+  22 14.00 23.12 18.3118      2.48902 
CFQ6-13                        33 9.60 16.70 14.4185      1.40554 
CFQ<6  17    13.29      20.9  16.0688       1.79721 
Total sample a                          
(N = 77) 
72 9.60 23.12 15.9978 2.50407 
          CFQ: Cystic Fibrosis Questionnaire; CFQ6-13: patients ≥ 6 and < 14 years of age; and CFQ14+:    
patients ≥ 14 years of age and CFQ<6 patients < 6 years of age. N: number of patients; a: five patients 
less than 2 years cannot measured BMI and have weight/length percentile. 
There were five patients that were less than 2 years of age, we used weight per length 
percentile to measure their health status. Their percentile's result were less than 5
th 
% 
so they in sever status (2.9kg/51cm, 9.7kg/79cm, 9kg/75cm, 11kg/88cm, 
2.65kg/49cm). 
 
Patients' knowledge and consultation about CF disease was screened with result in 
table below: 92.2% of patients have knowledge about the disease from Caritas Baby 
Hospital lectures (Table 14). 
          Table 14: Patients' knowledge and consultation about CF disease 
 
  
 
 
 
Age at CF diagnosis is determined in Table 15 with the overall mean age of diagnosis 
for CF patients in our sample is 4.16 years of age. 
Knowledge 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid No 6 7.8 7.8 7.8 
Yes 71 92.2 92.2 100.0 
Total 77 100.0 100.0  
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Table 15: Age at time of diagnosis (years) 
Group N Minimum Maximum Mean Std. Deviation 
CFQ14+ 
22 1 30 9.68 9.068 
CFQ6-13                        
33 1 11 2.48        2.874 
CFQ<6  22 <1        2     1.14       0.3513 
Total sample                          
(N = 77) 
77 <1 30 4.16 6.239 
                 
Socio-economic status section; 
Table (16): Different parameter for CF patients  
Parameter N Minimum Maximum Mean Std. Deviation 
Number of Family member 
77 2 18 6.18 2.018 
Total number of people live in the 
same place                     
77 2 18 6.21 2.325 
CF patients in each family 77 1        4  1.6         0.845 
Number of death related to CF 
disease 
77 0 4 0.364 0.742 
 
 74.1% of families have one patient suffer from CF disease, 20.7% having two 
patients, 3.5% having three patients and 1.7% have four patients as determined below  
(Table 17): Number of CF patients in each family 
 
 
 19.5% of patients have one case of death due to CF disease, 3.9% having two 
case of death, 1.3% having three case of death and 1.3 have four cases as 
described below 
Number of CF patients in 
each family Frequency Percent Valid Percent Cumulative Percent 
Valid 1 43 74.1 74.1 74.1 
2 12 20.7 20.7 94.8 
3 2 3.5 3.5 98.3 
4 1 1.7 1.7 100.0 
Total 58 100.0 100.0  
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(Table 18): Death cases due to CF disease 
  CF  
Death cases  Frequency Percent Valid Percent Cumulative Percent 
Valid 0 57 74.0 74.0 74.0 
1 15 19.5 19.5 93.5 
2 3 3.9 3.9 97.4 
3 1 1.3 1.3 98.7 
4 1 1.3 1.3 100.0 
Total 77 100.0 100.0  
 
 29.9% of patients live in cities, 61% live in villages and 9.1% live in camps as 
described below. 
 (Table 19): Place of living 
 
Place of living Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid City 23 29.9 29.9 29.9 
Village 47 61.0 61.0 90.9 
Camp 7 9.1 9.1 100.0 
Total 77 100.0 100.0  
 
 89.6% of patients have property house and 10.4 have a rented house as 
described below. 
 (Table 20): Type of housing 
 
Type of housing 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Property 69 89.6 89.6 89.6 
Rent 8 10.4 10.4 100.0 
Total 77 100.0 100.0  
 
(Table 21): Transportation cost (NIS) 
Mean average traveler cost to receive care is 81.033 NIS 
 
N Minimum Maximum Mean 
Standard 
Deviation 
Transportation cost (NIS) 
Valid N (list wise)  
77 
77 
6.00 500.00 81.033 108.36137 
 
 Average monthly income of the families (66.2%) between 1500-3000 NIS, 
26% less than 1500 NIS and 7.8% between 3001-5000 NIS  
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       (Table 22): Monthly income 
 
Monthly income 
Frequency Percent Valid Percent Cumulative Percent 
Valid 1500> 20 26.0 26.0 26.0 
1500-3000 51 66.2 66.2 92.2 
3001-5000 6 7.8 7.8 100.0 
Total 77 100.0 100.0  
 NIS; new Israel shekel 
 Only 3.9% of CF patients have an external support from social affairs and 
children's village SOS (save our souls or selves) organization as described below. 
          Table 23: External support for CF cases          
 
External support Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid No 74 96.1 96.1 96.1 
Yes 3 3.9 3.9 100.0 
Total 77 100.0 100.0  
 
1.3 Health related economic endpoint section  
Table (24): Economic endpoint 
Health care resources N Minimum Maximum Mean Std. Deviation 
      
1. Monthly use of nebulized antibiotics per year. 
2. Hospital admission per year.  
77 
 
77 
 
         0 
 
0 
12 
 
15 
5.58 
 
2.99 
3.833 
 
2.458 
3. Total inpatient days receiving  parenteral 
antibiotic in hospital. 
77 0 21 7.51 6.752 
4. Out patients visits  
(no. of clinic visits per year). 
 
77 1 12 3.52 3.633 
5.  Number of times doing sputum culture test 
yearly.   
77 4 6 4.39 2.537 
6. Number of times doing blood tests yearly. 77 1 2 1.16 .365 
7. Number of times doing radiology exams 
yearly.  
 
77 1 2 1.04 .195 
8. Monthly productivity loss 
(No. of days at home due to CF illness per 
month a). 
64 1 30 4.88 6.909 
       Valid N (list wise)a 64     
a: thirteen patient under 6 years of age who don't enter school or kindergarten,                           
N: number of patients. 
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 53.2% of CF patients take influenza vaccine yearly as described below.   
       (Table 25): Influenza vaccine 
Influenza vaccine 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 41 53.2 53.2 53.2 
 No 36 46.8 46.8 100.0 
Total 77 100.0 100.0  
 
 7.8% of CF patients take drugs for treatment of other diseases. Such as Thyroxine 
(Eltroxin®) tablets, Ursolit® tablets (Ursodeoxycholic acid), Omega-3, Diabetic 
insulin pens, Growth hormone, Triple therapy for peptic ulcer disease and 
Normalax® Polyethylene glycol 3350 powder for oral solution for treatment of 
constipation.  
 Table (26): Drugs used by CF patients for other diseases 
 
Other drugs Frequency Percent Valid Percent Cumulative Percent 
Valid No 71 92.2 92.2 92.2 
 Yes 6 7.8 7.8 100.0 
Total 77 100.0 100.0  
 
 The themes asked about financial situation, support, patients believes about 
management strategies and mechanism of treatment, and asked about the effect of 
disease burden on social life, results are demonstrated as following 
a
.  
(Table 27): Themes  
    
Items a 
 
Themes 
 
 
Always   Often   Sometimes   Never  
Are you thinking about your financial 
situation? 
 
Financial situation 
 
88.3% 
 
9.1% 
 
2.6% 
 
0% 
Do you have confidence that your treatment 
will be available at all times? 
Support and occupation  
0% 
 
13% 
 
20.8% 
 
66.2% 
Are you satisfied with your access to health 
services? 
Mechanism of treatment 5.2% 9.1% 19.5% 66.2% 
Does the treatment currently used affect your 
social life? 
Mechanism of treatment 51.9% 22.1% 23.4% 2.6% 
Do you have sufficient financial resources for 
treatment? 
Financial situation  0% 2.6% 28.6% 68.8% 
Do you think your current treatment needs to 
be changed? 
Mechanism of treatment 79.2% 15.6% 3.9% 1.3% 
a: The data determined by percent of total number of patients 77.  
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 Willingness to pay (WTP) section 
When we told CF families to assume that inhaled TOBI
®
 or CASTON
®
 and 
Pulmozyme
®
 are a new medications that are available for reducing disease symptom 
and improving general health in different ways. Keeping in mind their income and 
household budget, would they have a willingness to pay out of pocket each month to 
get these new drugs?, 93.5% said yes and 6.5% said no. (the five families said no one 
of them from adult (14+) group; two from 6-13 group and two from group less than 6 
years of age).   
               Table (28): Willingness to pay answers. 
WTP 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 72 93.5 93.5 93.5 
 No 5 6.5 6.5 100.0 
Total 77 100.0 100.0  
 
 51.4% of patients are willing to pay 100 NIS out of pocket each month to get 
these new drugs, 37.5% are able to pay 50 NIS, 8.3% able to pay 500 NIS and 
2.7% able to pay 2000 NIS or more to get these new drugs.  
       (Table 29): Money to pay each month (NIS)  
Money to pay each month 
(NIS) Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid    50 27 35.1 37.5 37.5 
100 37 48.1 51.4 88.9 
500 6 7.8 8.3 97.2 
2000 or more 2 2.6 2.8 100.0 
Total 72 93.5 100.0  
Missing System 5 6.5   
Total 77 100.0   
           NIS: new Israel shekel.   
 When we asked about the important things they are willing to pay for, the results 
as following:  
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     (Table 30):The important things they are willing to pay for  
 
 Characteristic Items   Yes        No   Na 
1 Providing new medicines reduce 
disease symptom and improve general 
health in different ways. 
General health 
status 
 
 
98.6%        
(71) 
 
1.4%  
(1) 
 
72 
2 Facilitate the mechanism of treatment 
by providing modern equipment for 
treatment. 
 
 
Mechanism of 
treatment and 
time 
 
100% 
(72) 
 
 
 
 
72 
3 Minimize the time it takes to receive 
the treatment by nebulizer. 
100% 
(72) 
 72 
4 Reduce monthly health related costs 
by reducing the number of visits and 
admission to the hospital. 
Health related 
costs/visits 
98.6% 
(71) 
1.4% 
(1) 
72 
5 Improve the ability to live daily life 
normally. 
Performance  100% 
(72) 
 72 
N: the number of patients answered the questions. a: five of patient answered NO to pay so subtract 
from the total sample 77. Data demonstrated by percent and frequency.  
 Some patients preferred to add comments about things they are concerned about  
and requested to achieve them:   
1. The need of medical centers that care for CF patients, help in their 
treatment and follow up on their status. 
2. The need of community awareness and education about CF disease.  
3. Inpatient cases' ages in Caritas baby hospital should be less than 15 years 
as instructed, which cause a big problem for CF patients older than 15 
years and need for hospital admission. 
4. They request for complete recovery from the disease by a drug that treats 
the genetic cause of CF disease completely and cure them.  
5. Change the dosage form of Creon® (pancrelipase, pancreatic enzyme 
replacement therapy) tablet into drops form for children. 
6. The need of one dosage form of A, D, E, and K vitamins. 
 
 Table 31 shows rank order of the items by order of importance for the patient: 
40.3% of patients chose the most important thing they needed is characteristic 
number 2: Facilitate the mechanism of treatment by providing modern equipment 
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for treatment and 33.3% of patients chose characteristic number 1: Providing new 
medicines reduce disease symptom and improve general health in different ways, 
these results described below  
(Table 31): Rank order of the items by order of importance for the patient 
 The main reason for patients who do not want to pay (answer No), is poor 
financial situation and poverty. As described below  
      (Table 32): Poverty cause 
 
Poverty cause Frequency Percent Valid Percent Cumulative Percent 
Valid Yes 5 6.5 100.0 100.0 
Missing System 72 93.5   
Total 77 100.0   
 
(Table 33): The items used for patient saying No for willingness to pay  
 
 
 
 
 
 
 
 
 
N: the number of patients answered the questions. a: 72 of patient answered YES to pay so subtract 
from the total sample 77.  Data demonstrated by percent and frequency.  
 
Number of characteristic  
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 24 31.2 33.3 33.3 
2 29 37.7 40.3 73.6 
4 4 5.2 5.6 79.2 
5 6 7.8 8.3 87.5 
1 + 2 2 2.6 2.8 90.3 
1 + 4 4 5.2 5.6 95.8 
1 + 5 2 2.6 2.8 98.6 
4 + 5 1 1.3 1.4 100.0 
Total 72 93.5 100.0  
Missing System 5 6.5   
Total 77 100.0   
 Items   Yes     No   Na 
1 Poor financial situation and poverty 100%  
(5) 
 5 
2 Lack of desire for change  
 
100% 
(5) 
5 
 
3 I see the situation as appropriate  100% 
(5) 
5 
4 Get used to the available medications  100% 
(5) 
5 
5 Not want to treat at all   100% 
(5) 
5 
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PART 2 
Correlation and comparisons statistics     
Cystic Fibrosis Questionnaire-Revised scores related comparison  
The overall scoring for CF patients in this study is less than 50% which indicate poor 
quality of life (Table 34). The data appears to show the lowest score is for treatment, 
body and respiratory. The highest score appears to be for eat and emotion. 
When we compare the mean scores of the CFQ14+ group with CFQ6-13, we observed 
no statistically significant difference between them (Table 35) only in eat domain. As 
determined the scores for adult (14+) are slightly higher than child (6-13) scores 
except for emotion and social domain. But the score for patients less than 6 years of 
age is much higher than both. 
Table (36) below compare the data collected from questionnaires completed by the 
parents relative to patients. We observed good agreement between the mean scores on 
the CFQ Parents 6-13 and the information obtained by means of the questionnaires 
applied to the patients. But we found a statistically significant difference only in the 
physical domain (p = 0.010) and treatment domain (p = 0.000) as determined in     
table (37).  
Table (34): Quality of life scores from the questionnaires related to cystic fibrosis 
patients, by group 
a
.  
 
Domain 
Groups 
CFQ14+  
n (22) 
CFQ6-13 
n (33) 
CFQ parent 6-13 
n (33) 
CFQ<6 
n (22) 
Physical 31.0614 26.4310 37.6263 49.7222 
Emotion 47.2727 48.2323 45.8586 50.0000 
Eat 55.5568 46.1279 51.0101 43.1818 
Treatment 20.2005 17.5084 41.4141 38.3838 
Body 22.7268 14.4781 14.8148 32.8283 
      Respiratory 28.2832 27.5253 31.7460 42.2078 
Social 
Digest  
44.9486 
39.8986 
45.4545 
23.2323 
- 
30.6397 
- 
39.3939 
Weight 22.7264 - 15.1515 25.7576 
Health 26.7664 - 46.1279 41.4141 
Role 40.1527 - - - 
Vitality 28.4095 - 33.9394 36.9697 
School - - 45.9596 59.2593 
     
CFQ: Cystic Fibrosis Questionnaire; CFQ6-13: patients ≥ 6 and < 14 years of age; CFQ<6: patients 
<6 years of age; and CFQ14+: patients ≥ 14 years of age.  a: Values expressed as mean score. (-): set 
for not applicable. 
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Table (35) Compression between the mean scores of the CFQ14+ group with CFQ6-13 
group  
Ranks 
  
 
N 
Mean 
Rank 
Sum of 
Ranks 
Physical Child 33 27.00 891.00 
Adults 22 29.50 649.00 
Total 55 
  
Emotion Child 33 27.91 921.00 
Adults 22 28.14 619.00 
Total 55 
  
Eat Child 33 24.42 806.00 
Adults 22 33.36 734.00 
Total 55 
  
Body Child 33 26.85 886.00 
Adults 22 29.73 654.00 
Total 
 
55 
  
Treatment Child 33 28.82 951.00 
Adults 22 26.77 589.00 
Total 55 
  
Respiratory Child 33 27.45 906.00 
Adults 22 28.82 634.00 
Total 55 
  
Digest Child 33 24.91 822.00 
Adults 22 32.64 718.00 
Total 55 
  
Social Child 33 27.91 921.00 
Adults 22 28.14 619.00 
Total 55 
  
 
Test Statistics 
  Physical Emotion Eat Body Treatment Respiratory Digest Social 
Mann-
Whitney U 
330.0 360.0 245.0 325.0 336.0 345.0 261.0 360.0 
Asymp. 
Sig. (2-
tailed) 
.569 .959 .041 .492 .638 .756 .070 .959 
*P <0.05 
There is a significant statistics between adult (14+) and child (6-13) in eat domain for 
adult quality of life.   
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Table (36): comparison between CFQ parent 6-13 scores and CFQ 6-13child scores  
  N Mean Std. Deviation Std. Error Mean 
 Physical Parents 33 37.6263 14.30102 2.48949 
Child 33 26.4310 19.59418 3.41091 
Emotion Parents 33 45.8586 22.09560 3.84635 
Child 33 48.2323 15.13217 2.63417 
Eat Parents 33 51.0101 28.54680 4.96936 
Child 33 46.1279 26.94891 4.69120 
Body Parents 33 14.8148 16.35511 2.84706 
Child 33 14.4781 17.67436 3.07671 
Treatment Parents 33 41.4141 8.45865 1.47246 
Child 33 17.5084 13.61686 2.37039 
Respiratory Parents 33 31.7460 14.41738 2.50974 
Child 33 27.5253 19.92661 3.46878 
 Digest Parents 33 30.6397 22.05323 3.83897 
Child 33 23.2323 26.98360 4.69724 
 
Table (37): Level of significance
 
between CFQ parent 6-13 score and CFQ 6-13 child 
version scores in physical and treatment domains 
 
             Domains t Sig. (2-tailed)a 
Physical  2.651 .010 
Emotion  -.509 .612 
Eat  .714 .478 
Body  .080 .936 
Treatment  8.567 .000 
Respiratory  .986 .328 
 Digest   1.221 .227 
   
                            a:  P < 0.05  
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Correlation between quality of life scores with demographic data.  
 
 adult (14 years of age and more ) group  
- There is a no correlation between age and QoL score for adult (14+) group 
as described in table (38) below:  
            
                Table (38): Age parameter:  
               
 
 
 
 
 
 
 
 
 
 
 
                                        *P < 0.05 
 
 
 
 
Correlation Matrix 
       Age pearson sig. 
  
Physical -.009 .485 
Role .061 .393 
Vitality -.040 .430 
Emotion -.181 .210 
Social .076 .368 
Body .021 .463 
Eat -.137 .271 
Treatment -.137 .272 
Health .145 .260 
Weight -.249 .132 
Respiratory -.115 .305 
Digest -.158 .241 
Adult (14+) N Minimum Maximum Mean Std. Deviation 
Age 22 14 35 19.36 5.770 
Valid N (listwise) 22     
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Table (39): Gender parameter  
Ranks 
 
Sex of patients N Mean Rank Sum of Ranks 
Physical 
 
Male 13 11.96 155.50 
Female 9 10.83 97.50 
Total 22   
Vitality 
 
Male 13 12.38 161.00 
Female 9 10.22 92.00 
Total 22   
Emotion 
 
Male 13 12.12 157.50 
Female 9 10.61 95.50 
Total 22   
Eat 
 
Male 13 11.85 154.00 
Female 9 11.00 99.00 
Total 22   
Treatment 
 
Male 13 14.12 183.50 
Female 9 7.72 69.50 
Total 22   
Health 
 
Male 13 12.19 158.50 
Female 9 10.50 94.50 
Total 22   
Social 
 
Male 13 11.54 150.00 
Female 9 11.44 103.00 
Total 22   
Body 
 
Male 13 11.54 150.00 
Female 9 11.44 103.00 
Total 22   
Role 
 
Male 13 12.73 165.50 
Female 9 9.72 87.50 
Total 22   
Weight 
 
Male 13 11.88 154.50 
Female 9 10.94 98.50 
Total 22   
Respiratory 
 
Male 13 13.08 170.00 
Female 9 9.22 83.00 
Total 22   
Digest 
 
Male 13 11.04 143.50 
Female 9 12.17 109.50 
Total 22   
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Table (40): Level of significance for QoL related to gender 
Test Statistics  
 
Physical Vitality Emotion Eat Treatment Health 
Mann-Whitney U 52.500 47.000 50.500 54.000 24.500 49.500 
Exact Sig. [2*(1-tailed Sig.)] .695 .471 .601 .794 .021 .556 
 
Social Body Role Weight Respiratory Digest 
Mann-Whitney U 58.000 58.000 42.500 53.500 38.000 52.500 
Exact Sig. [2*(1-tailed Sig.)] 1.000 1.000 .292 .744 .186 .695 
*P<0.05 
There are no significant differences in QoL for adult group with respect to gender 
with the exception of treatment (0.021) to male only. 
Table (41): Vacation without disease parameter 
Ranks 
Vacation without 
disease 
 
N Mean Rank Sum of Ranks 
Physical 
 
Yes 9 15.44 139.00 
No 13 8.77 114.00 
Total 22   
Vitality 
 
Yes 9 15.78 142.00 
No 13 8.54 111.00 
Total 22   
Emotion 
 
Yes 9 13.89 125.00 
No 13 9.85 128.00 
Total 22   
Eat 
 
Yes 9 12.28 110.50 
No 13 10.96 142.50 
Total 22   
Treatment 
 
Yes 9 13.78 124.00 
No 13 9.92 129.00 
Total 22   
Health 
 
Yes 9 15.11 136.00 
No 13 9.00 117.00 
Total 22   
Social 
 
 
 
 
Yes 9 9.83 88.50 
No 13 12.65 164.50 
Total 22   
Body 
 
Yes 9 15.72 141.50 
No 13 8.58 111.50 
Total 22   
Role 
 
Yes 9 15.44 139.00 
No 13 8.77 114.00 
Total 22   
Weight 
 
Yes 9 12.56 113.00 
No 13 10.77 140.00 
Total 22   
Respiratory 
 
Yes 9 14.17 127.50 
No 13 9.65 125.50 
Total 22   
Digest 
 
Yes 9 15.83 142.50 
No 13 8.50 110.50 
Total 22   
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Table (42): Level of significance of QoL for adult (14+) group related to vacation 
without disease 
Test Statistics 
  
Physical Vitality Emotion Eat Treatment Health 
Mann-Whitney U 23.000 20.000 37.000 51.500 38.000 26.000 
Exact Sig. [2*(1-tailed Sig.)] .017 .009 .164 .647 .186 .030 
  
Social Body Role Weight Respiratory Digest 
Mann-Whitney U 43.500 20.500 23.000 49.000 34.500 19.500 
Exact Sig. [2*(1-tailed Sig.)] .324 .009 .017 .556 .110 .007 
 *P < 0.05 
There are statistically significant differences in physical (0.017), vitality (0.009), 
health (0.03), body (0.009), role (0.017) and digest (0.007) domains with respect to 
vacation without disease for adult (14+) group. 
 Marital status parameter for adult (14+) (single/married) correlated with QoL 
There is a no correlation between marital status and QOL score for adult (14 and 
more) group as described in table (43): 
Table (43): Marital status parameter for adult (14+) correlated with QOL 
Test Statistics 
  Physical Vitality Emotion Eat Treatment Health 
Mann-Whitney U 3.000 15.500 8.500 5.000 13.000 5.000 
Exact Sig. [2*(1-tailed 
Sig.)] 
.052 .623 .216 .104 .485 .104 
 
Social Body Role Weight Respiratory Digest 
Mann-Whitney U 9.500 12.500 19.500 9.000 9.500 9.000 
Exact Sig. [2*(1-tailed 
Sig.)] 
.260 .424 .952 .260 .260 .260 
*P <0.05 
 
 Education level of adult (14+) group related to QoL 
There is a no correlation between educational level and QoL score for adult (14+) 
group as described in table below. 
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    Table (44): Education level parameter  
Test Statistics a, b 
  Physical Emotion Vitality Social Eat  Role 
Chi-square 4.485 .358 1.908 4.298 .999 
2.507 
df 3 3 3 3 3 
3 
Asymp. Sig. .214 .949 .592 .231 .802 
.474 
  Body Treatment Health Respiratory Digest Weight 
Chi-square .098 1.837 3.193 3.070 .312 .975 
df 3 3 3 3 3 3 
Asymp. Sig. .992 .607 .363 .381 .958 .807 
    a. Kruskal Wallis Test        
    b. Grouping Variable: Education level       
   *P < 0.05 
 
 
 Work or school status of adult (14+) related to QoL 
There is a correlation between work or school status and QoL score of physical 
(0.039) and role (0.016) domains for taking educational courses at home as described  
Table (45): Work or school status of adult parameter 
Test Statistics a, b 
  Physical Emotion Vitality Social Eat  Role 
Chi-square 10.090 7.280 8.625 1.578 8.710 
12.204 
df 4 4 4 4 4 
4 
Asymp. Sig. .039 .122 .071 .813 .069 
.016 
  Body Treatment Health Respiratory Digest Weight 
Chi-square 5.610 6.428 6.331 
4.958 8.032 
2.207 
df 4 4 4 4 4 4 
Asymp. Sig. .230 .169 .176 
.292 .090 
.698 
    a. Kruskal Wallis Test        
    b. Grouping Variable: Work of patients    
   *P < 0.05 
 
Child (6-13) group: 
 In child (6-13) group there is no differences in QoL with respect to gender with 
the exception of the eat (0.03) domain related to male. 
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Table (46): Gender parameter effect 
Test Statistics 
  Physical Emotion Social Eat Treat Body Reparatory Digest 
Mann-Whitney U 115.50 112.00 97.00 68.50 106.0 80.00 99.500 116.0 
Exact Sig. [2*(1-
tailed Sig.)] 
.699 .618 .291 .030 .471 .089 .326 .726 
*P < 0.05 
 
 In child (6-13) group there is no difference in QoL with respect to vacation 
without disease with the exception of the eat (0.049) domain related to yes 
answers. 
Table (47): Vacation without disease parameter 
 
Test Statistics 
 Physical Emotion Social Eat Treat Body Respiratory Digest 
Mann-Whitney 
U 
61.00 97.00 82.00 53.5 86.50 91.00 90.000 96.000 
Exact Sig. [2*(1-
tailed Sig.)] 
.107 .918 .470 .049 .578 .726 .696 .885 
*P < 0.05 
 In child (6-13) group there is no differences in QoL with respect to education level 
with the exception of social (0.016) domain related to 7
th
 grade 
 (Table 48): Education level parameter  
Test Statistics
 a, b
 
 Physical Emotion Social Eat Treat Body Respiratory Digest 
Chi-square 12.182 8.299 17.293 10.138 11.291 5.226 10.348 7.671 
df 7 7 7 7 7 7 7 7 
Asymp. Sig. .095 .307 .016 .181 .126 .632 .170 .363 
a. Kruskal Wallis Test 
b. Grouping Variable: Education level 
p < 0.05 
 
 In child (6-13) group (mean age is 9.21 years of age) there is no difference in QoL 
with respect to age with the exception of social (0.004) domain  
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       (Table 49): Age parameter  
Correlation Matrix 
Age   correlation sig. 
  
 
 
 
 
Physical -.047 .397 
Emotion .008 .482 
Social .458 .004 
Eat .188 .147 
Body .060 .370 
Treatment -.187 .149 
Respiratory  .221 .108 
Digest .057 .377 
                                        *p < 0.05 
CFQ- Parent (6-13) group correlation:  
Parent's relationship (father, mother, grandfather and brother) parameter related to 
QoL domains. 
There is no difference in QoL score with respect to relationship as shown   
Table (50): Relationship effect  
Test Statistics  
  Physical Emotion Vitality School Eat   
Chi-square 3.168 4.083 1.972 .610 3.870 
  
df 2 2 2 2 2 
  
Asymp. Sig. .205 .130 .373 .737 .144 
  
  Body Treat Health Respiratory Digest Weight 
Chi-square 1.243 3.434 .898 2.500 3.601 .535 
df 2 2 2 2 2 2 
Asymp. Sig. .537 .180 .638 .287 .165 .765 
*p < 0.05 
 
 In CFQ- Parent (6-13) group there is no difference in QoL with respect to 
education level of the parents with the exception of emotion (0.013), vitality 
(0.006) and eat (0.02) domains (table 51) related to college degree. 
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  Table 51: Education level of the parents parameter 
Test Statistics 
  Physical Emotion Vitality School Eat   
Chi-square 4.471 10.846 12.300 6.086 9.795 
  
df 3 3 3 3 3 
  
Asymp. Sig. .215 .013 .006 .108 .020 
  
  Body Treat Health Respiratory Digest Weight 
Chi-square 2.595 7.197 4.515 6.090 6.330 3.391 
df 3 3 3 3 3 3 
Asymp. Sig. .458 .066 .211 .107 .097 .335 
*p < 0.05 
 
 In CFQ- Parent (6-13) group there is no difference in QoL with respect to work 
status of parents with the exception of school (0.021) domain (table 52) for 
seeking work. 
Table (52): Work status of parents parameter  
      *p < 0.05 
 Age of parents parameter: 
There is no difference in QoL of CF patients with respect to ages of their parents 
with the exception of physical (0.021), digest (0.008) domains with negative 
correlation as described  
Test Statistics 
  Physical Emotion Vitality School Eat   
Chi-square 3.459 4.194 5.119 9.687 5.971 
  
df 3 3 3 3 3 
  
Asymp. Sig. .326 .241 .163 .021 .113 
  
  Body Treat Health Respiratory Digest Weight 
Chi-square 1.699 2.238 2.824 5.729 4.283 3.026 
df 3 3 3 3 3 3 
Asymp. Sig. .637 .524 .419 .126 .232 .388 
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 Table (53): Ages of their parents effect  
Age of parents N Minimum Maximum Mean Std. Deviation 
age 33 24 60 34.67 7.326 
Valid N (list wise) 33     
 
 
 
 
 
 
 
 
                  *p < 0.05 
 Marital status of parents parameter (married /divorced) 
There is no significant statistical relationship between the marital status of parents and 
QoL of their patients as described below: 
Table (54): Marital status of parents and QoL of their patients correlation 
Test Statistics 
  Physical Emotion Eat Body Treat Respiratory Digest Social 
Mann-
Whitney U 
24.500 24.000 24.000 29.000 22.000 25.000 15.000 11.500 
Exact Sig. 
[2*(1-tailed 
Sig.)] 
.640 .640 .640 .909 .545 .689 .273 .159 
*P < 0.05 
 Monthly income parameter effect. 
There is no correlation between monthly income (NIS) and QoL score for all 
groups as described in table (55) below:  
Ages of parent Correlation Sig. 
  
Physical -.356 .021 
Emotion .109 .274 
Vitality -.057 .376 
School .086 .317 
Eat .240 .089 
Body .242 .088 
Treatment  -.146 .209 
Health .057 .376 
Respiratory .005 .489 
Digest -.418 .008 
Weight .132 .232 
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Table (55): Monthly income parameter effect 
Test Statistics 
  Physical Emotion Vitality School Eat Body 
Chi-square 3.928 2.931 .671 .783 .799 1.316 
df 2 2 2 2 2 2 
Asymp. Sig. .140 .231 .715 .676 .671 .518 
  Treat Health Respiratory Digest Weight 
 Chi-square 5.725 2.989 .296 1.113 1.941 
 df 2 2 2 2 2 
 Asymp. Sig. .057 .224 .862 .573 .379 
 *P < 0.05 
 Total number of family member live in the same place parameter effect on QoL.          
There is a statistically significant relationship between number of family member 
live in the same place and QoL score in vitality (0.032) and health (0.042) domain 
for all groups as described in table (56). Negative correlation: with high number of 
family member the vitality and the health status of CF patients decrease. 
Table (56): Correlation between number of family member live in the same place 
and QoL score 
                   
 
 
 
 
 
 
 
 
 
 
 
 
        
Correlation 
Matrix   
  
Number 
of 
family 
member 
Sig. 
Correlation Physical -.114 .385 
  
Emotion -.119 .380 
  
Vitality -.639 .032 
  
School .031 .468 
  
Eat -.304 .213 
  
Body -.246 .262 
  
Treatment .365 .167 
  
Health -.604 .042 
  
Respiratory .063 .436 
  
Digest -.023 .477 
  
Weight -.275 .237 
        *P < 0.05 
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 Geographic distribution of  CF patients results are described in table (57): 
      There are 58 families:   
1. The highest number of CF patients is from the Hebron district (50 patients). 
2. Hebron families were the most in which they have more than one patients in 
each family (8 families contain two patients). 
3. The family that has the highest number of patients (4 patients) was from 
Nablus district. 
Table (57) Geographic distribution of CF patients 
 
 
 
 
 
District 
Total Jerusalem Bethlehem Hebron Ramallah Nablus Jenin Qalqilia Tulkarem 
Number 
of CF 
patients 
in each 
family 
1 Count 1 2 28 3 3 4 1 1 43 
% of 
patients 
answered 
related to 
region   
2.3% 4.7% 65.1% 7% 7% 9.3% 2.3% 2.3% 100.0% 
2 Count 0 4 16 2 0 2 0 0 24 
% of 
patients 
answered 
related to 
region   
0% 16.7% 66.7% 8.3% 0% 8.3% 0% 0% 100.0% 
3 Count 0 0 6 0 0 0 0 0 6 
% of 
patients 
answered 
related to 
region   
0% 0% 100.0% 0% 0% 0% 0% 0% 100.0% 
4 Count 0 0 0 0 4 0 0 0 4 
% of 
patients 
answered 
related to 
region   
0% 0% 0% 0% 100.0% 0% 0% 0% 100.0% 
Total Count 1 6 50 5 7 6 1 1 77 
% of 
patients 
answered 
related to 
region   
1.3% 7.8% 64.9% 6.5% 9.1% 7.8% 1.3% 1.3% 100.0% 
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 QoL domain score correlated with CF patients living regions (Jerusalem, 
Bethlehem, Hebron, Ramallah, Nablus, Jenin, Qalqilia and Tulkarem). 
All our patients suffer from CF disease in the same level there is no differences 
between the districts as described below in table (58):                      
No significant correlation. 
Table (58): CF patients living regions parameter 
Test Statistics 
  Physical Emotion Vitality School Eat 
 Exact fisher 
test 
6.499 8.619 3.144 3.872 2.748 
 df 7 7 6 3 7 
 Asymp. Sig. .483 .281 .791 .276 .907 
 
 
Body Treatment Health Respiratory Digest Weight 
Exact fisher 
test 
4.757 8.225 4.961 11.012 5.919 7.605 
df 7 7 6 7 7 6 
Asymp. Sig. .690 .313 .549 .138 .549 .268 
*P < 0.05 
 
 QoL domain score correlated with patient kind of living (city, village or 
camp). 
No significant correlation in (table 59) below. 
Table (59): patient kind of living (city, village or camp)  
Test Statistics 
 Physical Emotion Vitality School Eat Body 
Exact fisher 
test 
2.946 2.879 .988 2.220 .590 .836 
df 2 2 2 1 2 2 
Asymp. Sig. .229 .237 .610 .136 .744 .658 
 
Treatment Health Respiratory Digest Weight 
 Exact fisher 
test 
2.150 .285 .478 .108 .713 
 df 2 2 2 2 2 
 Asymp. Sig. .341 .867 .787 .947 .700 
 *P < 0.05 
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    Percentage of death cases due to CF disease in families and their geographic 
distribution 
The study shows that 21% of families (12/58) having death cases related to CF 
disease, 58.3% (7/12) from Hebron district, two families from Ramallah (16.7%), 
the other two families from Jenin (16.7%) and one family from Nablus (8.3%) 
district as described in table (60): 
Table (60): CF Death cases geographic distribution by district 
 
District 
Total Jerusalem Bethlehem Hebron Ramallah Nablus Jenin Qalqilia Tulkarem 
Number 
of death 
related 
to CF 
disease 
0 Count 1 4 31 2 3 3 1 1 46 
% of 
families  
2.17% 8.7% 67.4% 4.4% 6.5% 6.5% 2.17% 2.17% 100% 
1 Count 0 0 3 2 1 2 0 0 8 
% of 
families 
  37.5% 25% 12.5% 25%   100% 
2 Count 0 0 2 0 0 0 0 0 2 
% of 
families 
  100%      100% 
3 Count 0 0 1 0 0 0 0 0 1 
% of 
families 
  100%      100% 
 4 Count 0 0 1 
100% 
0 0 0 0 0 
 
1 
100% % of 
families 
Total Count 1 4 38 4 4 5 1 1 58 
% of 
families 
1.73% 6.89% 65.52% 6.89% 6.89% 8.62% 1.73% 1.73% 100% 
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Quality of life related to health profile parameter.  
2.3.1 Quality of life scores correlated with BMI (Kg/m
2
) 
There is a significant statistic between physical domain (0.042) in quality of life 
questionnaire and BMI results of Pearson correlation coefficients (r) as described in 
Table (61): BMI results of Pearson correlation coefficients 
  
 
 
 
 
 
 
 
 
                           *P < 0.05 
Quality of life scores correlated with FEV1 
For child and adult groups there is no statistical significant between quality of life 
domain score and FEV1level measured as described in tables below: 
Table (62): FEV1 for child 6-13 years of age correlated with QoL domain 
Test Statistics 
a, b 
 
 Physical Emotion Eat Body Treatment Respiratory Digest Social 
Chi-square .191 .102 1.455 .667 5.133 1.813 .648 1.444 
df 2 2 2 2 2 2 2 2 
Asymp. 
Sig.* 
.909 .950 .483 .716 .077 .404 .723 .486 
a. Kruskal Wallis Test  
b. Grouping Variable: Section V. Health Profile FEV1 for child (6-13) 
* P < 0.05  
 
 
 
Correlation 
Matrix 
    
  
  Domain 
BMI 
results  sig. 
Correlation Physical .605 .042 
  Emotion .424 .128 
  Vitality .054 .446 
  School .486 .092 
  Eat .397 .145 
  Body .579 .051 
  Treatment .418 .131 
  Health .186 .315 
  Respiratory -.497 .087 
  Digest -.207 .297 
  Weight .346 .181 
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Table (63): FEV1 for adult 14 years of age and more correlated with QoL domain 
Test Statistics 
a, b 
  Physical Vitality Emotion Eat Treatment Health 
Chi-square 
 
df 
 
Asymp. Sig. 
3.599 
 
3 
 
.308 
2.061 
 
3 
 
.560 
.694 
 
3 
 
.875 
.492 
 
3 
 
.921 
1.564 
 
3 
 
.668 
3.573 
 
3 
 
.311 
 
Social Body Role Weight Respiratory Digest 
Chi-square 
 
df  
 
Asymp. Sig. 
2.248 
 
3 
 
.523 
1.998 
 
3 
 
.573 
4.992 
 
3 
 
.172 
2.034 
 
3 
 
.565 
.598 
 
3 
 
.897 
3.150 
 
3 
 
.369 
a. Kruskal Wallis Test 
b. Grouping Variable: Section V. Health Profile FEV1 
* P < 0.05 
 
There is no statistical significant correlation between quality of life domain scores and 
FEV1 level measured. 
 
Quality of life scores correlated with age of diagnoses 
There is a correlation between diagnostic age and CFQ-R score in social domain 
(0.03) with negative relation as the patient diagnose earlier in their life have good 
CFQ-R score in sociality as described in table (64) below: 
 Table (64): Pearson correlation between diagnostic age and CFQ-R score 
Correlation Matrix   
  
Diagnostic age         sig 
Correlation Physical -.225 .157 
Emotion -.041 .428 
Vitality -.063 .390 
Eat -.327 .069 
Body -.021 .464 
Treatment -.011 .481 
Health -.129 .284 
Respiratory -.134 .276 
Digest -.029 .450 
Weight -.170 .224 
Social -.407 .030 
                            *P<0.05 
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Correlation between quality of life domain scores and willingness to pay  
There is no statistical significant correlation between quality of life domain score 
and WTP as measured in table (65). 
 Table (65): WTP correlation  
Ranks 
 Willingness to pay  
N Mean Rank Sum of Ranks 
Physical 
 
Yes 71 39.23 2785.50 
No 5 28.10 140.50 
Total 76 
  
Emotion 
 
Yes 72 39.95 2876.50 
No 5 25.30 126.50 
Total 77 
  
Vitality 
 
Yes 41 22.93 940.00 
No 3 16.67 50.00 
Total 44 
  
Eat 
 
Yes 72 38.83 2795.50 
No 5 41.50 207.50 
Total 77 
  
Body 
 
Yes 72 39.42 2838.50 
No 5 32.90 164.50 
Total 77 
  
Treatment 
 
Yes 72 38.35 2761.00 
No 5 48.40 242.00 
Total 77 
  
Health 
 
Yes 41 22.76 933.00 
No 3 19.00 57.00 
Total 44 
  
Respiratory 
 
Yes 72 39.03 2810.50 
No 5 38.50 192.50 
Total 
 
 
77 
  
Digest 
 
Yes 
 
72 39.87 2870.50 
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No 5 26.50 132.50 
Total 77 
  
Weight 
 
Yes 41 22.41 919.00 
No 3 23.67 71.00 
Total 44 
  
Social 
 
Yes 52 27.29 1419.00 
 No 3 40.33 121.00 
 Total 55 
  
 
 
Table (66): level of significance between QoL and WTP 
  Physical Emotion Vitality Eat Body 
 Mann-Whitney U 125.500 111.500 44.000 167.500 149.500 
 Exact Sig. [2*(1-tailed Sig.)] .285 .161 .448 .802 .539 
 
 
Treatment Health Respiratory Digest Weight Social 
Mann-Whitney U 133.000 51.000 177.500 117.500 58.000 41.000 
Exact Sig. [2*(1-tailed Sig.)] .347 .659 .960 .203 .895 .186 
*P < 0.05 
There is no significant statistical correlation between QoL domains and WTP 
 
Relationship between taking influenza vaccine and QoL domain scores.  
There is no correlation between quality of life domain scores and taking influenza 
vaccine in CF cases as described in table (67). 
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Table (67): Effect of taking influenza vaccine  
  Physical  Emotion Vitality School Eat Body 
Mann-Whitney U 674.000 621.000 186.500 5.000 579.000 721.500 
Asymp. Sig. (2-
tailed) 
.649 .232 .205 .539 .102 .861 
  Treat Health Respiratory Digest Weight Social 
Mann-Whitney U 667.000 224.500 695.000 646.500 204.000 364.500 
Asymp. Sig. (2-
tailed) 
.464 .713 .660 .341 .362 .952 
*P < 0.05 
 41 of patient took influenza vaccine. 9.8% patients didn't enter hospital and 2.4% 
enter hospital 8 times yearly. And 36 patients who did not take influenza vaccine 
2.8% enter the hospital 15 times yearly as described below in table (68). 
Table (68): Taking influenza vaccine related to number of hospitalization 
Taking influenza vaccine * Number of hospitalization Cross tabulation 
 
Number of hospitalization 
Total 0 1 2 3 4 5 6 7 8 15 
Taking 
influenza 
vaccine  
Yes Count 4 7 11 7 5 1 2 3 1 0 41 
% 
answered  
9.8% 17.1% 26.8% 17.1% 12.2% 2.4% 4.9% 7.3% 2.4% .0% 100.0% 
No Count 1 9 10 7 1 0 4 3 0 1 36 
% 
answered  
2.8% 25.0% 27.8% 19.4% 2.8% .0% 11.1% 8.3% .0% 2.8% 100.0% 
Total Count 5 16 21 14 6 1 6 6 1 1 77 
% 
answered  
6.5% 20.8% 27.3% 18.2% 7.8% 1.3% 7.8% 7.8% 1.3% 1.3% 100.0% 
         
Exact fisher test 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson fisher test 8.141
a 9 .520 
Likelihood Ratio 9.650 9 .380 
Linear-by-Linear Association .361 1 .548 
N of Valid Cases 77   
a. 14 cells (70.0%) have expected count less than 5. The minimum expected count is .47. 
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2.6 Comparison between quality of life domain score for our CF patients to 
normative CF international data  
There is a huge difference between our CF quality of life domain scores and US 
international data scoring [53], with our patients the scores were less than 50% of 
all domains for all patients group version which indicated sever status of our 
patients relative to data for US sample in table (69). 
Table (69): CFQ-R domains by version for a national, US sample [53].    
 
      
        
 
 
 
 
 
 
 
 
          
 
 
 
 
 
 
 
 CFQ-R: Cystic Fibrosis Questionnaire-Revised. NA: not applicable. SD: standard deviation.                     
          a: Data from the children for whom the parents are reporting 
 
. 
CFQ-R scale   Teen/adult                 Child                       Parent
 a
 
  Mean ± SD              Mean ± SD             Mean ± SD 
   n = 4,679                 n = 2,068                 n = 2,728 
Physical functioning 
Role functioning 
Vitality 
Emotional functioning 
Social functioning 
Body image 
Eating problems 
Treatment burden 
Health perceptions 
Weight 
Respiratory symptoms 
Digestive symptoms 
School functioning 
71.7 ± 27.4 
80.1 ± 20.2 
59.5 ± 20.6 
76.4 ± 20.0 
72.4 ± 17.9 
70.6 ± 26.7 
89.7 ± 18.2 
61.5 ± 21.0 
67.2 ± 24.1 
66.5 ± 37.2 
62.9 ± 22.6 
80.3 ± 19.1 
NA 
77.3 ± 21.1 
NA 
NA 
73.9 ± 14.8 
67.9 ± 18.0 
77.8 ± 26.2 
82.8 ± 22.2 
68.8 ± 22.1 
NA 
NA 
73.6 ± 20.0 
71.8 ± 27.1 
NA 
83.8 ± 19.1 
NA 
69.7 ± 15.5 
82.7 ± 15.3 
NA 
71.7 ± 28.0 
78.4 ± 27.6 
63.5 ± 23.1 
77.1 ± 19.3 
60.3 ± 37.2 
75.4 ± 19.2 
71.4 ± 19.2 
76.9 ± 23.2 
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Other quality of life assessment in patients with cystic fibrosis by means of the cystic 
fibrosis questionnaire carried out at the State University at Campinas school of 
medical sciences, Campinas, Brazil [54]. This study indicated that our patients with 
CF disease have poor quality of life compared with patients followed at the Brazilian 
center as described in table (74): 
 
Table (70): Quality of life scores from the questionnaires related to cystic fibrosis 
patients at Brazilian center, by group [54].  
Domain 
 
                         Group 
a
 
   CFQ6-11                  CFQ12-13                  CFQ14+                Parent 6-11          Parent 12-13 
(n = 39)                   (n = 12)                  (n = 24)                  (n=39)                 (n=12) 
Physical              71.4 ± 25.3             66.2 ± 28.1            72.4 ± 24.9              85.3 ± 19.5         79.3 ± 23.2 
Body image        77.5 ± 25.9             63.0 ± 23.4             78.7 ± 20.7              81.5 ± 26.7        74.1 ± 29.3 
Digestive            78.6 ± 22.3             75.0 ± 20.7             88.4 ± 14.5              77.2 ± 20.4        74.1 ± 18.6 
Respiratory        74.4 ± 16.0              69.4 ± 25.0            68.7 ± 15.4               78.5 ± 15.9        80.6 ± 13.9   
Emotional          79.4 ± 11.5              71.5 ± 19.0            82.8 ± 15.2               86.2 ± 14.3        73.9 ± 22.6 
Social                 73.0 ± 16.5              59.5 ± 22.3            68.1 ± 16.1              83.4 ± 18.3         77.8 ± 28.8 
Eat                     79.8 ± 22.1              75.0 ± 28.5            89.3 ± 16.2              79.9 ± 28.7         70.8 ± 28.5 
Treatment          83.5 ± 14.4              70.4 ± 24.3            64.8 ± 19.0               78.1 ± 19.8        82.4 ± 20.4 
Vitality                                                                            76.7 ± 16.7               74.4 ± 15.9        71.1 ± 20.4 
Health                                                                              65.3 ± 26.1              80.3 ± 22.4         73.1 ± 27.0 
Role                                                                                 77.4 ± 20.5                      NA                      NA 
Weight                                                                             63.9 ± 38.0              60.7 ± 37.4         50.0 ± 43.8 
CFQ: Cystic Fibrosis Questionnaire; CFQ6-11: patients ≥ 6 and < 12 years of age; CFQ12-13: 
patients ≥ 12 and < 14 years of age; and CFQ14+: patients ≥ 14 years of age.                                                       
a: Values expressed as mean ± SD. 
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Part 3  
Economic evaluation of using new medications for cystic fibrosis patients in our 
countries. 
 
Costs of a disease as described in table (71) are divided in direct and indirect costs. 
For CF the clinical visit, hospital admission, outpatient drug costs (antibiotics, 
hypertonic saline, Creon, etc.) and laboratory tests are seen as direct costs. Direct non-
medical costs include out of pocket expenses for dietary recommendations and travel 
costs to receive care. The indirect costs include for example productivity losses. 
Detailed description of direct medical and non-medical cost is described below in 
Tables 72 to 74.  Direct costs appear to account for most expenses of health care in 
CF patients. Total costs for patient with the mean age of our sample 10.7 years of age 
were estimated to be around 35650.2 NIS per patient per year.  
 
Table (71): Mean (S.D) medical consumption per patient over 1 year, stratified by 
outpatient and inpatient (hospital) care and costs.  
 
Type  Health care resources  Mean (S.D) 
 
 
 
Direct medical  
costs 
 
- Inhaled antibiotics therapy (months) 
- Hospital admission [No.]  
- IV-antibiotic therapy [days] 
- Clinic visits [No.] 
- Sputum culture test [No.]   
- Blood tests [No.] 
- Radiographs [No.]   
 
 
5.58 (3.833) 
2.99 (2.458) 
7.51 (6.752) 
3.52 (3.633) 
4.39 (2.537) 
1.16 (0.365) 
1.04 (0.195) 
Direct 
non-medical costs 
 
 
- Travel costs to receive care  
 
81.033 NIS 
 
Indirect costs 
 
- Productivity loss [No. per month] 
 
 
4.88 (6.909) 
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Direct medical costs burden  
 
Table (72) described the payment expenses for CF patients services  
 
 
Service 
Branch 
Description Price  (NIS) 
 
 
 
 
 
Laboratory 
tests 
 
Sputum Culture / Gram Stain 
CBC 
BUN (Blood Urea Nitrogen) 
Creatinine (Serum) 
Electrolytes (Na/K - Serum) 
CRP (C-Reactive Protein Titer) 
Alkaline Phosphatase 
GPT/ALT (Alanine Aminotransferase) 
GOT/AST (Aspartate transaminase) 
PTT (Partial Thromboplastin Time) 
PT (Prothrombin Time) / INR 
Protein Total (Serum) 
Albumin (Serum) 
Glucose (Serum) 
HbA1C 
Vitamin D (Total)  
Vitamin E Level 
Vitamin K Level 
Acid Fast Bacilli test  
IgE Level test 
Sweat Chloride test 
Genetic Analysis (CF Mutations) 
 
40 
20 
16 
16 
20 
25 
16 
15 
15 
24 
24 
16 
16 
10 
35 
100 
350 
550 
40 
60 
50 
2500 
 
Radiology 
exams Chest-STANDARD FRONTAL VIEW 
Chest-Frontal + lateral 
 
20 
30 
 
Pulmonology 
clinic services Pulmonology Clinic - New Visit 
Pulmonary function test  
 
70 
800 
 
Inpatient 
night fees 
Pediatrics hospitalization night 
ICU hospitalization night 
*The escort pays 20 NIS per night       
170 
450 
20 
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Inpatient services for CF disease  
 
Total inpatient hospital services 
- Chest Therapy Session (cost 25 NIS for each session).  
- All laboratory tests and radiology exams previously discussed. 
- Most commonly inpatient medications. 
 
Creon 10000 IU Capsules                             
Hypertonic saline 3%, 7% solution for Inhalation 
Vitamin K 2 mg Oral - I.M. - I.V. (Konakion®) 
Salbutamol 5mg/1ml solution (Ventoline (®  
Tocopherol 100, 200 or 400mg Tabs. (Evitol (®  
Vitamin A 10.000 I.U. + Vitamin D3 4000 I.U.) / 1 ml "Adol" 
Azithromycin 250 mg Cap 
Ciprofloxacin 500 mg Tabs 
Gentamycin-NaCl- 0.8mg/ml-0.09%-100ml (80mg/BAG) 
Ceftazidime 1 g Vial. (Fortum   (®  
Amikacin 500mg/2ml Vial 
Vancomycin 500mg vial 
Meropenem (Meronem 1gm IV vial) 
 
 
Average hospitalization days: 7.51 days 
Average hospitalization admission numbers: 2.99  
 
Daily Average Real Cost around 300 NIS  
The real cost of the stay around 2400 NIS 
Average cost per patient per year around 7200 NIS   
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Health related economical endpoint for CF patients 
 
Table (73): Total Economical endpoint costs per patient per year in NIS 
Notes Total Cost Cost/Unit Mean Main Cost Items 
Gentamycin 80 mg / 2 ml Ampoule 
Can be obtained free from MOH.  
 
300*7.51*2.99 = 7200  
For total 7 times back and forth. 
± 1900 
± 280 
± 176 
± 1634 
± 31.2 
± 7200 
 
±1200 
5.4 (BID) 
70 
40 
1408 
30 
170 
300 per night 
 
5.58 
3.52 
4.39 
1.16 
1.04 
2.99 
7.51 
 
82 
- Inhaled antibiotics therapy [months] 
- Clinic visits [No.] 
- Sputum culture test [No.] 
- Blood tests [No.] 
- Radiographs [No.] 
- Hospital admission [No.] 
- Total hospital services [days] 
 
- Travel costs to receive care  
Notes Total cost Cost/Unit - Drugs: 
Can be obtained free from MOH 
 
Unit of 200 mg form used = 23 
NIS 
Must obtained free from MOH 
 
Obtained free from MOH 
 
Free from Caritas baby hospital 
only 
 
Free from Caritas baby hospital 
only 
 
Can be obtained free from MOH 
 
Can be obtained free from MOH 
 
 
Can be obtained free from MOH 
360 
 
 
552 
 
2520 
 
 
12528 
 
375.7 
 
 
1123 
 
 
720 
 
 
900 
 
 
 
 
 
360 
 
 
420 
 
 
192 
 
 
 
792 
10 NIS 
 
 
46 NIS 
 
7 NIS 
 
 
145 NIS 
 
20 NIS 
 
 
46.8 NIS 
 
 
20 NIS 
 
 
25 NIS 
 
 
 
 
 
30 NIS 
 
 
35 NIS 
 
 
16 NIS 
 
 
 
44 NIS 
 
1. Adol® drops 10ml 
(Vitamin A 500 IU & D3 200 IU). 
 
2. Tocopherol (Evitol®) 400 mg tablet. 
 
3. Vitamin K  2 mg / 0.2 ml 
       oral - I.M.- I.V. (Konakion®). 
 
4. Creon 10000 IU (100 capsule). 
 
5. Hypertonic saline 3% prepared from 23.4% HTS 
230ml.  
 
6. Hypertonic saline 7% solution (180ml). 
 
7. Salbutamol (5mg/ml) respiratory solution 
(Ventolin® solution 20ml). 
 
8. Azithromycin 250 mg EOD  
      (box of 6 caps). 
 
 
9. Other oral antibiotic: 
 
a. Augmentin®  syrup ES (600mg/5ml). 
 
b. Ciprofloxacin 500mg                (15 tablets). 
 
c. Trimethoprim 40mg with 
Sulphamethoxazole 200mg/5ml (Sulprim® 
suspension 100ml).   
 
d. Cefuroxime axetil Suspension 250mg/5ml 
(Zinnat® 100ml) 
No.: number; BID: twice daily; NIS: new Israel shekel; EOD: every other day; MOH: ministry of 
health.                          
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 Total costs for CF patient 10.7 years of age  
Table (74): Total costs per year 
Total Cost (NIS) 
per year  
Main Cost Items 
1900 
280 
176 
1634 
31.2 
50 
2500 
7200 
800 
1200 
1782 
15960 
1123 
720 
294 
- Inhaled antibiotics therapy 
- Clinic visits  
- Sputum culture test  
- Blood tests  
- Radiographs 
- Sweat Chloride test 
- Genetic Analysis (CF Mutations) 
- Total hospital services  
- Pulmonary function test 
- Travel costs to receive care  
- Oral antibiotics medications  
- Vitamins and enzymes  
- Airway clearance medications 
- Bronchodilators 
- Other medications 
                                       Total cost = 35650.2 NIS 
 
 
 According to pharmaco-economic analysis of aerosol Dornase alfa (rhDNase) 
drug the reduced costs of RTI-related care are expected to be about 33% (18.3-
37.5%) of the total costs [3, 22, 55]. A significant impact on our total health care 
budget will be seen when introducing this medication to our CF patients, 
preliminary estimate from this study indicates that if rhDNase could be used, a 
reduction in the cost-effectiveness ratio can be obtained and costs reduction by 
11765 NIS can be estimated. This added value can help in part of the cost for 
making aerosol Dornase alfa available for CF patients.  
 Economic evaluation of Tobramycin nebulizer solution in cystic fibrosis showed 
that cost offsets may occur through changes in overall patient management with a 
reduction in the use of other healthcare resources to be about 25.5% of the total 
costs [38, 56]. A significant impact on our total health care budget will be seen 
when introducing this medication to our CF patients with costs reduction by 
9269.1 NIS can be estimated. This added value can help in part of the cost for 
making Tobramycin nebulizer solution available for CF patients. 
 
71 
 
Chapter 5: Discussion 
We described the clinical characteristics and outcomes of the 77 patients included in 
the Caritas baby hospital who visited pediatric pulmonology clinic. Our data indicate 
that the patients with CF followed under study have poor QoL, this has been 
confirmed by the death of two participant one month after we finished the study,         
a boy at 16 years of age and a girl didn't complete the seven months of her life, they 
died from their respiratory complication.  
Our sample was the population sample of CF disease as we took the available CF 
patients in West Bank. There were nine other CF patients that Caritas was aware of, 
but three of them refused to participate as they do not acknowledge the existence of 
the disease and three others cannot be reached because they traveled to other countries 
for treatment and the other three have not been confirmed as CF yet.   
Regarding patients’ characteristics, mean age at diagnosis was 4.16 years of age, 
ranging from <1 to 30 years, and the main clinical manifestations were pulmonary 
infections, malnutrition and pancreatic insufficiency, as in other studies; as already 
known, the late diagnosis results in worse prognosis of CF lung disease. Fortunately, 
improvements in age at diagnosis has been observed in recent years [57]. 
In this study, CF patients were divided into age groups according to the original 
protocol of the CFQ-R [58]. The formal inclusion of CFQ-R questionnaires as a 
clinical outcome was essential, as it detected the impact of treatment over QoL, from 
the perspective of patients and their families. It allowed the identification of baseline 
reference values for QoL in the different age groups, and the progression of the QoL 
domains scores over time. The present study was an attempt to rescue the outcomes of 
distinct age groups. Thus, it would be possible to make comparisons between these 
groups, to evaluate individual patients in relation to the baseline characteristics of 
their respective age groups, and to plan future strategies. 
At Caritas baby hospital, disease severity and its impact in patients with CF on the 
respiratory tract is determined by spirometery (FEV1), body mass index (BMI, Kg/m
2
) 
from their health profile and cystic fibrosis clinical score are also used. However, 
these methods cannot translate the patient perception of what it is like to live with a 
fatal chronic illness and therefore tell us little about the daily routine of patients and 
how they live. 
Our results show that the QoL of all patients is dissatisfactory in all domains (health, 
physical functioning, psychosocial functioning, and treatment burden), This is 
possibly due to the fact of poor health care services of medical and diagnostic 
procedure given to our patients relative to other population. In addition, self-perceived 
QoL varies from individual to individual and as values, beliefs, cultural context, and 
social context change their views over the years [54]. 
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Comparison of mean scores of the CFQ14+ group with CFQ6-13, no statistically 
significant difference between them was observed but in general the scores for adult 
(14+) are slightly higher than child (6-13) scores except for emotion and social 
domain This is possibly due to the fact that children are less anxious, less depressed 
but stubborn and refuse permanent treatment and they are distracted because they are 
in a transitional school stage of their life. There is a significant statistic between adult 
and child in eat domain as adult cares about the nature of his/her eating more than 
child. Although the score for patients less than 6 years of age is much higher than 
both as parents take care of their food needs. 
Symptoms of anxiety and depression in child, adolescents and adults correlate with 
low scores on instruments designed to quantify QoL and have been described as risk 
factors for poor treatment compliance, increased morbidity, and increased health care 
use in chronic diseases in many studies [59]. 
Regarding the questionnaires completed by the parents, we observe good agreement 
between the mean scores on the CFQ Parents 6-13 and the information obtained by 
means of the questionnaires applied to the patients. As determined in the score result 
of the parents the lowest scores were observed for the weight and body domains, 
suggesting parental dissatisfaction with the gastrointestinal functioning of their 
children. And statistical significance was seen in physical and treatment domain only. 
Some studies have shown differences between parent and child reporting of QoL, 
especially regarding physical and emotional aspects [60]. This is probably due to the 
high level of emotional distress experienced by parents. The health problems of 
children with CF limit their participation in physical activities, as well as in school 
and family activities, causing caregivers anxiety and depression [61]. 
In addition, concerns about the life expectancy, together with the expensive and 
demanding treatment regimens, contribute to the onset of depressive symptoms in 
caregivers, directly affecting activities of daily living and treatment compliance [61]. 
Illness severity as measured by FEV1 ranged from 33 to 111 percent predicted with 
mean value of 69.6 percent, was done for only 26 patients as the rest of patients (29) 
unable to pay due to poverty with high test price (800 NIS) and other 22 patients were 
less than 6 years of age and can't do the test. For child and adult groups there is no 
correlation between quality of life domain score and FEV1level measured as shown in 
other study FEV1 percent predicted may not improve substantially in patients whose 
lung function is > 75% predicted; however, these patients may report improvement in 
respiratory symptoms after treatment with antibiotics. Thus, in some cases, the patient 
reported outcomes may be more sensitive to change in symptoms than traditional 
pulmonary function indexes [62-65].  
In three studies conducted in the 2000s, the correlation between QOL and FEV1 in 
individuals with CF was assessed by the Child Health Questionnaire, with conflicting 
results. In two of the studies, no such correlation was found. However, the authors of 
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the third study observed that adolescents and adults with abnormal FEV1 reported a 
poor perception of their physical health [54, 66, 67]. 
There is a correlation between BMI results for 72 patients sample with mean value 
15.9978 Kg/m
2
 ranged from 9.60-23.12 and physical domain in quality of life 
questionnaire only, as described in the literature as an important factor for the onset of 
physical stress in individuals with CF, since it correlates with higher morbidity and 
mortality, requiring treatments that are even more demanding. 
The assessment of QoL in individuals with CF is important because it reveals the 
patient perception of what it is like to live with a fatal chronic illness and can improve 
treatment compliance [54, 68] In addition, it provides information for economic 
planning and make it possible to determine the impact of new treatments, as shown in 
a recent studies [69]. 
Most studies suggest that self-perceived health is directly related to age and to 
respiratory system impairment, becoming more evident in adolescents and adults with 
greater lung injury [70, 71]. 
In our study, as we compared quality of life score with demographic data we conclude 
that there is no correlation between age and QoL score for adult (14 and more) group 
as described. There are no differences in QoL with respect to gender with the 
exception of treatment to male as male compliance to treatment may be more than 
female because of different female concerns (body image, and weight). Specifically, 
social pressures to be thin were expected to affect females differentially. As detected 
in many studies with women experiencing greater declines in lung function than men 
[72]. 
However in many studies, women reported better functioning on scales that measured 
body image and weight, which could be related to a societal preference for thinness in 
women, regardless of the health consequences of low body weight in CF [53].  
For adult group, there are differences in physical, vitality, health, body, role and 
digest domains with respect to vacation without disease. There is no statistical 
difference with marital status as they were single or married all of them suffered from 
the disease with the same level. There are no differences between the levels of 
education for quality of life domains as all of patients are educated there is no 
uneducated patients. There is a correlation between quality of life physical and role 
domains related with work or school status for patients taking educational courses at 
home as they feel good and are more active and keep up their duties more than others 
status.  
In child (6-13) group there is no differences in QoL with respect to gender just in the 
eat domain related to male as males with no problem with eating more than female. 
There are no differences in QoL with respect to vacation without disease just in the 
eat domain related to yes answers as they eat well during vacation when they are 
73 
 
without disease problem. There is no difference in QoL with respect to education 
level just in social domain related to 7
th
 grade as they more mature than other and deal 
with their friends as easily as they can. In child (6-13) group (mean age is 9.21 years 
of age) there are no differences in QoL with respect to age with the exception of 
social domain as we said as they grow up they are better in dealing with people.  
In Parents (6-13) group, in the correlation between relationship (father, mother, 
grandfather and brother) parameter with QoL domains there is no differences in QoL 
score with respect to relationship. And there are no differences in QoL with respect to 
education level of the parents just in emotion, vitality and eat domains related to 
college degree. As the level of education for parents increase their knowledge about 
the disease and their ability to control increases. There is no differences in QoL with 
respect to work status of parents just in school domain for seeking work status as they 
able to educate their children and teach them well and feel the importance of science 
and keeping up with studying. There are differences in QoL of CF patients with 
respect to ages of their parents in physical, digest domains with negative correlation 
as they get older the quality of life of their children decreased. There is no correlation 
between marital status of the parents (married or divorced) and quality of life of their 
children.   
There is no correlation between monthly income (NIS) and QoL score for all groups 
in contrast to many studies indicate that as the income increase the QoL increase. 
There is a significant statistic between number of family member live in the same 
place and QoL score in vitality and health domain for all groups with negative 
correlation, with high number of family members the vitality and the health status of 
CF patients decrease. 
With geographic distribution of  CF patients results as described for 58 families,  
Hebron is the district with most patients suffering from CF disease (50 patients from 
Hebron) and it was the highest in which they have more than one patient in each 
family (8 families contain two patients). The reason for this is the high rate of 
marriage between relatives as indicated in many studies the rate of consanguineous 
marriages in Palestine was found to be 45% in 2004 [41]. The family that has the 
highest number of patients (4 patients) was from Nablus district. In all districts 
studied, patients suffer from CF disease in the same level there is no differences in 
quality of life between the districts and there is no significant correlation between 
QoL domain score and patient kind of living (city, village and camp) this indicates 
that all Palestinian CF patients live in the same conditions, whether in a village, town 
or camp from north to south. 
In our study, 21% of families (12/58) reported death cases related to CF disease, one 
family from Hebron has four CF death cases, this high rate of diagnosed CF death 
cases related to poor management strategies, therapies, and lack of earlier diagnostic 
procedures.  
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46.8% of CF patients don't take influenza vaccine yearly to prevent them from 
recurrent infections as confirmed in many studies [73, 74]. There are many reasons 
for this clarified when we asked the patients. One of reasons given is the lack of 
knowledge about the benefit from vaccination and they should take it, or for not being 
able to buy it or get it from Ministry of Health, or some patients said that they used it 
without any benefit. 
As we measured in the willingness to pay section, 93.5% answered yes for paying and 
6.5% answered no for that. Of patients who said yes 51.4% willing to pay are able to 
give 100 NIS out of pocket each month to get these new drugs, 37.5% are able to pay 
50 NIS, 8.3% able to pay 500 NIS and 2.8% able to pay 2000 NIS or more to get 
these new drugs. This mean that our patients looking for a solution to their current 
situation.  
In our study, 40.3% of patients chose among the things that were presented to them 
the most important thing they needed is to facilitate the mechanism of treatment by 
providing modern equipment for treatment and 33.3% of patients chose to pay in 
return for new medicines that reduce disease symptom and improve general health in 
different ways.  
One might anticipate that patients who are willing to pay may have the worse QoL but 
in our study there is no statistical significant correlation between willingness to pay 
and quality of life domains as all CF patient in our country have poor quality of life 
scores as they suffer from the disease in the same level without differences and most 
of them willing to pay and the main reason for patients who don't want to pay is poor 
financial situation and poverty. The amount of money they are willing to pay is 
related to their monthly income not to the severity of the disease status.   
In our study we compared our CF patient’s quality of life scores to normative CF 
international data, US sample and Brazilian sample. As we see Palestinian CF patients 
have poor quality of life, this is related to that our treatment regimen for CF is highly 
complex and time consuming, requiring 2–4 h of treatment every day. The treatment 
regimen includes multiple inhaled therapies, airway clearance two times per day, oral 
medications, and boosting calories to 110–200% of the recommended daily 
allowance. The challenges of adhering to this regimen include the time required, the 
complexity of using and cleaning the equipment, and its considerable cost. In 
addition, patients experience frequent pulmonary exacerbations, hospitalizations, and 
segregation from peers due to multi-resistant bacteria. High rates of depression and 
anxiety have also been reported by both patients and caregivers. 
After economic evaluation of health care resources use and costs, the total costs of 
care for CF patient 10.7 years of age were estimated to be around 35650.2 NIS per 
patient per year as the treatment burden of this disease in the West Bank is very huge 
and expensive as we discussed. This total cost can be reduced by 33% and 25.5% with 
administration of Dornase-alpha mucolytic drug and Tobramycin antibiotic drug 
75 
 
respectively [22, 38]. According to literature review studies which indicated that by 
using these drugs, cost offsets may occur through changes in overall patient 
management with a reduction in the use of total health care resources. The savings 
obtained from using recommended drug may help offset the cost of adding them to 
the health care of CF patients.  
Limitation 
These results should be interpreted in light of some limitations. First, as a result of the 
lack of special centers that monitor and deal with CF patients and clarify many 
clinical aspects and outcomes of CF patients, we had difficulty in obtaining the full 
number of patients in West Bank and Gaza strip. As well, the sample size, although 
reasonable for this rare disease, was relatively small for the analyses that were 
conducted. Thus, this study was likely underpowered to detect some of the predicted 
relationships. 
Second, the lack of a comparison group between our CF patients treated with new 
medication that we discussed in this study as Dornase-alpha or Tobramycin inhalation 
solution is a limitation that impairs a complete investigation about the benefits of 
these new drugs in the West Bank. In view of the current recommendations regarding 
the use of Dornase alpha or Tobramycin, it was decided to base our data on the 
literature studies due to high cost price for these medication and lack of financial and 
human resources to apply these drugs in the West Bank. Nevertheless, in our study, 
subjects served as their own controls as clinical information for our CF patients were 
compared to normative CF international data.    
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Chapter 6: Conclusion 
    CF places a large treatment burden on patients and their families with complex, 
time-intensive therapies and multiple medications administered throughout the day. 
Recent studies of adults with CF found that perceived treatment burden was highly 
associated with the number of nebulized medications prescribed. In addition, lengthy 
hospitalizations, which are commonplace in treatment plans, are disruptive to 
families, schooling, work, and extracurricular activities. 
In summary, We reported that CF patients and their families in the West Bank face 
many barriers including large treatment burden that may make adherence difficult, 
financial challenges, late diagnosis on their life with poor diagnostic procedure and 
lack of resources needed to ensure optimal care for patients with CF. These resources 
include adequate clinic space and a dedicated CF team with nurses, a nutritionist, 
social workers, pharmacists, and respiratory therapists, as well as ancillary support 
from psychology, clinical laboratories (microbiology, chemistry and molecular 
diagnostics), radiology, and pulmonary function testing. Confronted with complex 
medical care, it may not be possible to adequately address all issues in the time 
allotted, and assessing patient compliance is difficult, as self-reported adherence 
typically represents an overestimation. 
We have observed that our CF patients have significant disease morbidity and 
mortality despite all routine therapies that they receive. There is a significant decrease 
in the CFQ-R scores of the respiratory symptoms, emotional functioning, body image, 
and treatment burden domains in the subgroup of patients with cystic fibrosis. And 
quality of life for patients with CF is poor relative to international standards, the 
medications used including hypertonic saline and gentamycin are not first line 
therapies around the world, patients and their families demand better treatment and 
are willing to pay to get better treatment. 
So continued research and work are needed to identify optimal outcome measures, In 
order to provide everything new, advanced and useful in management of our CF 
patients specially by the role of pharmacist as pivotal to the medicines management 
program to support the optimization of medicines for patients. The benefits of a 
dedicated CF pharmacist have previously been described, including benefits in terms 
of financial savings, improvements in patient care and efficient use of resources. This 
role of the pharmacist in pharmaceutical care model needs to be enlarged to improve 
efficiency and safety of drug therapy, to guard compliance to medication, to improve 
patients quality of life, and to ameliorate patient satisfaction.  
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Future Directions and recommendations 
This study highlighted several possible future directions related to CF disease in the 
West Bank. Based on the findings from the current study, we can give an objective 
proof for the need of new therapies for CF patients in Palestine to Ministry of Health 
and government in order to improve their QoL, health status and longevity.  
Recommendations to Policy Makers and Health Providers: 
Establish a center for cystic fibrosis under supervision of Ministry of Health which 
includes specialists, trained nurses, dietitians, pharmacists, physiotherapists and 
psychologists with full equipment to follow up patients, note growth and development 
and give instructions, this could also expand to allocating special hospital departments 
for CF or even special clinics distributed in various localities to be able to better 
manage CF patients and assist them, this would enhance the trust in the medical body 
thus improving complicate from the patients side.                                                 
Specific criteria should be followed by physicians in the diagnosis of CF patients. The 
criteria for CF diagnosis must not relay on symptoms and sweat test only. Screening 
tests should be performed especially for families with CF history as we will ask for 
early medical screening program for the disease before marriage which are commonly 
applied in other countries. Training and counseling concerning the effects of 
consanguineous marriage involving religious and community leaders. Make neonatal 
screening program of CF for early diagnosis and to avoid complications of the 
disease. A comprehensive database must be established to hereditary diseases 
commonly found among Palestinian population including CF. 
Recommendations for Researchers  
Extensive mutation analysis to determine the relationship between the CFTR gene 
mutations and the course of the disease should be evaluated in order to provide better 
management and treatment for the CF patients. To concentrate on extra research 
projects on CF disease would benefit from an increase in the number of participants in 
future studies.     
Although the results of economic evaluation that has been done in this study could not 
be used specifically since they mirror some distortions and limitations, however, this 
study has succeeded in identifying the major trends of the QoL for cystic fibrosis 
patients in addition to pin pointing the relative importance of new therapeutic options 
in their lives and its specific attributes. It is however, important to have effective 
awareness campaigns about cystic fibrosis in society in order to further decrease the 
incidence levels of cystic fibrosis. 
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  mrof tnesnoc demrofnI :A xidneppA
 
ذمٍٍُ ٔٛعٍح حٍاج ِطػى اٌرٍٍف اٌىٍسً فً ( أقشُّ أّب اىَ٘قع إعَٜ أدّبٓ ثأّٔ قذ رٌ إعلاٍٜ ثفح٘ٙ ٕزٓ اىذساعخ
يٚ أُ أشبسك فٖٞب ىَب فٖٞب ٍِ ع ٗأّْٜ قذ ٗافقذ ثَحط إسادرٜ )اٌؼفح اٌغطتٍح ٚاٌرٍاضاخ اٌعلاجٍح اٌجسٌسج
 خذٍخ ىيعيٌ ٗاىَعشفخ.
 : ٗأقشُّ أٝعب ًأّٔ رٌ إعلاٍٜ ثدَٞع إٔذاف اىذساعخ ٕٜٗ
 دساعخ اى٘ظع اىصحٜ ىَشظٚ اىزيٞف اىنٞغٜ فٜ فيغطِٞ. 
 دساعخ اىعتء الاقزصبدٛ  ٗرنبىٞف اىعلاج اىحبىٞخ  ٗرأثٞشٕب عيٚ اىَشظٚ. 
خ ٍقبثو اىحص٘ه عيٚ علاج خذٝذ ٝحغِ ٍِ اى٘ظع اىصحٜ ٍعشفخ سغجخ اىَشظٚ فٜ اىَغبَٕخ اىَبىٞ 
 ٗٝقيو ٍِ اعشاض اىَشض ٗدساعخ اىع٘اٍو اىزٜ عزأثش عيٚ اخبثزٌٖ. 
 حبخخ اىٚ علاج خذٝذ ىَشض اىزيٞف اىنٞغٜ (ثبلاعزَبد عيٚ اىْزبئح).ىفذ اىْظش إىٚ اى 
رذاٗىٖب فٜ اىَحبفو اىعيَٞخ دُٗ  مَب ٗأعيَذ أُ اىَعيٍ٘بد اىزٜ ٝزحصو عيٖٞب ٍّْٜ ع٘ف رعبٍو ثغشٝخ ٗعٞزٌ
 رمش إعَٜ.
 مَب ٗأقّش أّٔ رٌ الإخبثخ ثشنو ٍشظٜ عِ خَٞع أعئيزٜ الأخشٙ ح٘ه اىذساعخ.
 
 
 ٌمس لطأخ اٌّعٍِٛاخ اٌساتك شوط٘ا أٚ ذُ لطاءذٙا ًٌ ٚأٚافك عٍى اٌّشاضوح فً اٌسضاسح.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 اسُ اٌّشاضن :
 
 ذٛلٍع اٌّشاضن:
 
 اٌراضٌد:
 
 اسُ اٌثاحس:
 
 ٛلٍع اٌثاحس:ذ
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Appendix B: Cystic Fibrosis Questionnaire – Revised (CFQ-R) form  
 
1. Child (6-11) years of age version 
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85 
 
86 
 
87 
 
2.Child (12-13) years of age version  
88 
 
 
89 
 
91 
 
 
 
 
 
 
91 
 
3.Adult 14 years and more version  
 
92 
 
93 
 
94 
 
95 
 
 
 
 
 
 
96 
 
4.Parent for child (6-13) years of age version  
 
97 
 
98 
 
 
99 
 
 111
 
 
  mrof yap ot ssengnilliw dna cimonoce-oicos ,sutats htlaeH :C xidneppA
  
 
 ِا ً٘ الازٌٚح اٌرً ذرٕاٌٚٙا ٚوٍف ذأذص٘ا : ___________________________________ . أ
 _______________________________________________________________
 ______________________________________________________________
 
 ِا ٘ٛ ٔٛع ِطػه: . ب
 ) 07 ≥ 98 <1VEFخفٞف (  o
  07 < 1VEF ≤ 04 (      ٍز٘عػ ( o
 ) 1VEF>  04حبد (  o
 
 وُ ٚظٔه ( وغُ) ٚوُ ؽٌٛه (ِرط) ؟ . خ
 ____________________________________________
 
 ِطع اٌرٍٍف اٌىٍسً؟ ترظٛص ذٛعٍح ٍىع حظٍد ً٘ . ز
 لا o
 ............................... ؟ ٍزٚ..............................................  ؟ أِٝ ؛ ّعٌ o
 
 
 
 _________________ عسز افطاز الاسطج (الاب/الاَ/الاتٕاء): . أ
 _________________________ وُ فطز ٌسىٓ فً اٌثٍد: . ب
 
 ٍخٌٞ □         قشٝخ  □          ٍذْٝخ□    :  اٌسىٓ ِىاْ . خ
 
       ٗاىجٞشح الله ساً ٍحبفظخ  □اىخيٞو      ٍحبفظخ  □     ىحٌ ٍحبفظخ ثٞذ  □   اىقذط   ٍحبفظخ  □ 
 أسٝحب    ٍحبفظخ  □خِْٞ         ٍحبفظخ □ّبثيظ         ٍحبفظخ  □غ٘ثبط    ٍحبفظخ  □ 
 غ٘ىنشً    ٍحبفظخ  □عيفٞذ        ٍحبفظخ  □قيقٞيٞخ      ٍحبفظخ  □ 
  
 اٝدبس   □ٍيل                   □        اٌسىٓ :   . ز
   
 وُ ذىٍفح ِٛاطلاذه ٌٍٛطٛي اٌى ِطاوع اٌعلاض؟ ____________________  . ض
 ِا ٘ٛ ِعسي اٌسذً اٌشٙطي ٌلأسطج ( تاٌشٍىً) ؟  . ح
 
  0051<  o
  0003 - 0051 o
 اٌحاٌح اٌظحٍح 
 
 اٌٛػع الاجرّاعً ٚالالرظازي
 
 111
 
   0005 - 1003 o
  0005>   o
 
  ٌح ِساعسج / زعُ ذاضجً ( جّعٍاخ، الاضب ٚغٍط٘ا ):ً٘ ذحظً عٍى ا . خ
 لا o
 ٍِ أِٝ؟ ________________ ؛ ّعٌ o
  o
 
 وُ شٙط تاٌسٕح ذأذص ذثرٍطاخ اٌّؼاز اٌحٍٛي: ____________ .1
 وُ ِطٖ ذسذً اٌّسرشفى تاٌسٕح:__________________ .2
ه وُ ً٘ اٌّسج اٌرً ذرٍمى فٍٙا اٌّؼازاخ اٌحٌٍٛح عٓ ؽطٌك اٌٛضٌس عٕس زذٌٛ .3
 ٌٍّسرشفى:__________________________
 وُ ِطٖ ذرٛاطً فٍٙا ِع اٌطثٍة لأسثاب ذرعٍك تّطع اٌرٍٍف اٌىٍسً سٌٕٛا:ً______ .4
 وُ ِطج تاٌسٕح ذمَٛ تاٌفحٛطاخ اٌراٌٍح: .5
 فحص اىجيغٌ:____________ . أ
 فح٘صبد اىذً:___________ . ة
 فح٘صبد اشعخ:__________ . خ
 ًّ لأسثاب ذرعٍك تّطع اٌرٍٍف اٌىٍسً شٙطٌا:ً__________ِا ٘ٛ ِعسي ذغٍثه عٓ اٌسضاسح اٚ اٌع .6
 ً٘ ذرٍمى ذطعٍُ الأفٍٛٔعا سٌٕٛا ً: .7
 ّعٌ o
 لا، ىَبرا؟_____________________________ o
 ً٘ ٕ٘اٌه ازٌٚح اػافٍح ذرٕاٌٚٙا :  .8
 لا o
 ؛ ٍب ٕٜ ٗمٌ رنيفزٖب ؟_____________________________________________ ّعٌ o
  
 
 
 
 
 ……………………….….…ً٘ ذفىط فً ٚػعه اٌّازي؟ .1
 
ً٘ ٌسٌه اٌصمح تأْ علاجه سٛف ٌىْٛ ِرٛفطاً فً جٍّع  .2
 ....………………………………..……….…الأٚلاخ؟
 
ً٘ أد ِمرٕع تحظٌٛه عٍى واًِ احرٍاجاذه اٌظحٍح  .3
  ...……………………………..……...……ٚاٌعلاجٍح؟
 اتسا ًلا
 
 
 
  اً زائّ غاٌثاً  احٍأاً  
 
   ً
 
 
 
 اٌٛػع الالرظازي تّا ٌرعٍك تظحح اٌّطٌغ
 
 اٌطجاء اذرٍاض اٌّطتع إٌّاسة لإجاتره.
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 ...………ٌحاٌٍح عٍى حٍاذه الاجرّاعٍح؟ً٘ ذؤشط ؽطق اٌعلاض ا .4
 
  ….…...………ً٘ ٌسٌه اٌّٛاضز اٌّاٌٍح اٌىافٍح ٌرٍمً اٌعلاض؟ .5
 
 ……......…ً٘ ذشعط تأْ ؽطق علاجه اٌحاٌٍح ٌجة اْ ذرغٍط؟ .6
 
 
عٍى اٌرمًٍٍ ِٓ اعطاع اٌّطع ٚاٌرحسٍٓ ِٓ  اٌحاٌح اٌظحٍح ِٓ  اشا ذٛفط ٌسٌه تعغ الازٌٚح اٌرً ذساعس
ِٓ الاعطاع ٚاٌّفالّاخ اٌطئٌٛح اٌرً ذظٍثه ، ٚذّٕحه فططح علاجٍح ذمًٍ ِٓ اٌحاجح ٌٍعٕاٌح ذلاي اٌررفٍف 
اٌظحٍح ٌىً ِا ٌرعٍك تالاٌرٙاتاخ اٌطئٌٛح اٌحازج ِٚا ٌطافمٙا ِٓ ذلاي الاسررساَ اًٌٍِٛ ٚاٌّرٛاطً ٌٍسٚاء 
 زْٚ اٌحاجح ٌٍعلاض عٓ ؽطٌك اٌٛضٌس اٚ زذٛي اٌّسرشفى . 
 سفع ِثٍغ اوثط ِٓ اٌصي ذسفعٗ حاٌٍا ِماتً  اٌحظٛي عٍى ذٍه الازٌٚح: ً٘ عٕسن اسرعساز ٌ
 ٔعُ  o
 
 لا  o
 :ٔعُ ب الاجاتح وأد اشا
ِسرعس اْ ذسفعٗ شٙطٌا ً تاٌشٍىًاٌّاي   ِثٍغ ِٓ ، ِا ٘ٛ أوثط ٍِٚعأٍح الأسطج ػع تاعرثاضن زذٍه اٌشٙطي
 ِماتً اٌحظٛي عٍى ذٍه الازٌٚح:  
 05 o
 001 o
 005 o
 0001 o
 0051 o
  أٗ أمثش 0002 o
 جسٌس علاض عٍى اٌحظٛي اتًِم اٌّاي ِٓ ِثٍغ ٌسفع الاسرعساز
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 ِا ً٘ اٌعٛاًِ / الأِٛض اٌرً ذطٌس ذحمٍمٙا ِٓ ذلاي ِساّ٘ره تاٌسفع:        
 لا ٔعُ اٌظفح 
 
 1
 
 
ر٘فٞش أدٗٝخ خذٝذح رقيو ٍِ الأعشاض ٗرحغِ اىحبىخ اىصحٞخ اىزٜ رحزبج اىٚ 
 اىَعبداد اىحٞ٘ٝخ اى٘سٝذٝخ 
  
 
 2
 
 ج ٍِ خلاه ر٘فٞش اخٖضح حذٝثخ ىيعلاىٞخ اىعلاج اّ رغٖٞو 
  
 
 3
 
 رقيٞو اى٘قذ اىزٛ رغزغشقٔ أثْبء ريقٞل اىعلاج ثبىزجخٞشح
  
 
 4
 
 ٍِ خلاه رقيٞو عذد صٝبساد/دخ٘ه اىَغزشفٚ اىزقيٞو ٍِ رنبىٞف اىعلاج اىشٖشٝخ
  
 
 5
 
  ٍَبسعخ اىحٞبح اىٍٞ٘ٞخ ثشنو غجٞعٜ قذسح عيٚاىرحغِٞ 
  
 
 6
 
 
 أٍ٘س اخشٙ،  امزجٖب: 
 
 عٍه ِسرعسا ٌسفع اٌّاي ِماتٍٗ تإٌسثح ٌه: _____________________ِّا سثك ِا ٘ٛ أُ٘ شًء ٌج
 اشا وأد الاجاتح ب لا:
 411
 
 ِا ً٘ الأِٛض اٌرً زفعره ٌلإجاتح ب لا: 
 لا ٔعُ اٌظفح 
 
 1
 
 اىحبىخ اىَبدٝخ عٞئخ 
  
 
 2
 
 عذً اىشغجخ فٜ اىزغٞٞش 
  
 
 3
 
 أسٙ اى٘ظع ٍْبعت
  
 
 4
 
 ىَز٘فشح ىذٛالاعزٞبد عيٚ اعزخذاً الأدٗٝخ ا
  
 
 5
 
عذً اىشغجخ فٜ اىعلاج ثشنو ٍطيق ع٘اء ثَب ٕ٘ ٍز٘فش ٍِ أدٗٝخ قذَٝخ أٗ 
 خذٝذح 
  
 
 6
 
 غٞش رىل، امزجٔ: 
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Appendix E: Data for results  
 Domain scored for each item of adult 14 years of age and more version  
Descriptive Statistics 
  N Minimum Maximum Mean Std. 
Deviation 
Section II. Quality 
of Life q1 
22 1.00 4.00 37.878788 .83355 
Section II. Quality 
of Life q2 
22 1.00 4.00 37.878788 .88884 
Section II. Quality 
of Life q3 
22 1.00 4.00 28.787879 1.03719 
Section II. Quality 
of Life q4 
22 1.00 4.00 31.818182 .95005 
Section II. Quality 
of Life q5 
22 1.00 3.00 22.727273 .77989 
Section II. Quality 
of Life q13 
22 1.00 4.00 62.121212 .88884 
Section II. Quality 
of Life q19 
22 1.00 4.00 25.757576 .75162 
Section II. Quality 
of Life q20 
22 1.00 4.00 25.757576 .92231 
Physical 22 .00 91.67 31.0614 24.42242 
Section III. 
School, Work, or 
Daily Activities q 
35 
22 1.00 4.00 43.939394 .94548 
Section III. 
School, Work, or 
Daily Activities q 
36 
22 1.00 3.00 36.363636 .68376 
Section III. 
School, Work, or 
Daily Activities q 
37 
22 1.00 4.00 34.848485 .72225 
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Section III. 
School, Work, or 
Daily Activities q 
38 
22 1.00 4.00 33.333333 .69007 
Role 22 .00 91.67 40.1527 21.76737 
Section II. Quality 
of Life q6 
22 1.00 4.00 71.212121 .83355 
Section II. Quality 
of Life q9 
22 1.00 3.00 30.30303 .81118 
Section II. Quality 
of Life q10 
22 1.00 4.00 13.636364 .79637 
Section II. Quality 
of Life q11 
22 1.00 4.00 40.909091 .92231 
Vitality 22 .00 91.67  22.95386 
Section II. Quality 
of Life q7 
22 1.00 4.00 43.939394 .94548 
Section II. Quality 
of Life q8 
22 1.00 4.00 56.060606 1.17053 
Section II. Quality 
of Life q12 
22 1.00 4.00 53.030303 1.00755 
Section II. Quality 
of Life q31 
22 1.00 4.00 53.030303 .73414 
Section II. Quality 
of Life q33 
22 1.00 4.00 30.30303 1.01929 
Emotion 22 6.67 100.00  24.85114 
Section II. Quality 
of Life q22 
22 1.00 4.00 43.939394 .94548 
Section II. Quality 
of Life q23 
22 1.00 3.00 40.909091 .75162 
Section II. Quality 
of Life q27 
22 1.00 4.00 57.575758 .98473 
Section II. Quality 
of Life q28 
22 1.00 4.00 53.030303 .73414 
Section II. Quality 
of Life q29 
22 1.00 3.00 31.818182 .57547 
Section II. Quality 
of Life q30 
22 1.00 4.00 40.909091 .81251 
Social 22 11.11 66.67  12.70508 
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Section II. Quality 
of Life q24 
22 1.00 4.00 18.181818 .85786 
Section II. Quality 
of Life q25 
22 1.00 44.00 83.333333 9.08557 
Section II. Quality 
of Life q26 
22 1.00 4.00 31.818182 .95005 
Body 22 .00 88.89 22.7268 27.32017 
Section II. Quality 
of Life q14 
22 1.00 4.00 40.909091 .68534 
Section II. Quality 
of Life q21 
22 1.00 4.00 51.515152 .85786 
Section IV. 
Symptom 
Difficulties q 50 
22 1.00 4.00 56.060606 .77989 
Eat 22 11.11 100.00  22.48673 
Section II. Quality 
of Life q15 
22 1.00 4.00 78.787879 .72673 
Section II. Quality 
of Life q16 
22 1.00 4.00 78.787879 .78954 
Section II. Quality 
of Life q17 
22 3.00 4.00 81.818182 .50965 
Treatment 22 .00 66.67 20.2005 17.69651 
Section II. Quality 
of Life q18 
22 1.00 4.00 66.666667 .69007 
Section II. Quality 
of Life q32 
22 1.00 4.00 25.757576 .97257 
Section II. Quality 
of Life q34 
22 1.00 4.00 21.212121 .78954 
Health 22 .00 100.00 26.7664 23.67253 
Section IV. 
Symptom 
Difficulties q 40 
22 1.00 3.00 25.757576 .86914 
Section IV. 
Symptom 
Difficulties q 41 
22 1.00 4.00 21.212121 .84771 
Section IV. 
Symptom 
Difficulties q 42 
22 1.00 3.00 19.69697 .73414 
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Section IV. 
Symptom 
Difficulties q 43 
22 1.00 4.00 65.151515 .72225 
Section IV. 
Symptom 
Difficulties q 44 
22 1.00 4.00 37.878788 .83355 
Section IV. 
Symptom 
Difficulties q 45 
22 1.00 4.00 33.333333 .87287 
Section IV. 
Symptom 
Difficulties q 46 
22 1.00 3.00 31.818182 .84387 
Respiratory 22 .00 77.78  22.73846 
Section IV. 
Symptom 
Difficulties q 47 
22 1.00 4.00 36.363636 1.01929 
Section IV. 
Symptom 
Difficulties q 48 
22 1.00 4.00 46.969697 1.05375 
Section IV. 
Symptom 
Difficulties q 49 
22 1.00 4.00 36.363636 1.01929 
Digest 22 .00 100.00 39.8986 28.20616 
 
 Quality of life domain scores for adult (14+) correlated with their marital 
status (single or married).  
Ranks 
 
Marital status of adult N Mean Rank Sum of Ranks 
Physical 
 
single 20 12.35 247.00 
married 2 3.00 6.00 
Total 22   
Vitality 
 
single 20 11.73 234.50 
married 2 9.25 18.50 
Total 22   
Emotion 
 
single 20 12.08 241.50 
married 2 5.75 11.50 
Total 22   
Eat 
 
single 20 12.25 245.00 
married 2 4.00 8.00 
Total 22   
Treatment  single 20 11.85 237.00 
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married 2 8.00 16.00 
Total 22   
Health 
 
single 20 12.25 245.00 
married 2 4.00 8.00 
Total 22   
Social 
 
single 20 12.03 240.50 
married 2 6.25 12.50 
Total 22   
Body 
 
single 20 11.88 237.50 
married 2 7.75 15.50 
Total 22   
Role 
 
single 20 11.48 229.50 
married 2 11.75 23.50 
Total 22   
Weight 
 
single 20 12.05 241.00 
married 2 6.00 12.00 
Total 22   
Respiratory 
 
single 20 12.03 240.50 
married 2 6.25 12.50 
Total 22   
Digest 
 
single 20 12.05 241.00 
married 2 6.00 12.00 
Total 22   
 
 Quality of life domain scores for adult (14+) correlated with level of 
education. 
Ranks 
 
Education level of adult N Mean Rank 
Physical Some high school or less 15 10.50 
High school diploma/GED 2 12.00 
College degree 4 16.88 
Professional or graduate 
degree 
1 4.00 
Total 22  
Vitality 
 
 
Some high school or less 15 10.30 
High school diploma/GED 2 12.50 
College degree 4 14.50 
Professional or graduate 
degree 
1 15.50 
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 Total 22  
Emotion Some high school or less 15 11.13 
High school diploma/GED 2 11.75 
College degree 4 13.13 
Professional or graduate 
degree 
1 10.00 
Total 22  
Eat Some high school or less 15 11.33 
High school diploma/GED 2 11.50 
College degree 4 13.38 
Professional or graduate 
degree 
1 6.50 
Total 22  
Treatment Some high school or less 15 10.33 
High school diploma/GED 2 12.75 
College degree 4 15.00 
Professional or graduate 
degree 
1 12.50 
Total 22  
Health Some high school or less 15 10.57 
High school diploma/GED 2 12.00 
College degree 4 16.13 
Professional or graduate 
degree 
1 6.00 
Total 22  
Social Some high school or less 15 11.53 
High school diploma/GED 2 7.75 
College degree 4 15.50 
Professional or graduate 
degree 
1 2.50 
Total 22  
Body Some high school or less 15 11.33 
High school diploma/GED 2 12.75 
College degree 4 11.63 
Professional or graduate 
degree 
1 11.00 
Total 22  
Role 
 
 
Some high school or less 15 10.57 
High school diploma/GED 2 12.50 
College degree 4 12.25 
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Professional or graduate 
degree 
1 20.50 
Total 22 
 
Weight Some high school or less 15 11.83 
High school diploma/GED 2 10.75 
College degree 4 12.00 
Professional or graduate 
degree 
1 6.00 
Total 22  
Respiratory Some high school or less 15 10.73 
High school diploma/GED 2 15.25 
College degree 4 14.38 
Professional or graduate 
degree 
1 4.00 
Total 22  
Digest Some high school or less 15 11.23 
High school diploma/GED 2 11.75 
College degree 4 12.88 
Professional or graduate 
degree 
1 9.50 
Total 22  
 
 Quality of life domain scores for adult (14+) correlated with work status. 
Ranks 
 
Work status of adult N Mean Rank 
Physical Attending school outside 
the home 
12 12.17 
Taking educational courses 
at home 
1 22.00 
Seeking work 1 2.00 
Working full or part time 
(either outside the home or 
at a home-based business) 
5 14.30 
Not attending school or 
working due to my health 
3 3.83 
Total 22  
Vitality Attending school outside 
the home 
12 11.50 
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Taking educational courses 
at home 
1 22.00 
Seeking work 1 3.00 
Working full or part time 
(either outside the home or 
at a home-based business) 
5 14.70 
Not attending school or 
working due to my health 
3 5.50 
Total 22  
Emotion Attending school outside 
the home 
12 12.33 
Taking educational courses 
at home 
1 22.00 
Seeking work 1 1.50 
Working full or part time 
(either outside the home or 
at a home-based business) 
5 12.50 
Not attending school or 
working due to my health 
3 6.33 
Total 22  
Eat Attending school outside 
the home 
12 12.88 
Taking educational courses 
at home 
1 21.50 
Seeking work 1 1.50 
Working full or part time 
(either outside the home or 
at a home-based business) 
5 12.00 
Not attending school or 
working due to my health 
3 5.17 
Total 22  
Treatment 
 
 
 
 
 
 
Attending school outside 
the home 
12 10.88 
Taking educational courses 
at home 
1 22.00 
Seeking work 1 3.50 
Working full or part time 
(either outside the home or 
at a home-based business) 
5 14.50 
Not attending school or 
working due to my health 
3 8.17 
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Total 22 
 
Health Attending school outside 
the home 
12 10.96 
Taking educational courses 
at home 
1 22.00 
Seeking work 1 2.00 
Working full or part time 
(either outside the home or 
at a home-based business) 
5 14.10 
Not attending school or 
working due to my health 
3 9.00 
Total 22  
Social Attending school outside 
the home 
12 12.04 
Taking educational courses 
at home 
1 5.50 
Seeking work 1 10.00 
Working full or part time 
(either outside the home or 
at a home-based business) 
5 12.90 
Not attending school or 
working due to my health 
3 9.50 
Total 22  
Body Attending school outside 
the home 
12 12.50 
Taking educational courses 
at home 
1 21.00 
Seeking work 1 4.50 
Working full or part time 
(either outside the home or 
at a home-based business) 
5 11.50 
Not attending school or 
working due to my health 
3 6.67 
Total 22  
Role Attending school outside 
the home 
12 12.63 
Taking educational courses 
at home 
1 22.00 
Seeking work 1 3.00 
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Working full or part time 
(either outside the home or 
at a home-based business) 
5 13.90 
Not attending school or 
working due to my health 
3 2.33 
Total 22  
Weight Attending school outside 
the home 
12 12.50 
Taking educational courses 
at home 
1 15.50 
Seeking work 1 6.00 
Working full or part time 
(either outside the home or 
at a home-based business) 
5 10.80 
Not attending school or 
working due to my health 
3 9.17 
Total 22  
Respiratory Attending school outside 
the home 
12 11.83 
Taking educational courses 
at home 
1 22.00 
Seeking work 1 8.50 
Working full or part time 
(either outside the home or 
at a home-based business) 
5 12.30 
Not attending school or 
working due to my health 
3 6.33 
Total 22  
Digest Attending school outside 
the home 
12 12.83 
Taking educational courses 
at home 
1 21.00 
Seeking work 1 2.50 
Working full or part time 
(either outside the home or 
at a home-based business) 
5 12.20 
Not attending school or 
working due to my health 
3 4.83 
Total 22  
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 Domain scores for each item of Child (6-13) years of age version   
Descriptive Statistics 
  
N Minimum Maximum Mean 
Std. 
Deviation 
Q.1 33 1.00 3.00 34.3434 .58549 
Q.2 33 1.00 3.00 25.2525 .75126 
Q.3 33 1.00 3.00 24.2424 .67420 
Q.4 33 1.00 3.00 24.2424 .62614 
Q.5 33 1.00 3.00 19.1919 .61392 
Q.6 33 1.00 4.00 31.3131 .86384 
Q.7 33 1.00 4.00 33.3333 .79057 
Q.8 33 1.00 4.00 46.4646 .82687 
Q.9 33 1.00 3.00 38.3838 .71244 
Q.10 33 1.00 4.00 52.5253 .79177 
Q.11 33 2.00 4.00 69.6970 .63066 
Q.12 33 2.00 4.00 65.6566 .30464 
Q.13 33 2.00 4.00 64.6465 .34816 
Q.14 33 1.00 3.00 15.1515 .71111 
Q.15 33 1.00 4.00 54.5455 .89506 
Q.16 33 1.00 3.00 30.3030 .52223 
Q.17 33 1.00 4.00 51.5152 .90453 
Q.18 33 1.00 3.00 13.1313 .55562 
Q.19 33 1.00 4.00 32.3232 .84723 
Q.20 33 1.00 3.00 28.2828 .61853 
Q.21 33 2.00 4.00 51.5152 .71111 
Q.22 33 1.00 2.00 10.1010 .46669 
Q.23 33 2.00 4.00 91.9192 .50189 
Q.24 33 1.00 3.00 35.3535 .49620 
Q.25 33 2.00 4.00 74.7475 .61392 
Q.26 33 1.00 3.00 26.2626 .59987 
Q.27 33 1.00 3.00 16.1616 .61853 
Q.28 33 1.00 3.00 13.1313 .60927 
Q.29 33 1.00 3.00 14.1414 .56071 
Q.30 33 1.00 3.00 9.0909 .57406 
Q.31 33 1.00 3.00 19.1919 .75126 
Q.32 33 1.00 3.00 36.3636 .80482 
Q.33 33 1.00 3.00 16.1616 .71244 
Q.34 33 1.00 3.00 38.3838 .83371 
Q.35 33 1.00 3.00 23.2323 .80951 
Valid N 
(list wise) 
33 
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 Correlation between child (6-13) years domain scores and their gender 
Ranks 
 
 Gender of patients N Mean Rank Sum of Ranks 
physical 
 
male 12 17.88 214.50 
female 21 16.50 346.50 
Total 33   
Emotion 
 
male 12 18.17 218.00 
female 21 16.33 343.00 
Total 33   
Social 
 
male 12 19.42 233.00 
female 21 15.62 328.00 
Total 33   
Eat 
 
male 12 21.79 261.50 
female 21 14.26 299.50 
Total 33   
Treatment 
 
male 12 18.67 224.00 
female 21 16.05 337.00 
Total 33   
Body 
 
male 12 20.83 250.00 
female 21 14.81 311.00 
Total 
 
33 
  
Respiratory  
 
male 12 19.21 230.50 
female 21 15.74 330.50 
Total 33   
Digest 
 
male 12 16.17 194.00 
female 21 17.48 367.00 
Total 33   
 
 Correlation between child (6-13) years of age domain scores and taking 
vacation without disease.  
Ranks 
 
Vacation from school N Mean Rank Sum of Ranks 
Physical 
 
yes 8 21.88 175.00 
no 25 15.44 386.00 
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Total 33 
  
Emotion 
 
yes 8 17.38 139.00 
no 25 16.88 422.00 
Total 33   
Social 
 
yes 8 19.25 154.00 
no 25 16.28 407.00 
Total 33   
Eat 
 
yes 8 22.81 182.50 
no 25 15.14 378.50 
Total 33   
Treatment 
 
yes 8 18.69 149.50 
no 25 16.46 411.50 
Total 33   
Body 
 
yes 8 18.13 145.00 
no 25 16.64 416.00 
Total 33   
Respiratory  
 
yes 8 18.25 146.00 
no 25 16.60 415.00 
Total 33   
Digest 
 
yes 8 16.50 132.00 
no 25 17.16 429.00 
Total 33   
 
 Correlation between child (6-13) years of age domain scores and level of 
education.  
Ranks 
 
         Education level N Mean Rank 
Physical 
 
Kindergarten 3 15.33 
1st grade 6 23.33 
2nd grade 1 1.50 
3rd grade 6 13.17 
4th grade 3 6.67 
5th grade 7 20.57 
6th grade 4 15.50 
7th grade 3 22.83 
Total 33  
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Emotion 
 
Kindergarten 3 22.83 
1st grade 6 20.42 
2nd grade 1 2.50 
3rd grade 6 12.92 
4th grade 3 15.33 
5th grade 7 14.43 
6th grade 4 16.50 
7th grade 3 25.67 
Total 33  
Social 
 
Kindergarten 3 12.33 
1st grade 6 15.33 
2nd grade 1 1.50 
3rd grade 6 14.58 
4th grade 3 5.83 
5th grade 7 19.57 
6th grade 4 23.50 
7th grade 3 31.50 
Total 33  
Eat 
 
Kindergarten 3 11.50 
1st grade 6 16.58 
2nd grade 1 19.50 
3rd grade 6 15.92 
4th grade 3 5.67 
5th grade 7 24.14 
6th grade 4 15.50 
7th grade 3 21.33 
Total 33  
Treatment 
 
Kindergarten 3 21.67 
1st grade 6 15.92 
2nd grade 1 3.00 
3rd grade 6 18.25 
4th grade 3 6.17 
5th grade 7 22.07 
6th grade 4 12.50 
7th grade 3 21.67 
Total 33  
Body 
 
 
 
Kindergarten 3 20.83 
1st grade 6 18.92 
2nd grade 1 9.00 
3rd grade 6 16.67 
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4th grade 3 19.50 
5th grade 7 18.07 
6th grade 4 9.00 
7th grade 3 18.33 
Total 33 
 
Respiratory 
 
 
 
 
 
 
 
 
 
Kindergarten 3 10.50 
1st grade 6 14.67 
2nd grade 1 2.50 
3rd grade 6 15.17 
4th grade 3 23.33 
5th grade 7 24.07 
6th grade 4 12.88 
7th grade 3 19.33 
Total 33  
Digest 
 
  Kindergarten 3 
 
23.00 
1st grade 6 14.67 
2nd grade 1 22.00 
3rd grade 6 15.50 
4th grade 3 9.00 
5th grade 7 18.71 
6th grade 4 14.25 
7th grade 3 24.67 
Total 33  
 
 Domain score for each item of parent (6-13) version  
Descriptive Statistics 
  
N Minimum Maximum Mean 
Std. 
Deviation 
Section II. 
Quality of 
Life q1 
33 1 4 32.32 .883 
Section II. 
Quality of 
Life q2 
33 1.00 4.00 31.3131 .65857 
Section II. 
Quality of 
Life q3 
33 1.00 4.00 30.3030 .76500 
Section II. 
Quality of 
Life q4 
33 1.00 4.00 28.2828 .83371 
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Section II. 
Quality of 
Life q5 
33 1.00 4.00 27.2727 .76871 
 Section 
II.Quality 
of Life q6 
33 1.00 4.00 35.3535 .99810 
 Section 
II.Quality 
of Life q7 
33 1.00 4.00 46.4646 .82687 
 Section 
II.Quality 
of Life q8 
33 1.00 3.00 31.3131 .78817 
Section II. 
Quality of 
Life q9 
33 1.00 4.00 33.3333 1.06066 
 Section 
II.Quality 
of Life q10 
33 1.00 4.00 35.3535 .89928 
 Section 
II.Quality 
of Life q11 
33 1.00 4.00 34.3434 .84723 
 Section 
II.Quality 
of Life q12 
33 1.00 4.00 35.3535 .74747 
Section II. 
Quality of 
Life q13 
33 1.00 4.00 48.4848 .75378 
Section II. 
Quality of 
Life q14 
33 1.00 4.00 57.5758 .87581 
Section II. 
Quality of 
Life q15 
33 2.00 4.00 61.6162 .66714 
Section II. 
Quality of 
Life q16 
33 1.00 3.00 32.3232 .68396 
 Section 
II.Quality 
of Life q17 
33 1.00 4.00 48.4848 .93845 
Section II. 
Quality of 
Life q18 
33 1.00 3.00 31.3131 .70442 
 Section 
II.Quality 
of Life q19 
33 1.00 4.00 18.1818 .75378 
Section II. 
Quality of 
Life q20 
33 1.00 3.00 15.1515 .56408 
 Section 
II.Quality 
of Life q21 
33 1.00 3.00 11.1111 .59512 
 Section 
II.Quality 
of Life q22 
33 1.00 4.00 31.3131 .82687 
Section II. 
Quality of 
Life q23 
33 1.00 4.00 52.5253 1.00095 
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 Section 
II.Quality 
of Life q24 
33 1.00 4.00 39.3939 1.04447 
 Section 
II.Quality 
of Life q25 
33 1.00 4.00 44.4444 .88976 
 Section 
II.Quality 
of Life q26 
33 1.00 4.00 50.5051 .90558 
 Section 
II.Quality 
of Life q27 
33 1.00 4.00 49.4949 .83371 
Section II. 
Quality of 
Life q28 
33 1.00 4.00 45.4545 .89506 
Section II. 
Quality of 
Life q29 
33 1.00 4.00 40.4040 .85723 
 Section 
II.Quality 
of Life q30 
33 1.00 3.00 19.1919 .61392 
 Section 
II.Quality 
of Life q31 
33 2.00 4.00 73.7374 .69631 
 Section 
II.Quality 
of Life q32 
33 2.00 4.00 67.6768 .58549 
Section III. 
Symptom 
Difficulties 
q33 
33 1.00 4.00 15.1515 .71111 
Section III. 
Symptom 
Difficulties 
q34 
33 1.00 3.00 14.1414 .56071 
Section III. 
Symptom 
Difficulties 
q35 
33 1.00 3.00 20.2020 .74747 
Section III. 
Symptom 
Difficulties 
q36 
33 1.00 3.00 12.1212 .65279 
Section III. 
Symptom 
Difficulties 
q37 
33 2.00 5.00 61.6162 .71244 
Section III. 
Symptom 
Difficulties 
q38 
33 1.00 4.00 41.4141 .96922 
Section III. 
Symptom 
Difficulties 
q39 
33 1.00 4.00 39.3939 .88227 
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Section III. 
Symptom 
Difficulties 
q40 
33 1.00 3.00 33.3333 .82916 
Section III. 
Symptom 
Difficulties 
q41 
33 1.00 3.00 31.3131 .82687 
Section III. 
Symptom 
Difficulties 
q42 
33 1.00 4.00 36.3636 .91391 
Section III. 
Symptom 
Difficulties 
q43 
33 1.00 3.00 24.2424 .80128 
Section III. 
Symptom 
Difficulties 
q44 
33 1.00 4.00 53.5354 .93339 
 
 Correlation between quality of life domain score and monthly income. 
Ranks 
 
Section V. Socio-economic 
status q9 N Mean Rank 
Physical 
 
1500> 20 44.10 
1500-3000 50 35.00 
3001-5000 6 49.00 
Total 76  
Emotion 
 
1500> 20 43.60 
1500-3000 51 36.03 
3001-5000 6 48.92 
Total 77  
Vitality 
 
1500> 9 23.72 
1500-3000 32 21.69 
3001-5000 3 27.50 
Total 44  
School 
 
1500> 3 4.33 
1500-3000 5 5.00 
3001-5000 1 7.00 
Total 9  
Eat 
 
1500> 20 40.95 
1500-3000 51 37.54 
3001-5000 6 44.92 
Total 77  
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Body 
 
1500> 20 43.43 
1500-3000 51 37.04 
3001-5000 6 40.92 
Total 77  
Treatment 
 
1500> 20 48.35 
1500-3000 51 34.75 
3001-5000 6 43.92 
Total 77  
Health 
 
1500> 9 24.61 
1500-3000 32 20.88 
3001-5000 3 33.50 
Total 44  
Respiratory 
 
1500> 20 41.33 
1500-3000 51 38.25 
3001-5000 6 37.67 
Total 77  
Digest 
 
1500> 20 36.55 
1500-3000 51 38.98 
3001-5000 6 47.33 
Total 77  
Weight 
 
1500> 9 27.28 
1500-3000 32 21.05 
3001-5000 3 23.67 
Total 44  
 
 Correlation between quality of life domain scores and relationship with 
patients  (father, mother, grandfather and brother).  
Ranks 
 
Relationship N Mean Rank 
Physical mother 28 16.05 
father 3 24.00 
Grandfather 1 6.50 
Total 32  
Emotion mother 28 17.70 
father 3 9.83 
Grandfather 1 3.00 
Total 32  
Vitality mother 28 17.09 
father 3 15.17 
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Grandfather 1 4.00 
Total 32  
School mother 28 16.64 
father 3 13.50 
Grandfather 1 21.50 
Total 32  
Eat mother 28 17.70 
father 3 9.00 
Grandfather 1 5.50 
Total 32  
Body 
 
 
 
mother 28 17.05 
father 3 14.17 
Grandfather 1 8.00 
Total 32  
Treatment mother 28 17.18 
father 3 15.17 
Grandfather 1 1.50 
Total 32  
Health mother 28 16.71 
father 3 17.33 
Grandfather 1 8.00 
Total 32  
Respiratory mother 28 17.02 
father 3 16.50 
Grandfather 1 2.00 
Total 32  
Digest mother 28 15.63 
father 3 26.00 
Grandfather 1 12.50 
Total 32  
Weight mother 28 16.75 
father 3 16.00 
Grandfather 1 11.00 
Total 32  
 
 Correlation between quality of life domain scores and level of education for 
parent. 
Ranks 
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School grade completed for 
parents N Mean Rank 
Physical Some high school or less 17 15.74 
High school diploma/GED 9 15.78 
Some college 3 15.17 
College degree 4 26.50 
Total 33  
Emotion 
 
 
 
 
 
Some high school or less 17 15.24 
High school diploma/GED 9 13.56 
Some college 3 18.00 
College degree 4 31.50 
Total 33 
 
Vitality Some high school or less 17 13.35 
High school diploma/GED 9 15.72 
Some college 3 22.67 
College degree 4 31.13 
Total 33  
School Some high school or less 17 15.24 
High school diploma/GED 9 18.61 
Some college 3 10.00 
College degree 4 26.13 
Total 33  
Eat Some high school or less 17 16.09 
High school diploma/GED 9 15.67 
Some college 3 9.00 
College degree 4 29.88 
Total 33  
Body 
 
 
 
 
Some high school or less 17 15.24 
High school diploma/GED 9 16.61 
Some college 3 22.50 
College degree 4 21.25 
Total 33 
 
Treatment Some high school or less 17 17.65 
High school diploma/GED 9 12.11 
Some college 3 16.00 
College degree 4 26.00 
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Total 33  
Health Some high school or less 17 16.00 
High school diploma/GED 9 17.00 
Some college 3 11.33 
College degree 4 25.50 
Total 33  
Respiratory Some high school or less 17 14.21 
High school diploma/GED 9 18.28 
Some college 3 15.50 
College degree 4 27.13 
Total 33  
Digest Some high school or less 17 19.26 
High school diploma/GED 9 10.22 
Some college 3 20.83 
College degree 4 19.75 
Total 33  
Weight Some high school or less 17 18.09 
High school diploma/GED 9 16.17 
Some college 3 21.33 
College degree 4 11.00 
Total 33  
 
 Correlation between quality of life domain scores and work status of parent. 
Ranks 
 
Work status for parents N Mean Rank 
Physical Seeking Work 1 17.00 
Working full or part time 9 21.11 
Full time homemaker 22 14.93 
Not working due to my 
health 
1 25.50 
Total 33  
Emotion 
 
 
 
 
 
Seeking Work 1 21.50 
Working full or part time 9 21.83 
Full time homemaker 22 15.25 
Not working due to my 
health 
1 7.50 
Total 33  
Vitality Seeking Work 1 14.50 
Working full or part time 9 22.28 
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Full time homemaker 22 15.55 
Not working due to my 
health 
1 4.00 
Total 33  
School Seeking Work 1 28.00 
Working full or part time 9 23.72 
Full time homemaker 22 14.41 
Not working due to my 
health 
1 2.50 
Total 33  
Eat Seeking Work 1 23.50 
Working full or part time 9 21.89 
Full time homemaker 22 15.39 
Not working due to my 
health 
1 2.00 
Total 33  
Body Seeking Work 1 22.50 
Working full or part time 9 18.67 
Full time homemaker 22 16.48 
Not working due to my 
health 
1 8.00 
Total 33  
Treatment Seeking Work 1 
 
7.00 
Working full or part time 9 19.33 
Full time homemaker 22 16.34 
Not working due to my 
health 
1 20.50 
Total 33  
Health Seeking Work 1 15.50 
Working full or part time 9 20.94 
Full time homemaker 22 15.86 
Not working due to my 
health 
1 8.00 
Total 33  
Respiratory Seeking Work 1 33.00 
Working full or part time 9 19.33 
Full time homemaker 22 14.82 
Not working due to my 
health 
1 28.00 
Total 33  
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Digest Seeking Work 1 18.00 
Working full or part time 9 20.33 
Full time homemaker 22 14.95 
Not working due to my 
health 
1 31.00 
Total 33  
Weight Seeking Work 1 26.50 
Working full or part time 9 14.44 
Full time homemaker 22 17.89 
Not working due to my 
health 
1 11.00 
Total 33  
 
 
 Correlation between quality of life domain scores and marital status of parent 
(married or divorced). 
Ranks 
 
Marital status for parents N Mean Rank Sum of Ranks 
Physical 
 
married 31 17.21 533.50 
Divorced 2 13.75 27.50 
Total 33   
Emotion 
 
married 31 16.77 520.00 
Divorced 2 20.50 41.00 
Total 33   
Eat 
 
married 31 17.23 534.00 
Divorced 2 13.50 27.00 
Total 33   
Body 
 
married 31 16.94 525.00 
Divorced 2 18.00 36.00 
Total 33   
Treatment 
 
married 31 17.29 536.00 
Divorced 2 12.50 25.00 
Total 33   
Respiratory 
 
married 31 16.81 521.00 
Divorced 2 20.00 40.00 
Total 33   
Digest 
 
married 31 17.52 543.00 
Divorced 2 9.00 18.00 
Total 33   
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Social 
 
married 31 17.63 546.50 
Divorced 2 7.25 14.50 
Total 33   
 
 
 Domain score for each item of children under 6 years of age version. 
Descriptive Statistics 
  
N Minimum Maximum Mean 
Std. 
Deviation 
Section II. 
Quality of 
Life q1 
21 1 4 46.03 .921 
Section II. 
Quality of 
Life q2 
21 1.00 4.00 47.6190 .92582 
Section II. 
Quality of 
Life q3 
20 1.00 4.00 46.6667 1.04630 
Section II. 
Quality of 
Life q4 
20 1.00 4.00 38.3333 1.03999 
Section II. 
Quality of 
Life q5 
20 1.00 4.00 36.6667 1.07115 
 Section 
II.Quality 
of Life q6 
22 1.00 4.00 39.3939 .95799 
 Section 
II.Quality 
of Life q7 
22 1.00 4.00 51.5152 .67098 
 Section 
II.Quality 
of Life q8 
22 1.00 4.00 45.4545 .72673 
Section II. 
Quality of 
Life q9 
22 1.00 3.00 22.7273 .71623 
 Section 
II.Quality 
of Life q10 
22 1.00 4.00 34.8485 .84387 
 Section 
II.Quality 
of Life q11 
22 1.00 3.00 39.3939 .73266 
 Section 
II.Quality 
of Life q12 
22 1.00 4.00 42.4242 .98473 
Section II. 
Quality of 
Life q13 
9 2.00 4.00 59.2593 .66667 
Section II. 
Quality of 
Life q14 
22 1.00 4.00 90.9091 .70250 
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Section II. 
Quality of 
Life q15 
22 2.00 3.00 48.4848 .50965 
Section II. 
Quality of 
Life q16 
22 1.00 4.00 45.4545 .72673 
 Section 
II.Quality 
of Life q17 
22 1.00 4.00 45.4545 .84771 
Section II. 
Quality of 
Life q18 
22 1.00 4.00 31.8182 .95005 
 Section 
II.Quality 
of Life q19 
22 1.00 4.00 30.3030 .97145 
Section II. 
Quality of 
Life q20 
22 1.00 4.00 33.3333 1.06904 
 Section 
II.Quality 
of Life q21 
22 1.00 4.00 34.8485 1.09010 
 Section 
II.Quality 
of Life q22 
22 1.00 4.00 27.2727 .90692 
Section II. 
Quality of 
Life q23 
22 1.00 4.00 62.1212 .83355 
 Section 
II.Quality 
of Life q24 
22 1.00 3.00 34.8485 .72225 
 Section 
II.Quality 
of Life q25 
22 2.00 3.00 54.5455 .49237 
 Section 
II.Quality 
of Life q26 
22 1.00 3.00 42.4242 .82703 
 Section 
II.Quality 
of Life q27 
22 1.00 4.00 56.0606 .64633 
Section II. 
Quality of 
Life q28 
5 2.00 4.00 53.3333 .89443 
Section II. 
Quality of 
Life q29 
5 2.00 4.00 53.3333 .89443 
 Section 
II.Quality 
of Life q30 
22 1.00 2.00 15.1515 .50965 
 Section 
II.Quality 
of Life q31 
22 2.00 4.00 68.1818 .65300 
 Section 
II.Quality 
of Life q32 
22 2.00 4.00 62.1212 .46756 
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Section III. 
Symptom 
Difficulties 
q33 
22 1.00 3.00 25.7576 .86914 
Section III. 
Symptom 
Difficulties 
q34 
22 1.00 4.00 28.7879 .77432 
Section III. 
Symptom 
Difficulties 
q35 
22 1.00 4.00 30.3030 .75018 
Section III. 
Symptom 
Difficulties 
q36 
22 1.00 4.00 30.3030 .81118 
Section III. 
Symptom 
Difficulties 
q37 
22 2.00 3.00 50.0000 .51177 
Section III. 
Symptom 
Difficulties 
q38 
22 1.00 4.00 56.0606 .83873 
Section III. 
Symptom 
Difficulties 
q39 
22 1.00 4.00 46.9697 .79637 
Section III. 
Symptom 
Difficulties 
q40 
22 1.00 4.00 53.0303 .66613 
Section III. 
Symptom 
Difficulties 
q41 
22 1.00 4.00 34.8485 1.17422 
Section III. 
Symptom 
Difficulties 
q42 
22 1.00 4.00 45.4545 .95346 
Section III. 
Symptom 
Difficulties 
q43 
22 1.00 4.00 37.8788 .94089 
Section III. 
Symptom 
Difficulties 
q44 
22 1.00 4.00 40.9091 1.02036 
 
 Correlation between child (6-13) quality of life domain score and health status 
FEV 1 level. 
Ranks 
                                           Child (6-13) years of age  
  Health Profile FEV1 N Mean 
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Rank 
Physical 
  
mild(89>FEV>=70) 8 16.56 
moderate(70>FEV>=40) 5 18.70 
Not available 20 16.75 
Total 33   
Emotion 
  
mild(89>FEV>=70) 8 16.50 
moderate(70>FEV>=40) 5 18.20 
Not available 20 16.90 
Total 33   
Eat 
  
mild(89>FEV>=70) 8 20.44 
moderate(70>FEV>=40) 5 14.90 
Not available 20 16.15 
Total 33   
Body 
  
mild(89>FEV>=70) 8 18.75 
moderate(70>FEV>=40) 5 14.60 
Not available 20 16.90 
Total 33   
Treatment 
  
mild(89>FEV>=70) 8 21.63 
moderate(70>FEV>=40) 5 21.30 
Not available 20 14.08 
Total 33   
Respiratory 
 
 
 
 
 
 
  
mild(89>FEV>=70) 8 17.19 
moderate(70>FEV>=40) 5 11.80 
Not available 20 18.23 
Total 33 
  
Digest 
  
mild(89>FEV>=70) 8 18.13 
moderate(70>FEV>=40) 5 14.20 
Not available 20 17.25 
Total 33   
     
 Social 
 
mild( 89>FEV>=70) 8 17.25 
moderate(70>FEV>=40) 5 21.50 
Not available 20 15.78 
Total 33  
 
 Correlation between adult (14+) quality of life domain scores and health status 
FEV 1 level. 
Ranks 
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Health Profile FEV1 for adult 
(14+) N Mean Rank 
Physical 
 
mild(89>FEV>=70) 2 16.75 
moderate(70>FEV>=40) 9 12.11 
sever 2 4.75 
Not available 9 11.22 
Total 
 
22 
 
Vitality 
 
mild(89>FEV>=70) 2 15.00 
moderate(70>FEV>=40) 9 12.44 
sever 2 6.75 
Not available 9 10.83 
Total 22  
Emotion 
 
mild(89>FEV>=70) 2 13.75 
moderate(70>FEV>=40) 9 11.39 
sever 2 8.50 
Not available 9 11.78 
Total 22  
Eat 
 
mild(89>FEV>=70) 2 10.00 
moderate(70>FEV>=40) 9 11.06 
sever 2 10.25 
Not available 9 12.56 
Total 22  
Treatment 
 
mild(89>FEV>=70) 2 15.00 
moderate(70>FEV>=40) 9 12.61 
sever 2 10.50 
Not available 9 9.83 
Health 
 
mild(89>FEV>=70) 2 18.75 
moderate(70>FEV>=40) 9 12.06 
sever 2 8.75 
Not available 9 9.94 
Total 22  
Social 
 
mild(89>FEV>=70) 2 7.00 
moderate(70>FEV>=40) 9 10.72 
sever 2 10.00 
Not available 9 13.61 
Total 22  
Body 
 
mild(89>FEV>=70) 2 16.50 
moderate(70>FEV>=40) 9 10.22 
sever 2 9.25 
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Not available 9 12.17 
Total 22  
Role 
 
mild(89>FEV>=70) 2 17.75 
moderate(70>FEV>=40) 9 13.33 
sever 2 6.75 
Not available 9 9.33 
Total 22  
Weight 
 
mild(89>FEV>=70) 2 10.75 
moderate(70>FEV>=40) 9 12.39 
sever 2 6.00 
Not available 9 12.00 
Total 22  
Respiratory 
 
 
 
 
mild(89>FEV>=70) 2 11.50 
moderate(70>FEV>=40) 9 11.61 
sever 2 8.25 
Not available 9 12.11 
Total 22  
Digest 
 
mild(89>FEV>=70) 2 19.00 
moderate(70>FEV>=40) 9 10.22 
sever 2 10.75 
Not available 9 11.28 
Total 22  
 
 Correlation between quality of life domain scores and geographic distribution 
of patients. 
Ranks 
  
 
 
 
District  N 
Mean 
Rank 
Physical Jerusalem 1 26.00 
Bethlehem 6 34.50 
Hebron 49 38.72 
Ramallah 5 48.10 
Nablus 7 31.79 
Jenin 6 32.42 
Qalqilia 1 65.00 
Tulkarm 1 73.00 
Total 76   
Emotion  Jerusalem 1 13.50 
Bethlehem 6 43.50 
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Hebron 50 39.12 
Ramallah 5 48.10 
Nablus 7 31.21 
Jenin 6 28.67 
Qalqilia 1 75.00 
Tulkarm 1 66.50 
Total 77   
Vitality 
 
 
 
 
Bethlehem 4 22.38 
Hebron 26 22.65 
Ramallah  4 26.75 
Nablus 4 17.13 
Jenin 4 17.50 
Qalqilia 1 31.50 
Tulkarm 1 34.50 
Total 44   
School Hebron 5 6.00 
Ramallah  2 2.25 
Nablus 1 3.50 
Jenin 1 7.00 
Total 9   
Eat 
 
 
Jerusalem 1 38.50 
Bethlehem 6 33.33 
Hebron 50 40.88 
Ramallah 
 
5 41.50 
Nablus 7 27.79 
Jenin 6 38.08 
Qalqilia 1 45.00 
Tulkarm 1 45.00 
Total 77   
Body 
 
 
 
 
 
 
Jerusalem 1 46.00 
Bethlehem 6 26.25 
Hebron 50 41.53 
Ramallah  5 39.90 
Nablus 7 33.93 
Jenin 6 36.50 
Qalqilia 1 16.50 
Tulkarm 1 50.50 
Total 77 
  
Treatment Jerusalem 1 23.00 
Bethlehem 6 27.67 
Hebron 50 41.45 
Ramallah 5 51.60 
Nablus 7 26.14 
Jenin 6 42.42 
Qalqilia 1 13.50 
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 Correlation between quality of life domain scores and kind of living (city, 
village and camp). 
Ranks 
 
     Kind of living  N Mean Rank 
Physical 
 
City 23 32.04 
village 46 41.68 
camp 7 38.79 
Tulkarm 1 32.50 
Total 77   
Health 
 
 
 
 
Bethlehem 4 19.13 
Hebron 26 23.65 
Ramallah  4 25.38 
Nablus 4 16.25 
Jenin 4 17.13 
Qalqilia 1 20.50 
Tulkarm 1 43.00 
 
 
 
Total  44  
Respiratory Jerusalem 1 49.50 
Bethlehem 6 35.33 
Hebron 50 38.11 
Ramallah  5 64.40 
Nablus 7 45.64 
Jenin 6 24.58 
Qalqilia 1 23.50 
Tulkarm 1 23.50 
Total 77   
Digestion Jerusalem 1 46.50 
Bethlehem 6 26.75 
Hebron 50 40.30 
Ramallah 5 41.10 
Nablus 7 39.21 
Jenin 6 31.00 
Qalqilia 1 38.50 
Tulkarm 1 76.50 
Total 77   
Weight  
 
Bethlehem 4 11.50 
Hebron 26 23.00 
Ramallah 4 26.38 
Nablus 4 24.38 
Jenin 4 22.25 
Qalqilia 1 42.50 
Tulkarm 1 11.50 
Total 44   
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Total 76  
Emotion 
 
 
 
City 23 32.52 
village 47 42.17 
camp 7 39.00 
Total 77  
Vitality 
 
City 13 22.38 
village 27 23.43 
camp 4 16.63 
Total 44  
School 
 
City 3 6.83 
village 6 4.08 
Total 9  
Eat 
 
City 23 41.35 
village 47 38.55 
camp 7 34.29 
Total 77  
Body  
 
City 23 36.78 
village 47 40.73 
camp 7 34.64 
Total 77  
Treatment 
 
City 23 36.87 
village 47 41.49 
camp 7 29.29 
Total 77  
Health 
 
City 13 22.85 
village 27 22.81 
camp 4 19.25 
Total 44  
Respiratory  
 
City 23 40.98 
village 47 37.61 
camp 7 41.86 
Total 
 
77 
 
Digest  
 
City 23 37.87 
village 47 39.65 
camp 7 38.36 
Total 77  
Weight 
 
City 13 24.00 
village 27 22.41 
camp 4 18.25 
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Total 44  
 
 
 
 
 
 Relationship between influenza vaccine and QoL domain scores. 
Ranks 
  
Taking influenza vaccine  N Mean Rank Sum of Ranks 
Physical 
 
Yes 41 39.56 1622.00 
No 35 37.26 1304.00 
Total 76   
Emotion 
 
Yes 41 41.85 1716.00 
No 36 35.75 1287.00 
Total 77   
Vitality 
 
Yes 20 25.18 503.50 
No 24 20.27 486.50 
Total 44   
School 
 
Yes 2 4.00 8.00 
No 7 5.29 37.00 
Total 9   
Eat 
 
Yes 41 35.12 1440.00 
No 36 43.42 1563.00 
Total 77   
Body 
 
Yes 41 38.60 1582.50 
No 36 39.46 1420.50 
Total 77   
Treatment 
 
Yes 41 37.27 1528.00 
No 36 40.97 1475.00 
Total 77   
Health 
 
Yes 20 23.28 465.50 
No 24 21.85 524.50 
Total 44   
Respiratory 
 
Yes 41 40.05 1642.00 
No 36 37.81 1361.00 
Total 77   
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Digest 
 
Yes 41 36.77 1507.50 
No 36 41.54 1495.50 
Total 77   
Weight 
 
Yes 20 20.70 414.00 
No 24 24.00 576.00 
Total 44   
Social 
 
Yes 32 28.11 899.50 
No 23 27.85 640.50 
Total 55   
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 تقييم نوعية حياة مرضى التميف الكيسي في الضفة الغربية والخيارات العلاجية الجديدة
 
 اعداد: سامية عزت محمد صلاح
 اشراف: الدكتور ماهر خضور والدكتور حسين حلاق
 
 رضاٌٍّ
أحدث التوقعات التي نشرت في مجمة الجهاز التنفسي د مرضى التميف الكيسي تتزايد في جميع أنحاء العالم، اعدأ
 ٪ من البالغين).57٪ من الأطفال، و 02( 5202٪ بحمول عام 05الأوروبي تشير إلى زيادة حوالي 
لانطباع العام أن المرض نادر لا توجد بيانات وبائية دقيقة عن مرض التميف الكيسي في فمسطين. وكان ا
ضعف طرق التشخيص أو خطأ في التشخيص بسبب الوعي نتيجة  عمى الأرجحيعود هذا  الحدوث، ولكن
 المحدود عن المرض في المنطقة.
لعلاج بسبب العدد المتزايد من الأدوية المتاحة والحاجة إلى ًا في اكبير  التميف الكيسي يحمل المرضى عبئا ً مرض
لة كل يوم لتناول هذه الأدوية. التكنولوجيا الجديدة المستخدمة في تناول الادوية هي مفيدة لمغاية إجراءات مطو 
هذه الخيارات  ض عن طريق تقميل وقت العلاج وتقديم المزيد من الفعالية والسلامة.المر لأنها قد تخفف عبء 
بدائية متوفرة ومن هنا تكمن المشكمة فقط العلاجات التقميدية ال غير متاحة لمرضى التميف الكيسي في فمسطين
 .الأساسية
ونوعية الحياة المرتبطة بالصحية والرضا يجب أن تكون جزءا من تحسن الأعراض  تقييم وجهة نظر المريض من
معظم دراسات نوعية الحياة لمرضى التميف الكيسي تمت في الدول المتقدمة وعدد قميل  اتخاذ القرار العلاجي.
 ولكن لم تجرى أية منها في فمسطين. نامية.منها في الدول ال
 
 الهدف من الدراسة
وكان الغرض من هذا المشروع دراسة الوضع الصحي لمرضى التميف الكيسي في فمسطين باستخدام عدة محاور 
لممقارنة تشمل؛ قضايا جودة الحياة لمرضى التميف الكيسي الذين يتمقون العلاج في مستشفى كاريتاس للأطفال 
م الصحية، دراسة العبء الاقتصادي وتكاليف العلاج الحالية وتأثيرها عمى المرضى، معرفة رغبة وحالته
المرضى في المساهمة المالية مقابل الحصول عمى علاج جديد يحسن من الوضع الصحي ويقمل من اعراض 
لمرض التميف الكيسي المرض ودراسة العوامل التي ستأثر عمى اجابتهم، لفت النظر الى الحاجة الى علاج جديد 
 بالاعتماد عمى النتائج.
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 اجراءات الدراسة 
دراسة مسحية وصفية أجريت لممرضى الذين يعانون من مرض التميف الكيسي في الضفة الغربية. يستخدم هؤلاء 
المرضى العلاجات الأساسية ويتمقون العلاج في عيادة أمراض الرئة لدى الأطفال في مستشفى كاريتاس 
مشاركًا أربعة محاور لمتقييم وقدموا معمومات ديمغرافية. تم دراسة حالة مرضى التميف  77أكمل حوالي  للأطفال.
ستبيان المعتمد لقياس جودة الكيسي في فمسطين باستخدام جوانب مختمفة. وتم قياس جودة حياتهم باستخدام الا
هم الصحية عن طريق قياس معايير مختمفة . وتم فحص حالتالحياة لمرضى التميف الكيسي والمترجم لمغة العربية
. وقد تم حساب وعدد الوفيات في كل اسرة عمر التشخيص تشمل: فحص وظائف الرئة، مؤشر كتمة الجسم،
لتحسين الوضع ستعداد لدفع مبم  من المال مقابل الحصول عمى علاج جديد التكاليف المتعمقة بالعلاج والا
سة، خلاق البحث العممي في مستشفى الكاريتاس للأطفال لعمل الدراالصحي. تم الحصول عمى موافقة لجنة أ
قبل تعبئة الاستبيان. تم تحميل النتائج باستخدام البرامج المتاحة لمتحميل  والموافقة المكتوبة من المرضى ووالديهم
 .SSPSوبرنامج 
 
 النتائج والتوصيات
الى  5.41 تراوحت من٪ 06لمرضى التميف الكيسي في الضفة الغربية أقل من  متوسطات قيم نوعية الحياةإن 
مما يدل عمى نوعية حياة رديئة مقارنة بالدول الأخرى. أدنى درجة كانت لممجال الذي يقيم الصحة  6.55
 ). ويبدو أن أعمى قيمة كانت لممجال5.72) وصحة الجهاز التنفسي (5.71) وطريقة العلاج (5.41الجسمية (
). ومتوسط شدة المرض بالاعتماد عمى 05) والحالة النفسية والعاطفية لممرضى (55الذي يقيم طبيعة الأكل (
٪. ومتوسط سجل مؤشر كتمة الجسم كان 6.96في المئة كانت بمعدل  1VEFفحص وظائف الرئة والذي يقيس 
سنة. وأظهرت  61.4نة كان ). مع متوسط العمر الإجمالي لمتشخيص في العيمتر مربع(كغم/ 899.51يعادل 
 ) من محافظة الخميل كان لديهم حالات وفاة تتعمق بمرض التميف الكيسي.21/7٪ (3.85الدراسة أن 
ون مرض والعمل أخذ عطمة بدالعمر والجنس و وكشفت النتائج أن نوعية الحياة لمرضى  التميف الكيسي  تتأثر ب
ومعايير تتعمق  ى،شر كتمة الجسم، وسن التشخيص لممرضوالمستوى التعميمي، ومقاييس مؤ  الدراسي الوضعأو 
العمل لموالدين. وتأثرت أيضا من العدد الإجمالي لمرضى والتي شممت: العمر والمستوى التعميمي و بالوالدين 
 التميف الكيسي  في كل عائمة.
زيع الجغرافي ومكان والتو  تتأثر بالحالة الاجتماعيةكما اظهرت الدراسة أن نوعية الحياة لمرضي التميف لا 
الاستعداد لدفع مبم  من المال مقابل الحصول ، و 1VEFالتدابير التي تتخذ في مدينة، قرية أو مخيم)، و الإقامة (
 . ، وتأثير أخذ لقاح الأنفمونزا سنويا ًللأسرة العلاقة بالوالدين (الأب أو الأم)، والدخل الشهري، و عمى علاج جديد
٪ 5.6وهم عمى استعداد لدفع مبم  من المال مقابل الحصول عمى علاج جديد و٪ من المرضى قالوا نعم 5.39
٪ عمى استعداد  7.2شيكل الى 001% منهم عمى استعداد لدفع 4.15قالوا لا نتيجة الحالية المادية السيئة. 
ريض يبم  شيكل أو أكثر. مع التقييم الاقتصادي لمرضى التميف الكيسي، فإن التكاليف الإجمالية لم 0002لدفع 
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شيكل لممريض سنويًا. وقد تم  2.05653سنين والذي يمثل متوسط اعمار العينة قدرت بنحو  7.01من العمر 
كدواء مفكك لمبمغم وتبخيرات محمول المضاد afla-esanroD ب تقدير تخفيض التكاليف الصحية بعد تزويدهم 
التحفيز عمى توفير هذه الأدوية المتاحة بمبال  كبيرة  التي من شأنها أن تساعد في  nicymarboT الحيوي
 لممرضى التميف الكيسي.
لدينا نوعية حياة رديئة بالنسبة لممعايير الدولية، والأدوية المستخدمة بما في ذلك وأخيرًا أظهرت الدراسة أن 
 المعتمدة في العالم،و المتطورة الادوية ليست   noitulos reziluben nicymatneGو enilas cinotrepyH
مقابل  مشاركة بمبم  من المالهم يطالبون بحياة افضل وعلاجات جديدة ، وعمى استعداد لممرضى وأسر الكذلك و 
مرضى التميف يثبت الحاجة إلى علاجات جديدة ل لدينا دليل شامل فانالحصول عمى علاج أفضل. لذلك 
 وسط اعمارهم.الكيسي في فمسطين من أجل تحسين نوعية حياتهم، حالتهم الصحية، وزيادة مت
 
  
 
